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Abstract 
In this thesis two aspects of carbohydrate research will be discussed. First, the total 
synthesis of N-glycans found on allergens that are known to stimulate an allergic 
immune response and second, the synthesis of iminosugars in an attempt to extend 
the scope of the PGF-methodology.  
 
Asthma affects 235 million people worldwide, with New Zealand ranking among the 
highest in the world. Although there is a good understanding of how allergens trigger 
the immune system on a “macroscopic” level, how an allergen’s molecular structure 
causes such an allergic response remains unknown. Upon close review of 
carbohydrates present on the allergens that are known to give an allergic T helper (Th 
2) immune response, a common structure has been identified. The structure consists 
of a complex type N-glycan made up of a pentasaccharide core (Man3(GlcNHAc)2), 
with additional 1,3-linked α-L-fucose and 1,2-linked D-xylose cappings. As part of a 
structure relationship study this heptasaccharide and structural derivatives thereof 
have been synthesised. The synthesis of these N-glycans will allow a more detailed 
study of the role of these defined structures in triggering an allergic immune 
response.  
 
The second part of this thesis focuses on the protecting group free (PGF) synthesis of 
iminosugars, which are potent glycosidase inhibitors and are currently used in the 
treatment of a variety of diseases. Synthetic strategies for the synthesis of 
iminosugars involve the use of protecting groups, which are necessary to block 
potential competing reactive centres within a molecule during the multistep 
synthesis. The disadvantage, however, is that the installation of protecting groups 
introduces additional steps to the total synthesis, which inevitably leads to lower 
yields and the generation of waste. Within our group, PGF methodologies have been 
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developed which allow for the synthesis of a variety of iminosugars. The work 
presented in this thesis extends the scope of this methodology for the synthesis of an 
important class of iminosugars, the 2,5-dihydroxymethyl-3,4-dihydroxypyrrolidines. 
For the purpose of introducing an additional hydroxymethyl group, a ketose starting 
material was required, and therefore an efficient Vasella/reductive amination 
reaction using ketoses was developed. Additionally, iodocyclisation and carbamate 
annulation of the intermediate alkenylamines provided successful entry to the 2,5-
dihydroxymethyl-3,4-dihydroxypyrrolidines, exemplified by the efficient 6-step 
synthesis of 2,5-dideoxy-2,5-imino-L-iditol and 2,5-dideoxy-2,5-imino-D-mannitol 
(DMDP). 
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Chapter 1: General introduction 
Glycans are the most abundant and the most diverse biopolymers in nature.1 Together 
with nucleic acids, proteins, and lipids, they are one of the most important types of 
natural organic products in living systems.2 Carbohydrates are involved in many 
biological functions, from energy storage to cell signalling, cell-cell and cell-matrix 
interactions, as well as being structural components of cell walls.3 Although our 
understanding of the role of carbohydrates in these processes is still developing, 
recent progress has brought carbohydrates into focus as potential targets for 
treatment of a range of diseases.4  
 
1.1 Glycobiology of glycoconjugates  
Glycans, or polysaccharides, are unique in the complexity of their structures. The 
diverse nature of glycans comes from the monomeric carbohydrate building blocks 
they are made up from. Monosaccharides have multiple hydroxyls that can be 
glycosylated which allows for the formation of both branched and straight chain 
oligosaccharides.5 Unlike oligonucleotides, oligosaccharides do not encode biological 
information in their monomer sequences. Here, it is the three dimensional structure of 
oligosaccharides that is responsible for their functions. In biological systems, glycans 
are generally covalently bound to non-carbohydrate molecules such as lipids or 
proteins (where they are attached to serine, threonine, or asparagine residues).6 
These glycans, or glycoconjugates, are found on red blood cells, in the cytoplasmic 
matrix and in subcellular organelles. The more complex glycans are mainly integrated 
into the lipid bilayer of the plasma membrane forming the glycocalyx (Figure 1).7 Cells 
and tissues use these glycans to communicate with the immune system, signalling if 
the tissue is healthy or injured. The recognition is based on a lock + key principle with 
carbohydrates forming ligands (keys) that can be recognised by a number of different 
molecules, such as lectins, enzymes, hormones and antibodies (lock).8 On the other 
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hand, tumour cells and viruses use the same recognition system to evade the immune 
system.9,10 In addition, microbes also use glycans to enable them to invade cells.11  
 
 
 
 
Figure 1. Representation of the plasma membrane with presence of 
several glycan moieties involved in cell adhesion and cell -cell 
interaction.  
 
 
An example of extracellular glycan interactions is the ABO blood group system. The 
ABO classification is based on the presence or absence of the antigens, A and/or B, on 
red blood cells (Table 1). In addition, there are two antibodies anti-A and anti-B that 
always occur in the absence of the corresponding antigen. The minimal determinant 
saccharides in blood group antigens are depicted in table 1, here the core structure 
consists of an α-1,2-fucosylated galactose. Individuals with blood group A have an 
additional α-1,3-linked N-acetylgalactosamine (GalNHAc), whereas for those with 
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blood group B this is galactose. When no additional sugars are present this gives blood 
group O.5 Understanding these serological relationships has allowed for safe blood 
transfusions from one person to another.12 
 
Phenotype of 
red blood cells 
Minimal determinant saccharide 
(blood group antigen) 
Antibodies found in 
plasma 
A 
 
A 
Anti-B 
B 
 
B 
Anti-A 
 
AB 
 
A and B - 
O 
 
H 
Anti-A and Anti-B 
Table 1. The ABO blood group system.5 
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1.2 The biosynthesis of oligosaccharides 
Two types of enzyme are involved in the biosynthesis of oligosaccharides: 
glycosyltransferases and glycosidases. Glycosyltransferases catalyse glycosylation 
reactions and ensure the stereo- and regio-specific build-up of oligosaccharides. 
Glycosidases, on the other hand, are involved in the complex process of glycoprotein 
modification and digestion.13 Glycosyltransferases use nucleoside diphosphate-sugars 
as activated-donors.14 An example is the uridine diphospho(UDP)-galactose donor 3 
(Scheme 1). This is an important donor in the biosynthesis of complex type N-
glycans.15 The nucleoside diphosphate-donor is synthesised, in two steps from 
galactose 1. First, galacto kinase selectively phosphorylates the monosaccharide to 
galactosylphosphate 2. Uridine diphopho(UDP)-galactosylpyro-phosphorylase then 
installs the nucleoside to give activated donor 3. Galactosyltransferase then 
glycosylates the GlcNHAc acceptor selectively to give saccharide 4.  
 
 
 
 
Scheme 1. Nucleosidediphosphate-sugars as donor substrates for 
glycosyltransferases in the synthesis of oligosaccharides. 
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Glycoside hydrolases (glycosidases) are enzymes which degrade poly- and oligo-
saccharides. Several types of these enzymes have been defined based on their modes 
of action.13 Exoglycosidases begin hydrolysing from the non-reducing end of a 
polysaccharide and endoglycosidases attack in the somewhere in the middle of the 
polysaccharide chain.13,16 Like glycosyltransferases, glycosidases are very specific and 
will only hydrolyse one specific linkage.13 
 
1.2.1 The biosynthesis of N-glycans 
Glycans can be linked to proteins via a nitrogen or an oxygen. Nitrogen bound glycans 
(N-glycans) are always attached the reducing end of a GlcNHAc residue to the side 
chain of an asparagine amino acid, whereas oxygen bound glycans (O-glycans) are 
generally bound to the hydroxyl group on the side chain of serine or threonine. 
Although structurally diverse, N-glycans follow the same biosynthetic pathway, 
whereas O-glycans do not have a general biosynthetic route.9,17  
 
The biosynthetic pathway for N-glycans in eukaryotes consists of three stages. The 
first stage is the dolichol cycle, second is transfer of the lipid bound glycans to protein-
bound glycans, and the final stage is a series of “trimming” and “processing” events 
generating a diverse spectrum of glycans (Figure 2).10 The dolichol cycle takes place in 
the rough endoplasmic reticulum (ER) and involves the addition of carbohydrate 
portions to a dolichol, a long chain of polyprenols consisting in total of 80 to 100 
carbon atoms.17,18 In the dolicholcycle an N-acetylglucosaminyl phosphate is attached 
to phosphodolichol (Figure 2). The resulting diphosphate then undergoes a series of 
addition reactions catalysed by membrane bound glycosyltransferases to form a 
Glc3Man9(GlcNHAc)2-dolichol (I). Next, the glycan-dolichol is transported to the lumen 
of the ER where an enzyme, called oligosaccharyltransferase, transfers the lipid bound 
glycan to an asparagine side chain (II).18 The site where the glycan is attached to the 
polypeptide chain contains the amino acid sequence Asn-X-Ser/Thr, where X is any 
amino acid except proline. However, not all Asn-X-Ser/Thr sequences are glycosylated 
because other factors such as sterics also influence the recognition process.19 Finally, 
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a series of glycosidases “trim” the Asn-bound glycan after which it is transported to 
the Golgi apparatus where the N-glycan is further processed (III).5,10 Post processing, 
N-glycans can be classified into three types; high mannose type, complex type and 
hydrid type N-glycans. High mannose type are the simplest form of N-glycan, they 
contain only α-mannose residues bound to the mannose capping of the common core. 
In complex type N-glycans, the trimannose capping is elongated and has a varied 
number of GlcNHAc and GalGlcNHAc portions. The hybrid type N-glycans are a 
combination of the other two glycan types.5 Interestingly, plants use the same 
biosynthetic pathway up to transport to the Golgi apparatus, after which plant specific 
enzymes modify the glycan further to give rise to more plant specific glycoforms.17 
 
 
  
 
Figure 2. A pictorial representation of the biosynthesis of N-glycans.17  
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As illustrated, carbohydrates participate in many biological processes.1 It is therefore 
not surprising that they also play a major role in many diseases. 20–22 As our 
understanding of the structure–function relationships of complex glycans increases, 
so does our ability to treat various diseases. Although our knowledge of carbohydrate 
interactions is increasing, much remains to be understood and continued research 
into these glycans is needed. 
  
This thesis will discuss the total synthesis of the carbohydrate portions of a complex 
type N-glycan, to study the structure–function relationship of allergens and their 
carbohydrate portions, and to understand their role in asthma and other allergic 
diseases. The second part of this thesis will discuss the protecting group free (PGF) 
synthesis of iminosugars, which are potential glycosidase inhibitors. Glycosidases are 
useful targets in the treatment of various diseases such as, diabetes,20 cancer,21 viral 
and bacterial infection20 and lysosomal processing disorders.22 
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Chapter 2: Introduction to N-glycans 
2.1 Asthma 
Asthma is a chronic respiratory disease that effects over 235 million people 
worldwide.23 Most of those affected live in western countries, however 80% of deaths 
caused by asthma occur in low to low-medium income countries.23 In New Zealand, 
over 600,000 people are affected by asthma, which as a percentage of the population 
is among the highest in the world.24  
 
Asthma is a recurrent disease that requires daily medication. When an asthma attack 
occurs, the person suffering will experience shortness of breath, wheezing and 
tightness in the chest. There are several triggers that can cause an attack such as 
exercise, stress, and for some even cold air, though allergens that are inhaled are the 
most common cause of asthma attacks and are responsible for 70-80% of the cases in 
New Zealand.25 Allergens can include dust mites, pollen, plant material, food, and 
animal hair and dander. 
 
Despite there being a good understanding of the general causes of an asthmatic attack, 
little is known about how allergens stimulate the immune system at a molecular level. 
Accordingly, current asthmatic medications are non-specific and alleviate the 
symptoms only.25 These medications are either anti-inflammatory (e.g 
corticosteroids) or bronchodilator drugs and help by relaxing the muscle bands 
around the airways thus opening the airways further. Inhaled corticosteroids are a 
very effective anti-inflammatory drug and can be used for patients of all ages and 
disease severity.23,25 They can be used daily on a long term basis as the human body 
will not build up immunity towards the drugs and, when used in standard doses, show 
minor side effects.25 For an effective treatment with corticosteroids, regular usage is 
required. Bronchodilators can help relieve wheezing, coughing and tightness in the 
chest and, as they function instantaneously, are taken when needed. However, like 
corticosteroids, bronchodilators do not treat the underlying cause of asthma. 
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Accordingly, more specific medications that treat the cause of asthma rather than the 
symptoms are required. 
2.2 Asthma and the Immune response 
When an asthmatic attack occurs, an immune response known as a T helper (Th) 2 
response is triggered. T helper cells are part of a class of white blood cells called 
lymphocytes and play an important role in the body’s natural immune defence system. 
There are two T-cell lineages: the CD4+ T-cells (which contain the CD4 protein on their 
cell surface) and the CD8+ T-cells (those containing the CD8 protein on their cell 
surface). When stimulated by an allergen, the CD4+ T-cells mature and release a 
variety of cytokines such as interleukin (IL)4, IL5, IL10 and IL13. This gives rise to the 
recruitment of other cells such as B cells, mast cells, eosinophils and basophils at the 
site of inflammation.26–28 During an asthma attack, these cells build up in the bronchial 
tubes leading to inflammation, mucous formation and the tightening of the muscles 
around the bronchial tube. As a result the person suffering will feel tightness in the 
chest and will have difficulty breathing.26–28  
 
Though much is known about the macroscopic triggers of the Th2 asthmatic response, 
little is known on the microscopic level about the causes of asthma. A review of the 
literature, however, reveals that the structural features of allergens known to give a 
Th2 immune response, such as pollen,29–31 schistosomes,32,33 and food allergens,34 are 
remarkably similar. In these allergens, core Man3GlcNHAc2 pentasaccharide (shown in 
black, Figure 3) is glycosylated with β-1,2-D-xylose (blue) and/or α-1,3-L-fucose (red) 
residue(s), whilst in humans, the core Man3GlcNHAc2 is instead capped with high 
mannose, lactosamine, and sialic acid residues.29–36 These N-glycans are asparagine 
(Asn) bound in an Asn-X-Ser/Thr sequence, with X being any amino acid except 
proline.37 It is also interesting to note that N-glycans found on bacteria and viruses do 
not contain these additional xylose or fucose carbohydrate residues and also do not 
stimulate the Th2 immune response.38–40 
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Figure 3. Heptasaccharide found on different allergens . (A) pollen (B) 
schistosome. 
 
To demonstrate that specific xylose and/or fucose containing glycoproteins elicit an 
allergic immune response, various studies have been performed using isolated 
glycoproteins containing N-glycans with α-1,3-L-fucose and/or β-1,2-D-xylose 
residues. These studies illustrated that such glycoproteins caused an increase in the 
production of Th2 specific cytokines (such as IL4, IL5, IL10 and IL13),29,32,33,35,36,41 and 
a reduction in the Th1 cytokine IFN-γ.36,42 Production of immunoglobulin E (IgE)36,43,44 
(a Th2 specific antibody) and IgE binding43,45–47 to a number of glycoproteins from 
different classes of allergen (i.e. cross reactivity between allergens) has also been 
observed. When the carbohydrate residues of the glycoprotein were cleaved, IgE 
antibody binding was inhibited30,48 and there was a significant decrease in the 
production of Th2 specific cytokines. These results suggest that the carbohydrate 
moiety of the glycoprotein allergen plays a vital role in producing the Th2 immune 
response.  
2.3 Synthetic approach for the preparation of complex N-glycans 
In nature, N-glycans exist as a heterogeneous mixture of glycoforms, which provide a 
wide range of functional diversity. Glycoproteins play an important role in controlling 
protein properties such as conformation, stability, susceptibility to proteases, and 
A B 
1 
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circulatory lifetime. In addition, glycans are fundamental in cell-cell interaction and 
immune responses.49–51 It is therefore not surprising to find that N-glycans are 
immunogenic. To be better able to understand the effects that these individual N-
glycans have on the immune response, there is a need to synthesise homogeneous 
glycoproteins. Due to the size and complex nature of these N-glycans, the only reliable 
way in which they can be obtained as a single glycoform is through chemical 
synthesis. Not surprisingly, the development of synthetic methodologies for the 
synthesis of homogeneous glycoproteins has become the objective of many synthetic 
chemists and many elegant strategies have been developed.52–55 These approaches are 
outlined below and focus on the key methodologies used to conjugate N-glycans to 
proteins or peptide chains and strategies for the synthesis of the complex N-glycans. 
2.3.1 Conjugation strategies: Native chemical ligation 
Native chemical ligation, a method developed by Kent and co-workers,56 is a technique 
that allows for the direct synthesis of homogeneous native backbone proteins of a 
moderate size. In this methodology, thioester 4 and cysteine bearing peptide 5 
undergo a chemoselective thiotransesterification to give the thioester-linked species 6 
(Scheme 2). Spontaneous rearrangement of intermediate 6 by nucleophilic attack of 
the neighbouring primary amine then yields peptide 7, which contains a native 
peptide linkage at the ligation site. Application of the native chemical ligation method 
to the total synthesis of a protein molecule was illustrated by the preparation of 
human interleukin 8 (IL-8). The ligation of a 33- and 39-residue gave the full length 
peptide (72 AA) with a native amino acid backbone. Kajihara and Dawson proposed 
the first synthetic derived asparagine bound N-glycan using the native chemical 
ligation methodology.57 In addition Bertozzi and co-workers developed milder 
conditions for NCL which allowed for the synthesis of homogeneous O-linked 
glycans.55 Several methods have been developed for the glycosylation of asparagine 
linked glycopeptides. Lansbury and co-workers were the first to report on a 
convergent method for the synthesis of small glycopeptides, via the conjugation of β-
glucosamine with activated asparagine on a protected peptide of 4-5 amino acids (AA) 
long. 58 Overcoming problems such as intramolecular cyclisation through 
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intramolecular reaction of the activated amino acid and the development of a 
deprotecting strategy that did not cleave the newly formed bond were some of the 
challenges they had to overcome. The limitation of this methodology is that cysteine 
needs to be present in the peptide chain. 
 
 
Scheme 2. Native chemical ligation. 
 
2.3.2 Chemoenzymetic synthesis:  
Another technique that has recently been explored for the synthesis of glycopeptides 
is a chemoenzymatic approach which uses glycosidases for transglycosylation. For a 
number of years, enzymes have been used to couple lactols to peptide backbones and 
a number of large N-glycans have been synthesised in this manner, albeit in low yield 
(ca. 5-20%)59–61 due to competing enzyme hydrolysis of the newly formed product, as 
well as limitations of using only natural N-glycans as the donor substrates. Fuijta and 
co-workers were the first to show that oxazoline donors, mimics of the presumed 
oxazolinium ion intermediate formed in a retaining glycosylation mechanism, could 
be used as donor substrates for both Endo M and Endo A to give a significant increase 
in yield (77% Endo M, 44% Endo A).62 In 2005, Wang and co-workers took this 
concept further and used Endo-A and Endo-M for the introduction of more complex 
natural and unnatural glycans to small proteins (7-34 amino acids), thereby 
broadening the substrate availability as well as allowing for higher yielding syntheses 
of large N-glycans onto small proteins (Scheme 3).63 In 2006, Fairbanks and co-
workers further extended the scope of this methodology, by using proteins which 
were released of their natural glycans. Here the glycoprotein was treated with Endo A 
which cleaved the 1,4 GlcNHAc2 glycosidic linkage to leave the singular GlcNHAc 
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residue attached to the peptide backbone, which was then used for the enzyme 
assisted glycosylation.54 
 
Chemoenzymetic synthesis of glycopeptides has provided a great tool for the 
synthesis of large well-defined glycoproteins but, even though some structural 
variations still result in product formation, the substrates which can be used are 
limited. For example chemoenzymatic introduction of an α-1-3-L-fucose bearing N-
glycan is not accessible through this method, as it does not form a substrate for any of 
the glycosyltransferase enzymes. 
 
 
Scheme 3. Wang and co-workers coupling of oxazoline donor to HIV-1 gp41 
fragment.63 
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2.3.3 Conjugation to a carrier protein 
When studying the ability of small molecules (e.g. haptens) to modulate the Th2 
response, haptens by themselves can not elicit an immune response. To be able to 
induce an immune response haptens need a carrier such as a protein that can be 
recognised by the immune system.64 Once the body has generated antibodies to a 
hapten-carrier complex, the small-molecule hapten may also be able to bind to the 
antibody. Examples of such carrier proteins are Keyhole Limpet Hemocyanin (KLH) 
and Ovalbumin (OVA).65 
 
For the conjugation of carbohydrate portions to a carrier protein such as KLH several 
methods have been developed, allowing a carbohydrate to be covalently bound either 
directly or through a linker to the protein. KLH is particularly suitable as a carrier 
protein with the presence of a large number of lysine residues containing a primary 
amine on the side chain, that are available for binding. One of the ways to directly 
conjugate a carbohydrate portion to KLH is through a reductive amination with 
NaCNBH3 as the reducing agent (Scheme 4).66 Here, the primary amine of a lysine 
residue attacks lactol 8 in the aldehyde form resulting in the formation of imine 
intermediate 9, subsequent nucleophilic attack of the hydride then results in 
glycoconjugate 10. This process results in ring opening of the terminal sugar and 
covalently binds the glycan to the carrier protein. While this has been proven to be an 
effective method for the conjugation of carbohydrates to proteins, the downside is 
that the terminal sugar is reductively aminated and the structure altered from its 
natural form. In a structure-relationship study this is not ideal. 
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Scheme 4. Conjugation of carbohydrates to a protein through reductive amination. 
 
Alternatively, a β-glycosylamines can be conjugated to a carrier protein through 
reductive amination with the addition of a linker (for instance glutaraldehyde). The β-
glycosylamines itself can be obtained through the Kotchetkov amination reaction 
(Scheme 5).67 This involves treatment of a lactol with a large excess of ammonium 
bicarbonate in water. Here, nucleophilic attack of ammonia on GlcNHAc 11 in the 
aldehyde form results in the formation of imine intermediate 12, ring closure through 
nucleophilic attack of the hydroxyl at the 5-position then gives the desired 
glycosylamine 13. A large excess of the ammonium source is used not only to push the 
equilibrium to favour the anomeric amine, but also to prevent the formation of the 
dimer side product that can be formed as a result of the β-glycosylamine reacting with 
another molecule of lactol starting material. The disadvantage of this strategy is that 
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several milligrams of fully deprotected oligosaccharide are needed for the final 
conversion to the anomeric amine, before it can be coupled.  
 
 
 
Scheme 5. Kotchetkov amination reaction to give β-glycosylamine. 
 
 
As illustrated above the reducing end of a sugar can readily be converted to an 
anomeric amine when subjected to an amine source. In a similar way N-alkylated β-
glycosylamines can readily be obtained by subjecting a reducing sugar to the desired 
aliphatic amine to give the corresponding N-alkylated β-glycosylamine in excellent 
yield.68–70 With the abundance of lysine residues on KLH it is envisioned that a glycan 
(14) can be conjugated to KLH in a similar manner without the need of an additional 
reducing agent like sodium cyanoborohydrate (15, Scheme 6). This will allow small 
quantities of oligosaccharide to be conjugated to KLH directly without altering the 
three dimensional structure of the oligosaccharide. 
 
 
 
 
Scheme 6. The direct conjugation of carbohydrates to a protein. 
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2.3.4 Glycan syntheses 
Several routes have been developed for the synthesis of complex N-glycans with each 
using a variety of protecting group manipulations (e.g. acetylation, benzylation, de-
silylation, hydrogenation and Birch reduction). Each applying key synthetic 
transformations to install the structural features present in the naturally occurring 
glycans, such as oxidation/reduction or Sn2 displacement for the inversion of stereo 
centers, and glycosylation reactions (e.g. intramolecular aglycon delivery (IAD) for β-
mannose coupling, and thiol and imidate couplings). Two representative synthetic 
routes are summarised below. 
 
In 2007, Nakano et al. synthesised complex-type glycans derived from parasitic 
helminths (Scheme 7).52 The key reactions in their synthesis were the use of IAD for β-
mannosylation, de-silylation under high-pressure, and glycosylation in frozen solvent, 
is discussed in more detail below.  
 
 
 
Scheme 7. Target glycans derived from parasitic helminths. 
 
In glycosylation reactions D-mannose favours the formation of the α-anomer as this 
leads to the favoured trans relationship between the hydroxyl at the 2-position and 
the anomeric hydroxyl.71 Therefore to form the necessary β-mannose linkage, their 
route began with the subjection of PMB-ether 17 to the IAD process using alcohol 18 
as the acceptor (Scheme 8). This led to the formation of hemiacetal 19, which 
subsequently underwent a MeOTf promoted glycosylation to liberate dissacharide 20 
as the β-mannoside exclusively (82% yield over 2 steps).  
18 
 
 
 
 
Scheme 8. Presumed reaction pathway of PMB ether assisted IAD. 72 
 
Dissacharide 20 was then subjected to a TMSOTf promoted glycosylation reaction 
with xylose imidate donor 28 or, for the synthesis of shorter fragments, acetylated 
(Scheme 9). Desilylation using HF/pyridine under high pressure then yielded xylose 
acceptor 21a and acetylated acceptor 21b, which underwent MeOTf promoted 
glycosylation with GlcMan donor 29 to yield the penta- and tetra-saccharide 
precursors 22a and 22b, respectively. p-TsOH∙H2O catalysed removal of the 
cyclohexylidene, followed by regioselective glycosylation of the 6-position with 
mannosyl chloride 30 (77-89% yield) gave hexa- and pentasaccharide 23a and 23b. 
Subsequent debenzylation, peracetylation and conversion to the trichloroacetimidate 
(TCA) gave donor 24a and 24b. Attempts were then made to conjugate donor 24a 
and 24b to a 3,6-bis-fucosylated glucose acceptor 32c, however several attempts to 
achieve this coupling resulted in no significant product formation, highlighting the 
severe steric congestion of the acceptor 4-hydroxy group. Glycosylation to a 3-O-
fucosylated disaccharide acceptor also gave poor yields (<10%). To overcome this 
problem, a more divergent strategy was adopted and a less sterically hindered 
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fucosylated acceptor (32a or 32b) was coupled to 24a/b to give the corresponding 
complex oligosaccharides (25a-d) in good yield (70-81%). With saccharides 25a-d in 
hand, acceptors 26a-d were readily obtained under mild oxidation conditions using 
DDQ/ Mn(OAc)3∙2H2O to remove the PMB protecting group. Fucosylation of acceptor 
26b and 26d with thiofucoside donor 33 proceeded smoothly, resulting in 27b and 
27d. For the fucosylation with the 6-O-fucosyl bearing acceptors 26a and 26c 
however, moderate yields were obtained and a large excess of donor (5 equiv.) had to 
be used. In addition, poor separation of acceptor and product made this an 
undesirable route. It was subsequently found that the glycosylation with methylthio 
glycoside 33 in p-xylene could be improved under ‘frozen conditions’ (whereby the 
reaction in p-xylene was cooled to 4°C to freeze the solvent and slow down the 
reaction) and this resulted in near full conversion of acceptors 26a and 26c into 27a 
and 27c, respectively. Oligosaccharides 25a, 25c, 26b, 26d and 27a-d were then 
subjected to global deprotection in a uniform manner (i.e, sequential 
dephthaloylation, acetylation, O-deacetylation, and debenzylation) to provide the 
target structures 16a-h. 
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Scheme 9. i TMSOTf, 28, 68%; ii Ac2O, Py, DMAP, 97%; iii HF∙Py, 1GPa, 88-89%; iv 29, MeOTf, DTBMP, 79-
94%; v TsOH∙H2O, 86-91%; vi 30, AgOTf, 77-89%; vii Pd(OH)2, cyclohexene–EtOH–AcOH (2:1:1); viii Ac2O, 
Py, 93-94% (2 steps); ix N2H4∙AcOH; x DBU, Cl3CCN, 74-75% (2 steps); xi TMSOTf, 31a or 31b; xii DDQ, 
Mn(OAc)3∙2H2O, 64-81% (2steps); xiii MeOTf, DTBMP, 32, 80-92%; xiv (H2NCH2)2; xv Ac2O, Py; xvi NaOMe, 
MeOH; xvii Pd(OH)2, aq MeOH, H2, 68-88% (4 steps). 
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In 2006, Fairbanks and co-workers prepared a series of oxazoline donors,54 which 
could be used subsequently in Endo-A and Endo-M mediated chemoenzymatic 
syntheses.73 Key steps in this approach were the installation of the 1,4 β-D-Man-D-
GlcpNAc linkage via epimerisation of glucose disaccharide substrates by sequential 
triflation and Sn2 nucleophilic substitution, according to the methodology of Schmidt 
and Boons,74,75 direct oxazoline formation from the O-p-methoxyphenyl protected N-
acetyl glucosamine and efficient endohexosaminidase catalysed glycosylation of a 
synthetic β-D-GlcpNAcAsn glycosyl amino acid. Again, a specific example is outlined 
below. 
 
Target oxazoline 33 was obtained in 5 steps from protected precursor 34 (Scheme 
10), via sequential dephthaloylation, acetylation, catalytic hydrogenolysis, acetylation 
and treatment with acetyl bromide, BF3∙OEt2, and zinc iodide. Hexasaccharide 34 itself 
was obtained by a [3+3] glycosylation methodology involving the TMSOTf-mediated 
glycosylation between the reducing trisaccharide 36 and mannose-capping residue 
35.  
22 
 
 
 
Scheme 10. Retrosynthesis [3+3] coupling 
 
Preparation of the reducing end trisaccharide 36 commenced with the selective 
glycosylation of diol 38 on the 3-position using a TMSOTf promoted glycosylation 
with mannose imidate donor 37 to give 39 as the α-product selectively (Scheme 11). 
Protection of the 2-position as the levulinic ester then yielded glycosyl donor 39. 
Glycosylation of glucosamine acceptor 40 with the thioglycoside 39 by activation with 
MeOTf yielded the β-trisaccharide 41 in good yield and again complete control of the 
anomeric stereochemistry due to neighbouring group participation. Removal of the 
levulinoyl ester was achieved with hydrazine acetate (H2NNH2∙AcOH), triflation of the 
liberated 2-position and subsequent nucleophilic substitution by treatment with n-
Bu4NOAc in toluene under sonication yielded trisaccharide 42. Finally, removal of the 
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4,6-benzylidene protecting group using aqueous acetic acid yielded the key diol 
acceptor 36. 
 
  
 
Scheme 11. i TMSOTf, 50%; ii Levulinic acid, DCC, DMAP, 99%; iii MeOTf, 77%; 
iv H2NNH2∙AcOH, 89% v (a) Tf2O, Py, (b) n-Bu4NOAc, 90% (2 steps) vi aq AcOH, 
86%. 
 
To prepare the required mannose capping residue (35), benzyl mannoside 43 was 
treated with trimethylorthobenzoate and p-TsOH in acetonitrile to yield a bis-
orthoester, which was subsequently hydrolysed by exposure to aqueous 
trifluoroacetic acid (TFA) to give the 2,4-di-O-benzoate 44 (Scheme 12). 
Bisglycosylation of diol 44 by treatment with boron tri-fluoride diethyl etherate and 
an excess of trichloroacetimidate donor 45 then yielded trisaccharide 46 in 89% 
yield. Removal of the benzyl protecting group by catalytic hydrogenolysis followed by 
treatment with trichloroacetonitrile and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) 
then gave donor 35.  
 
24 
 
 
 
Scheme 12. i (a) PhC(OMe)3, TsOH, (b) 10% aq TFA, 46% (2 steps) ii BF3∙OEt2, 
89%; iii H2, Pd (10% on C), 76%; iv DBU, Cl3CCN, 92%. 
 
 
2.4 Target N-glycans 
To determine how different N-glycans influence the Th2 immune response, the 
heptasaccharide (Figure 4), and structural versions thereof, will be synthesised, and 
screened for their ability to modulate the Th2 response. To provide an optimum Th2 
immune response, the glycan will be conjugated to a carrier protein (KLH). To this end 
the focus of this Masters thesis is the synthesis of heptasaccharide 48a, two 
hexasaccharide derivatives bearing either the β-D-xylose 48b or the α-L-fucose 48c 
capping residues, the inner core Man3GlcNHAc2 48d, and the xylose trimer 47 (Figure 
4). KLH has been chosen as a protein carrier since it contains 300-600 lysines 
available for conjugation and is also highly antigenic, stimulating a strong CD4+ T cell 
response. 
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Figure 4. Synthetic targets.  
The proposed retrosynthetic analysis for the preparation of glycans 48a-d is provided 
in Scheme 13. Here, the target glycans 48a-d are obtained from their fully protected 
counterparts via reduction of the azide and subsequent acetylation and global 
deprotection. The protected glycans 49a-d are in turn formed via a [5+2] or [5+1] 
coupling between TCA-donor 50 and fucosylated acceptor 51 or 52, respectively. 
Though Nakano et al. reported poor yields (<10%) when attempting a similar [6+2] 
coupling when using a 3-O-fucosylated disaccharide acceptor, we anticipated that by 
using more electron donating protecting groups (e.g. benzyls, and silianes) a better 
glycosylation yield could be obtained and thus a more convergent (and shorter) 
strategy could be achieved. Donors 50a and b, are in turn obtained via a bis-
glycosylation of 53 with 54a or 54b, respectively, and subsequent protecting group 
manipulations. Trisaccharide 54a can be obtained by the coupling of xylose donor 56 
with disaccharide 55, itself formed via the glycosylation reaction between 52 and 57 
with subsequent inversion of the stereochemistry at C2’ via an oxidation/reduction 
protocol and protecting group manipulations. Building blocks 52, 53, 56, and 57 are 
in turn derived from their parent saccharides in 3-6 steps. Target 47 can be obtained 
from fully protected saccharide 54a via reduction of the azide and subsequent 
acetylation and global deprotection. 
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Scheme 13. Retrosynthesis of target N-glycans. 
  
27 
 
Chapter 3: Results and discussion 
3.1 Synthesis of tetra and penta-saccharide precursors 
3.1.1 Overview 
A key aspect of this MSc thesis is the synthesis of the non-reducing end of the target N-
glycans 58a and 58b and the coupling of this to the GlcNAc monomer 52 or dimer 51 
to prepare the larger N-glycans (Scheme 14). Formation of 58a-b could be achieved 
via the glycosylation of ManGlc dimer 55, (previously prepared as part of the 
candidate’s Bachelor of Science degree) with mannose imidate 53, and xylose donor 
56 when necessary. The focus of the first part of this report concerns the synthesis of 
key tetra- and pentasaccharide, 58a and 58b, respectively. 
 
 
 
Scheme 14. Retrosynthesis of the key tetra- or pentasaccharide. 
 
3.2 Synthesis of di- and trimer acceptor precursors 
The first step in the strategy, was to prepare the ManGlc core required for the 
synthesis of the non-xylosated N-glyans (Scheme 15). To this end, it was envisioned 
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that ManGlc dimer 55 could be benzoylated at the 2-postion of the mannose residue 
as this would provide a protecting group that could be efficiently removed during the 
global deprotection strategy at the end of the synthesis. Accordingly, ManGlc dimer 55 
was first treated with benzoyl chloride (BzCl) and 4-dimethylaminopyridine (DMAP) 
in pyridine to give an overall concentration of dimer in pyridine of 5.0 mL/mmol. 
Following work-up and purification by gradient flash chromatography, this gave 
benzoylated dimer 54b in a 72% yield. Though this result was acceptable, it was 
thought that the reaction yield could be improved if the reaction was performed at a 
higher concentration (2.5 mL/mmol) and, in addition, if the BzCl was added drop-wise 
to the solution at 0 °C. Indeed, using these conditions, benzoylated dimer 54b was 
obtained in an excellent yield of 92%. 
 
 
Scheme 15. Benzoylation ManGlc Dimer 54b. 
 
Having prepared the core building block required for the formation of the non-
xylosylated N-glycans, we then turned our attention to finding a suitable xylose donor 
for the preparation of the xylosylated N-glycans. To this end, thio donor 61 was first 
prepared from D-xylose 59 in 2-steps (Scheme 16). This derivative was initially 
chosen due to its ease of synthesis, with an acetate being chosen at the 2-position to 
ensure β-linkage through neighbouring group participation.76 Thus, D-xylose 15 was 
peracetylated using Ac2O and NaOAc to give pyranoside 60, from which the β-anomer 
could be selectively recrystallized using PE/EtOAc (1:2) in 30% yield.77 Whilst the 
yield for 60 was only modest, this is in agreement with literature reported yields, and 
the crystallinity of 60 ensures a cheap and practical route to this building block.77 
Thus, xylose peracetate 60 was treated with tin tetrachloride (SnCl4) and ethanethiol 
to give thioglycoside 61 in good yield (70%).78 
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Scheme 16. Synthesis of thioglycoside donor. 
 
Having successfully prepared thioglycoside 61, attempts where then made to couple 
this to ManGlc acceptor 55 (Scheme 17). In glycosylation reactions, hydrolysis of the 
donor is common problem in the presence of trace amounts of water. To minimise 
hydrolysis, acceptor 55 and xylose donor 61 were thus co-evaporated three times 
with toluene under an argon atmosphere prior to commencing the reaction. This is 
undertaken to azeotropically remove the last traces of water. In addition, the CH2Cl2 
used in the reaction was freshly distilled over phosphorus pentoxide (P2O5) prior to 
use, and 4Å molecular sieves, activated by heating under a high vacuum, were added 
to the reaction before the promoter was added. Having undertaken these steps, N-
iodosuccinimide (NIS) (1.5 equiv.) and TfOH (1%) were thus added to a solution of 
thioglycoside 61 and ManGlc acceptor 55 at -50 °C. There was no appreciable change 
in the reaction, which was unusual since the formation of a red solution is indicative of 
an activated thio donor. Accordingly, the reaction was allowed to warm to room 
temperature and an additional portion of TfOH (2%) was added. Upon the addition of 
the addition TfOH, a colour change to dark red was indeed observed, however no 
product formation could be detected, as gauged by TLC analysis. The reaction was left 
for a further 24 h, but after work up, only donor, hydrolysed donor, and unreacted 
acceptor were isolated. This finding tended to suggest that although formation of the 
required oxocarbenium ion had occurred, (62, Figure 5), the required glycosylation 
reaction at the 2-position of mannose residue was slow, as evidenced by the formation 
of hydrolysed donor. Given the poor reactivity of the acceptor, a more reactive xylose 
donor was prepared. 
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Scheme 17. Attempted at the glycosylation reaction of ManGlc acceptor with 
thiodonor 17. 
 
 
 
 
Figure 5. Mechanism of thioglycoside donor activation with NIS and TfOH.  
 
Trichloroacetimidates are valuable glycosyl donors that can be activated under mild 
conditions and have been successfully used for the preparation of a variety of complex 
carbohydrates.52,54,79,80 The most common type of imidate used is the 
trichloroacetimidate, however, more recently, an N-phenyl trifluoroacetimidate has 
been synthesised as this is less prone to immidate rearrangement.81 The disadvantage 
of using an N-phenyl trifluoroacetimidate, however, is that unlike the 
trichloroacetimidate, which is readily prepared using commercially available 
tricholoracetonitrile, trifluoroacetimidoyl chloride must first be synthesised. As we 
had an interest in preparing both xylose imidates to compare how these performed in 
glycosylation reactions with ManGlc acceptor 55, trifluoroacetimidoyl chloride 67 
was thus obtained in a one-pot procedure (Scheme 18). Here, triphenylphosphine, 
CCl4, and triethylamine were added together followed by the drop-wise addition of 
trifluoroacetic acid (TFA) at 0°C. Aniline was then added drop-wise and the reaction 
initiated by gentle heating at which point white solids could be observed in the flask. 
Following completion of the reaction, dry hexanes were added and the resulting solids 
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filtered and washed. The mother liquer was then concentrated and the crude oil 
purified by vacuum distillation (52-54°C, 8 mbar) to give trifluoroacetimidoyl chloride 
67 in 42% yield.82 Mechanistically, first chloride 63 forms via nucleophilic attack of 
the Ph3P on the carbon of CCl4 (Scheme 18). Second, nucleophilic attack of TFA on the 
phosphonium cation then forms intermediate 64, aniline then reacts with the 
carbonyl carbon of 64 to form 65. Imine formation followed by nucleophilic attack on 
another portion of phosphonium cation then forms imine 66, Finally, displacement of 
Ph3P=O with chloride then results in trifluoroacetimidoyl chloride 67.  
 
 
 
Scheme 18. Reaction mechanism for the formation of trifluoroacetimidoyl 
chloride 67. 
 
Having successfully prepared, trifluoroacetimidoyl chloride 67, both xylose imidate 
donors 69 and 70 were then prepared (Scheme 19). Starting from intermediate β-
acetate 60, the anomeric acetate was selectively removed using H2NNH2·H2O and 
glacial AcOH (1/1) to give lactol 68 in 60% yield. Treatment of lactol 68 with Cl3CCN 
and DBU in CH2Cl2 then gave trichloroacetimidate 69 in a good (80%) yield.83 In a 
similar manner, lactol 68 could be treated with N-phenyl trifluoroacetimidoyl chloride 
and caesium carbonate (Cs2CO3) to give the desired xylose imidate 70 in 89% yield.84  
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Scheme 19. Total synthesis xylose donors. 
 
With xylose donors 69 and 70 in place, attempts were then made to conjugate either 
donor to ManGlc acceptor 55 (Scheme 20). Again, all care was taken to ensure the 
reaction was free from traces of water and the donor and acceptor were co-distilled 
with toluene (3 x) prior to use. The first glycosylation reaction attempted involved the 
reaction of 55 with trichloroacetimidate 69 (Entry 1, Table 2). A sub-stoichiometric 
amount of TMSOTf (3%) was used and the reaction was kept at 0 °C for the duration 
of the reaction. After 75 min, TLC analysis of the reaction showed a higher running 
product (Rf = 0.56, 3/1, toluene/EtOAc, v/v), though as imidate donor 69 was still 
present, an additional portion of TMSOTf (3%) was added. This resulted in complete 
disappearance of the donor by TLC analysis and following work-up, the desired 
trisaccharide 54a was obtained in 31% yield. Although an optimum yield was not 
obtained these results were encouraging, thus the reaction was repeated with donor 
69 (entry 2, Table 2), this time using more activator (4%). Again the reaction was 
allowed to warm to room temperature and although formation of the desired product 
was observed via TLC analysis, product degradation was also observed, as evidenced 
by the presence of lower running products by TLC analysis which were subsequently 
determined to be trimer 54a lacking the PMB ether and/or the benzylidine protecting 
group. Nevertheless, following aqueous work-up and purification by gradient flash 
chromatography, the desired trimer 54a was obtained in an improved (46%) yield. 
Although an improved yield was obtained this was not ideal with the degradation of 
product observed, and we therefore decided to explore the glycoylation of ManGlc 
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acceptor 55 with N-phenyl trifluoroacetimidate donor 70 to determine if this would 
lead to improved yields. Acceptor 55 was thus glycosylated with imidate 70 using 2% 
TMSOTf (Entry 3). TLC analysis, however, revealed the presence of unreacted donor 
and acceptor, and additional TMSOTf was added to the reaction mixture. Following 
work-up and purification, this approach, however, only gave a 20% yield of 
trisaccharide 54a. With no significant improvement of yield we continue our 
glycosylation studies with the trichloro imidate donor 69.  
 
 
Scheme 20. ManGlc dimer glycosidation. 
 
Entry Donor Equivalents  Conditions Scale Product 
yield 
Additional 
activator 
1 69 3.5 3% TMSOTf 
0°C  rt 
0.15 g 
acceptor 
31% 3% TMSOTf 
2 69 3.3 3.3% TMSOTf 
0°C  rt 
0.40 g 
acceptor 
46% 4% TMSOTf  
3 70 2.6 2.0% TMSOTf, 
0°C 
0.11 g 
acceptor 
20% 2%, 1% 
TMSOTf 
4 69 1.5 +2.5 2.5% TMSOTf, 
0°C  rt 
0.22 g 
acceptor 
70% 2.5% 
TMSOTf 
5 69 3.5 2.5% TMSOTf, 
0°C  rt 
1.15 g 
acceptor 
72% - 
Table 2. Attempt at forming xylose trimer 54a. 
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With the best yield obtained with donor 69 so far, the manner in which the donor was 
added to the reaction vessel was explored (entry 4, Table 2), and in addition, the 
TMSOTf was freshly distilled prior to use to ensure the quality of this regent. Indeed, 
by adding imidate 69 in two portions to the reaction vessel, an improved (70%) yield 
of trisaccharide 54a was observed. (Table 2, entry 5). Encouraged by this result, 
freshly distilled TMSOTf (2.5%) was thus added to a solution of donor 69 and ManGlc 
acceptor 55 in CH2Cl2 and the reaction allowed to warm to room temperature (entry 
5, Table 1). Indeed, this strategy resulted in a good (72%) yield of the desired 
trisaccharide 54a, for which the identity was confirmed by HRMS [calcld. for 
[C61H76Cl3NNaO20Si]+: 1298.3688, obsd.: 1298.3687]. To confirm that the desired β-
anomer was formed, a combination of 1D (1H and 13C) and 2D (HH-COSY, HSQC and 
HMBC) NMR spectroscopic analyses were performed. In the 1H NMR, a coupling of 
J1’’,2’’ = 8.1 Hz was observed for the xylose anomeric proton, which is consistant with 
the formation of the β-linkage. A correlation between C-1’’ and H-2’ in the HMBC 
confirmed linkage to the 2-position of the mannose residue (Figure 6).  
 
 
Figure 6. Correlation between C-1’’ and H-2’ in the HMBC spectrum .  
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3.3 Synthesis of the di and trimer acceptor 
Having successfully obtained trisaccharide 54a and disaccharide 54b, synthesis of 
diol acceptor, suitable for coupling with the mannose imidates to form the mannan 
capping residues, could then be explored. This involved removal of the para-
methoxyphenyl ether and selective ring opening of the benzylidine to give the free 6’-
OH. 
 
First, investigations into the synthesis of the non-xylosed N-glycans was explored 
(Scheme 21). Accordingly, ManGlc dimer 54b was treated with 5,6-chloro-2,3-cyano-
1,4-benzoquinone (DDQ) in CH2Cl2/H2O to give benzylidine protected dimer 71 in 
77% yield (rf = 0.44 Pe/EtOAc, 2/1 v/v). Here, it should be noted that careful 
monitoring of the reaction by TLC was required as prolonged reaction times resulted 
in the loss of a benzyl protecting group, as evidence by the formation of a lower 
running product on TLC (Rf = 0.31, Pe/EtOAc, 2/1 v/v) and LRMS [calcld. for 
[C42H52Cl3NNaO13Si]+: 934.2, obsd.: 934.2]. Selective ring opening of the 4´,6´-
benzylidine to the free 6´-OH position proved more difficult and several attempts 
were made to achieve this transformation. The use of BH3.THF and Cu(I)Cl in CH2Cl2 
gave only starting material despite prolonged reaction times and the use of additional 
portions of the reagents, while the use of BH3.THF and Bu2BOTf.THF in CH2Cl2 
resulted in cleavage of the benzylidine and TBDMS protecting groups. A change to 
triethylsilane (Et3SiH) and dichlorophenyl borane (PhBCl2) however, gave the 
corresponding diol dimer 72 in good (81%) yield. HMBC analysis was used to confirm 
that the desired product had formed with a correlation between C-4’ and the CH2 of 
the benzyl group observed (Figure 7).85 The regioselectivety of this reductive ring 
opening arises from coordination of PhBCl2 to the less sterically hindered 6-hydroxyl, 
followed by reduction to give the desired 4-O-Bn.85 
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Scheme 21. Synthesis diol acceptor 72. 
 
 
Figure 7. HMBC long range coupling between CH 2 and 4’ .  
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Diol acceptor 74 was then obtained using a similar strategy as that for acceptor 72 
(Scheme 22). Thus, xylose trimer 8 was treated with DDQ in CH2Cl2/H2O to give the 
selectively deprotected trimer 73 in 62% yield (Scheme 22). Again, the reaction 
should be carefully monitored to avoid additional debenzylation under extended 
reaction times. Selective ring-opening of the benzylidine group in 73 was then 
attempted. Trimer 73 was thus subjected to Et3SiH and PhBCl2 in CH2Cl2 and the 
reaction stirred at -78°C for 2 hr. Following work-up and purification by gradient flash 
chromatography, a disappointing (50%) yield of diol 74 (Rf = 0.46, 2/1, 
toluene/EtOAc, v/v), was obtained. In addition to the desired product, a side-product 
was also isolated (~ 35% yield), which was later identified as the deacetylated product 
(Rf = 0.14, 2/1, toluene/EtOAc, v/v) by NMR, with the absence of one of the acetates 
and (lower molecular weight MS, calcld. for [C51H68Cl3NNaO18Si]+: 1138.3163, obsd.: 
1138.3167). During the course of the reaction, this by-product was initially mistaken 
for the desired product by TLC analysis and the reaction was thus left to stir for a 
longer time than required, thus accounting in part for the low yield of 74. In addition, 
only a small Rf difference between starting material (Rf = 0.49, 2/1, toluene/EtOAc, 
v/v) and product (Rf = 0.46, 2/1, toluene/EtOAc, v/v) also meant that care needed to 
be taken when analysing the reaction by TLC so as to not mistake the desired product 
for starting material. With this knowledge, the reductive ring-opening of the 
benzylidine was thus repeated though this time, the reaction was quenched after 40 
min, and following aqueous work-up and purification, trisaccharide 74 was obtained 
in a much improved 82% yield. As with dissacharide 72, conformation that the 6’-
position contained the hydroxyl was achieved via 1D and 2D NMR analysis. 
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Scheme 22. Preparation of trisaccharide acceptor 74. 
 
3.4 Bis-glycosylation with Mannose imidate donor 
The next step in the reaction sequence involved installation of the mannose capping 
residues. First, attempts were made to couple mannose imidate 53 to the recently 
prepared disaccharide 72 to form the core mannose-capped tetrasaccharide 58b 
(Scheme 23). Synthesis of the mannose imidate 53 itself can be achieved in seven 
steps starting with D-mannose.79,86 This building block was previously prepared by 
other members of the candidate’s research group and was thus readily available in the 
laboratory. 
 
 
Scheme 23. Coupling of the mannose imidate donor to acceptor 72. 
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The first attempt at forming tetrasaccharide 58b involved the coupling of acceptor 72 
with five equivalents of imidate donor 53 using TMSOTf (2%, 8 µl of a 0.1M stock 
solution) as the activating agent. The reaction was started at -40 °C then allowed to 
warm to room temperature. Under these conditions, however, no product was 
observed by TLC analysis and only a lower running spot (corresponding to hydrolysed 
donor) was noted. The reaction was then cooled to -45 °C and two additional portions 
of TMSOTf (1.5% after 1 h and 2% after 3 h) were then added and the reaction 
allowed to warm to 0 °C in an attempt to generate the desired tetrasacharide. 
Unfortunately, there was no significant product formation by TLC analysis, so an 
additional 2% TMSOTf was added (at 0 °C). This resulted in complete disappearance 
of the dissacharide acceptor 72 on TLC and a major product running higher than the 
diol acceptor by TLC analysis was observed. Following an aqueous work-up, 1H NMR 
of the crude reaction mixture indicated that the desired tetrasaccharide had been 
formed, however, the complexity of the spectra and the presence of more than one 
product made it difficult to determine this with certainly. Attempts were then made to 
purify the complex product mixture by silica gel gradient flash chromatography, 
however, this proved problematic. Accordingly, size exclusion chromatography 
(Sephadex® LH-20, bead size 25-100µ) was attempted as it was thought that, in 
addition to the desired bis-mannosylated product 58b, mono-manosylated products 
(e.g. 75a and 75b, Scheme 24), were formed. Fortunately, size-exclusion 
chromatography did allow for partial purification of tetrasaccharide in modest (ca. 
45%) yield; (HRMS (ESI) m/z calcld. for [C117H124Cl3NNaO25Si]+: 2098.7189, odsd.: 
2098.7188). The two side products, however, eluted together (Rf = 0.50, 
CH2Cl2/EtOAc, 20/1 v/v) suggesting that they were of similar size, with high 
resolution mass spectrometry confirming the presence of mono-glycosylated products 
(HRMS (ESI) m/z calcld. for [C83H92Cl3NNaO19Si]+: 1532.4991, odsd.: 1532.4993). 
Another attempt was then made at synthesising tetramer 58b, this time taking into 
account the previous results which indicated that activation of the imidate donor 53 
required > 5% of TMSOTf, with the reaction occuring at 0 °C. In addition, to encourage 
the reaction to go to completion, an additional portion of donor (0.5 equiv.) was added 
after TLC analysis indicated complete disappearance of the imidate donor and the 
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presence of a mono-glycoslated product. Indeed, using this approach, only minor 
traces of the trimer were observed and the desired tetrasaccharide 75 could be 
obtained in excellent (91%) yield with following purification by silica gel gradient 
flash chromatography.  
 
 
 
Scheme 24. Bisglycosylation to form tetrasaccharide 58b. 
 
Though a benzoyl participating group at the C-2 position of imidate donor 53 is 
expected to give the desired α-product, this needed to be confirmed. Here, 1H NMR 
could not provide conclusive proof as to the stereochemistry of the newly formed 
glycosylated linkages as both α- and β-mannoses give a small coupling constant for 
the anomeric proton (J1,2 = >2 Hz). Pedersen and co-workers, however, have shown 
that the 1JC1,H1 coupling constant can be used to determine the anomeric 
configuration.87 For β-anomers, a JC1,H1 of ca. 160 Hz is observed, whereas the α-
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anomers have a 1JC1,H1 of ca. 170 Hz.87 Detailed analysis of 1D and 2D NMR spectra of 
tetrasaccharide 58b thus enabled all 1H and 13C resonances of the molecule to be 
assigned and a 13C-1H coupled HSQC provided the coupling constants for the [13] 
and [16] mannose residues (Figure 8). For 13 linked mannose, a coupling of 
173.0 Hz was observed, while for the 16 linked residue, a coupling of 173.1 Hz was 
seen, thus confirming that the desired α-linkage was obtained for both mannose 
capping residues.  
 
 
Figure 8. Coupled HSQC proving the desired α -linkage was formed.  
 
Having successfully prepared tetrasaccharide 58b, it was thus expected that similar 
bis-glycosylation conditions could be used for the synthesis of target pentasaccharide 
58a (Scheme 25). Accordingly, five equivalents of mannose donor were added to a 
solution of acceptor 74 in CH2Cl2 at 0 °C and to this TMSOTf (5.5%) was added. 
Multiple products were observed by TLC analysis, though there was no trace of both 
acceptor 74 or mannose donor 53. The reaction was then quenched with sat. aq. 
NaHCO3 and the products separated by gradient flash chromatography, followed by 
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size exclusion chromatography, to reveal the presence of both the desired 
pentasaccharide 58a as well as the mono-glycosylated product 76. Tetrasaccharide 
76 was identified to be the 16 mannosylated product by NMR spectroscopy with a 
coupling between the H-1’’’ and the C-6’’ observed, in the HMBC which is not 
surprising given the greater reactivity of the less sterically hindered primary 6-
hydroxyl compared to the secondary 3-hydroxyl. Having illustrated that 
pentassacharide 58a can be formed, the reaction was then repeated, again using 5 
equivalents of imidate donor 53, though this time an additional 0.5 equivalents of 
mannose donor 53 was added after 1.5 h to ensure that the reaction had gone to 
completion. No further conversion was observed after stirring the solution for an 
additional 2 h, so the reaction was quenched and, following an aqueous work-up, 
purified by silica gel gradient flash chromatography then size exclusion 
chromatography to give pentasaccharide 58a in 66% yield. In addition, a 24% yield of 
the mono-glycosylated product 76 was obtained, indicating the difficulties of 
undertaking a bis-glycosylation on trisaccharide 74. Applying the same coupling 
conditions to mono-mannosylated product 76 then gave the desired pentasaccharide 
58a in excellent (93%) yield. Taken together, this gives a combined yield of 88% for 
pentasaccharide 58a (Scheme 25). NMR spectroscopy revealed the desired α-linkage 
was also obtained for product 58a [α-Man (13) JC1,H1 = 171.9 Hz, α-Man (16) JC1,H1 
= 172.7 Hz].  
 
Scheme 25. Synthesis of pentasaccharide 76. 
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3.5 Synthesis of the trichloro-imidate donor 
The next step in the total synthesis was the assembly of suitable donors from 
tetrasaccharide 58b or pentasaccharide 58a to be used for the subsequent 
glycosylation reactions with the reducing end mono- or di-saccharides. To meet this 
objective, the anomeric silane from tetrasaccharide 58b and pentasaccharide 58a 
needed to be removed and a suitable leaving group then introduced at the anomeric 
position. 
 
With this objective in mind, lactol 77 was thus prepared in 99% yield via the 
desilylation of tetrasaccharide 58b using 70% HF in pyridine (Scheme 26).88 To 
achieve this transformation, the protected tetrasaccharide 58b was transferred to a 
falcon tube, dissolved in THF (freshly distilled over sodium wire), and a solution of 
70% HF in pyridine added to the reaction vessel. The reaction was then left to stand 
until clean conversion was observed by TLC analysis (Rf = 0.31, 1/1, Pe/EtOAc, v/v). 
Using this approach, an excellent (99%) yield of the desired lactol was obtained 
following work up with sat. aq. NaHCO3, and purification by gradient flash 
chromatography. A solution of lactol 77 in CH2Cl2 was then subjected to 
trichloroacetonitrile and DBU and the reaction stirred at room temperature for 75 
min at which point complete disappearance of starting material was observed and a 
higher running product was formed by TLC analysis (Rf = 0.22, 2/1, PE/EtOAc, v/v). 
Given that the transformation into trichloracetimidate 50b appeared to occur 
smoothly by TLC analysis, it was thus surprising to find that, after work-up and 
purification by gradient flash chromatography, only a 54% yield of the desired 
tetrasaccharide imidate 50b was isolated. Analysis of other material that eluted from 
the column in more polar solvents, however, saw recovery of significant amounts of 
impure hydrolysed donor. Imidates are reactive intermediates which can be 
hydroysed under mildly acidic conditions, and thus it was believed that the silica 
column had catalysed hydrolysis of imidate 50b during purification. To overcome this 
problem, 1% triethylamine solution can be used to neutralize the column prior to the 
subjecting the crude reaction to gradient flash chromatography, however, as sufficient 
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material was obtained for the subsequent coupling reaction, attempts were first made 
to forge forward with the synthesis rather than spending time on optimising the yield 
for the imidate formation. 
 
 
 
 
Scheme 26. Formation of trichloroimidate donor 50b.  
 
With the trichloracetimiate donor 50b in hand, an attempt was made to conjugate this 
with FucGlc acceptor 51 using TMSOTf as an activator (Scheme 28). To this end, a 
solution of imidate 50b and FucGlc acceptor 51 were co-distilled with toluene (3 x) 
then dissolved in CH2Cl2 and the solution cooled to –40°C prior to the addtion of 
TMSOTf (5%, via the addition of 6 µL of a 0.1 M stock solution in CH2Cl2). Shortly after 
addition of the activator, TLC analysis showed two higher running products (Rf = 0.59, 
Rf = 0.49 6/1, toluene/EtOAc, v/v) and remaining imidate donor. An additional 
portion of TMSOTf (25%, 30 µL at 0 °C) was then added which resulted in the 
complete disappearance of the donor. The reaction was then quenched, via the 
addition of triethylamine, the solvent removed under reduced pressure, and the crude 
reaction purified by gradient flash chromatography (PE/EtOAc, 5/14/1 v/v) to 
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provide pure samples of the two higher running products, as well as unreacted 
acceptor and hydrolysed donor. NMR and mass spectrometry analysis then allowed 
the higher running product to be identified as the desired hexasaccharide 49c [HRMS 
(ESI) m/z calcld. for [C157H167Cl3N4NaO33Si]+: 2792.0240, odsd.: 2792.0244]. Coupled 
HSQC was used to confirm that the desired -linkage was obtained (JC1’’,H1’’ = 158.0 Hz) 
as it was impossible to conclusively determine the configuration by 1H NMR due to the 
complexity of the 1H spectrum. HRMS of the lower running product revealed an 
identical molecular weight to that of the desired imidate donor 50b, however, the 1H 
NMR spectra did not match that of the imidate with no distinct NH signal at 8.5 ppm 
and was therefore believed to be the rearranged imidate. Rearranged imidates are not 
uncommon when using tricholoracetimates donors for difficult glycosylation 
reactions,81 and their formation can be readily be explained, when a imidate is 
activated (78, Scheme 27) the imidate group leaves as an amide (80) during the 
course of the glycosylation reaction and can then subsequently react with donor 
starting material (79) to result in the formation of a rearranged imidate (81).  
 
 
Scheme 27. Mechanism of rearranged imidate formation. 
 
 
Overall, 15% of the desired fucose containing hexasaccharide 49c, and 19% of the 
rearranged imidate, were isolated. Even though only a moderate yield of 
hexasaccharide 49c was obtained, this was nonetheless promising as Nakano et al. 
reported no significant product formation (<10%) when using a similar acceptor. 52 
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Scheme 28. First attempt at the [4+2] coupling. 
 
Given the generation of the rearranged imidiate during the glycosylation of 
tetrasaccharide 50b with the FucGlcNAc donor 51, it was decided that an N-phenyl 
trifluoroacetimidate donor should be used. The more electron-withdrawing phenyl 
and trifluoromethyl groups reduce the nucleophilicity of the formed amide via 
delocalisation of the electron pair of the nitrogen and by reducing the electron density 
on the nitrogen, the amide becomes less nucleophilic, thus reducing the chance of 
rearranged imidate being formed. In addition to the electronic effect, the phenyl group 
creates more steric bulk, which also disfavours imidate rearrangement. Having 
previously synthesised the necessary trifluoracetamidoyl chloride 67 for the 
synthesis of the xylose N-phenyl trifluoroacetimidate donor, this was added to a 
solution of lactol 77 in acetone and the solution cooled to 0 °C before caesium 
carbonate (Cs2CO3) was added and the solution stirred at room temperature for 2 hr 
until there was no more starting material, as determined by TLC analysis. (0). The 
reaction mixture was then filtered over celite to remove remaining Cs2CO3 and the 
solvent removed under reduced pressure, and imidate donor 82 was subsequently 
obtained in a good (81%) yield following purifiction by gradient flash 
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chromatography. Here, it should also be noted that minor amounts of an unidentified 
side-product (Rf = 0.61, 6/1, toluene/EtOAc, v/v; HRMS (ESI) m/z odsd.: 1998.6487) 
was also formed after prolonged reaction times, though this could be circumvented by 
careful monitoring of the reaction. To reduce the acid catalysed hydrolysis of the 
target imidate during silica gel gradient flash chromatography, as was previously 
observed for the analogous tricholoracetimate, the column was pre-neutralised by 
passing one column volume of 1% triethylamine in CH2Cl2 through the column prior 
to use. 
 
 
 
Scheme 29. Formation of trifluoro imidate 82. 
 
With the N-phenyl trifluoroacetimidate donor 82 now in hand, another attempt was 
made to form hexasaccharide 49c (Scheme 30). To this end, imidate 82 and acceptor 
51 were subjected to a TMSOTf-promoted coupling reaction in CH2Cl2 with the 
reaction being activated with a sub-stoichiometric amount of TMSOTf (5%, 7.5µl of a 
0.1 M stock solution) and the resulting mixture left to react for 18 h at room 
temperature. At this point, TLC analysis indicated no product formation and the 
continued presence of donor imidate, so additional portions of TMSOTf (totalling 
greater than 1 equiv. over 3 h) were added. Unfortunately, this did not result in 
activation of the donor and the reaction was discontinued. When the solvent was 
changed to toluene and TfOH was used as activator, however, hexasaccharide 49c was 
obtained in an improved 31% yield. In addition to the desired hexasaccharide 49c, 
trehalose octamer 83 was also formed (Scheme 30), which results from the 
hydrolysed donor reacting with imidate donor 82, indicating the poor reactivity of 
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FucGlc acceptor 51. Although a relatively low yield was obtained for the target 
pentasaccharide 49c, this was deemed sufficient considering the difficult nature of the 
coupling reaction due to the steric congestion of the 3-OH on the FucGlc acceptor. In 
additon, formation of donor trehalose suggested that an alternative donor would not 
give a significant increase in product formation and therefore no further optimisation 
was attempted. 
 
 
 
Scheme 30. Improved coupling reaction.  
 
After the establishment of a suitable method for the preparation of tetrasaccharide 
donor 82 and subsequent conditions for the glycosylation reaction with the FucGlc 
donor 51, it was envisioned that the core (non-xylosyated or fucosylated) 
pentasaccharide 50d could be synthesised using similar reaction conditions (Scheme 
31). Thus, trifluoro imidate 82 and azide acceptor 52 were subjected to a TfOH-
mediated glycosylation, which resulted in the formation of two higher running 
products by TLC analysis (Rf α = 0.47, Rf β = 0.53, 6/1, toluene/EtOAc, v/v). Separation 
of the two products was achieved by careful silca gel gradient flash chromatography 
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to reveal the formation of an α/β mixture of 49d (1/1) in a combined yield of 63%. 
Formation of the α-product was unexpected as the Troc protecting group had been 
used because of its ability to favour formation of the β-anomer due to neighbouring 
group participation.89 In each instance, the anomeric configuration of the newly 
formed glycosidic bond was determine by the coupling constant from a coupled HSQC, 
whereby the α-anomer had a 1JC1’,H1’ = 176.5 Hz, where the β-anomer had a 1JC1’,H1’ = 
160.0 Hz. Additionally, a small coupling constant of 3.4 Hz was observed in the 1H 
spectrum of the α-product, which further supports the formation of the newly formed 
α-linkage. 
 
 
 
Scheme 31. Synthesis of core pentasaccharide 49d. 
 
 
Having demonstrated that the N-phenyl trifluoroacetimidate is a suitable donor for 
the glycosylation reaction of the non-xylosylated carbohydrate motifs, the 
glycosylation properties of pentasaccharide 58a containing a similar imidate donor 
were then explored (Scheme 32). To this end, pentamer imidate 85 was obtained in 
two steps from pentasaccharide 58a, the first step of which involved anomeric 
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desylilation (mediated by HF/Pyridine) to give lactol 84 in excellent (99%) yield 
according to protocols previously discussed. The trifluoroimidate leaving group was 
introduced at the anomeric centre via treatment of lactol 84 with trifluoracetamidoyl 
chloride 67 and Cs2CO3 in acetone at 0 °C. Purification of the crude product, obtained 
as a yellow oil after work-up and removal of the solvents under reduced pressure gave 
target donor 85 in good (80%) yield. Though this yield was good, it should also be 
noted that, in a similar manner to the previously prepared N-phenyl 
trifluoroacetimidate, prolonged reaction times resulted in the formation of an 
unknown side product (Rf = 0.61, 6/1, toluene/EtOAc, v/v), and thus the reaction (84 
 85) had to be be monitored carefully by TLC. It should also be noted that a pre-
neutrilised silica column was used during the purification step.  
 
 
 
  
Scheme 32. Pentasaccharide donor 85 formation. 
 
The next step in the synthetic strategy was the synthesis of xylose hexasaccharide 49b 
via a [5+1] coupling reaction between donor 85 and azide acceptor 52 (Scheme 33). 
To this end, trifluoro imidate 85 and azide acceptor 52 were subjected to a TfOH 
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mediated glycosylation reaction in toluene which resulted in the formation of a higher 
running product by TLC analysis (Rf = 0.34, 6/1, toluene/EtOAc, v/v). NMR analysis of 
this product revealed that although the target hexassacharide had been formed in 
70% overall yield, this consisted of a 1:1 α:β mixture with an coupling of 3.4 Hz 
observed in the 1H spectrum and a coupling of 1JC1’,H1’ = 171.6 Hz in the coupled HSQC. 
Despite several attempts to separate the anomers by silica gel gradient flash 
chromatography, this could not be achieved at this stage of the synthesis and the 
hexasaccharide 50b was thus used in the subsequent reaction as an α/β mixture. 
 
 
 
Scheme 33. Synthesis of xylose baring hexa saccharide 50b.  
 
The last remaining target was heptasaccharide 49a, which was accessible via TfOH-
mediated [5+2] glycosylation between donor 85 and FucGlc acceptor 51 (Scheme 33). 
Again, traces of water where azeotropically removed from donor and acceptor with 
toluene (3 x) prior to use. In the first attempted glycosylation reaction, the imidate 
donor was activated at -40 °C using TfOH (1% as 0.1 M stock solution). After 45 min 
TLC analysis revealed some hydrolysed donor, suggesting activation of the donor, and 
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also the presence of remaining donor. Accordingly, additional portions of TfOH were 
added, however after work-up and purification, no product was isolated. Having 
observed better results when performing imidate couplings at 0°C and bearing in 
mind that a more stable imidate was used in this reaction, the coupling reaction was 
repeated though this time activation was achieved using 2% TfOH at 0 °C. These 
conditions resulted in complete disappearance of donor 85 and the starting material 
after 3 hr, and the formation of what initially appeared to be two products (Rf = 0.32 
and 0.43, Pe/EtOAc, 2/1, v/v). Following work-up and gradient column 
chromatography (toluene/EtOAc, 2%  6%) the acceptor could be separated from 
the two products, however, NMR analysis of these products revealed the presence of 
three products, of which the major was identified to be the desired heptasaccharide 
49a. Following careful silica gel gradient flash chromatography, the top product (Rf = 
0.43) was identified as heptasaccharide 49a, though unfortunately this contained a 
small amount of an unidentified side product which couldn’t be separated from the 
target product despite several attempts. Separation of a second by-product, however, 
was achieved, and this product was tentatively assigned using HRMS (ESI) (HRMS 
(ESI) m/z [C115H118Cl3NNaO30]+ calcd.: 2120.6696 odsd.: 2120.6777) to be 
trichloroethoxyoxazoline 86 (Scheme 34), which can be formed by participation of the 
troc protecting group. In 2005, Imamura et al. reported on the formation of an 
oxazoline by-product for some of their reactions and using TLC analysis, observed that 
the oxazoline was an intermediate in all of their coupling reaction.90 Imamura also 
showed that the isolated the oxazoline could be coupled in absence of an activator to 
give the desired product in good yield (85%). It was therefore believed that a 
prolonged reaction time at a higher temperature and the use of more activator would 
reduce the formation of oxazoline side product. Accordingly, the coupling reaction 
was repeated, though this time additional TfOH (5% ) was added at 0°C, after which 
time the reaction was allowed to warm to room temperature. Additional TfOH was 
added during the course of the reaction (5% after 3 h and 2.5% after 7 h) and the 
reaction was left to react for a total of 12 h. This resulted in the formation of 
heptasaccharide 49a in addition some oxazoline was still formed though, given the 
53 
 
difficulty of this [5+2] glycosylation, it was deemed that enough of the desired 
heptasaccharide had been obtained. 
 
 
 
Scheme 34. Trifluoroimidate coupling. 
 
3.6 Deprotection strategy 
Given the lengthy synthesis of the protected oligossacharides and the low yields 
obtained for some of the glycosylation reactions, a short and convergent deprotection 
strategy was desired so that sufficient quantities of the target N-glycans could be 
obtained. Here, the protected amines needed to be converted to their acetamide 
counterparts, then the aromatic, ester, and anomeric silane protecting groups needed 
to be removed. In addition, it is known that the α-L-fucose glycosidic bond is 
susceptible to hydrolysis under acidic conditions91 and thus strongly acidic conditions 
for the deprotection steps needed to be avoided. With the objective of preparing a 
variety of truncated substrates that could be coupled to KLH for biological 
assessment, the deprotection methodology was first developed on the small di- and 
tri-saccharide motifs, and then later extended to the more complex and larger 
oligosaccharides. 
 
54 
 
 
3.6.1 Conversion of the Troc- and azide-protecting amines to acetamides. 
The 2,2,2-trichloroethoxycarbonyl (Troc) group can be reductively removed by 
activated zinc under mildly acidic conditions (Scheme 36). One acid commonly used 
for this purpose is acetic acid66,92 and accordingly, this was the first strategy used for 
the attempted conversion of the fully protected reducing end GlcGlc disaccharide 87 
into its N-acylated counterpart 89 (Scheme 36). Here, oxidative insertion of the zinc 
into the carbon chloride bond of 87 followed by elimination results in the formation of 
amine 88 and 1,1-dichloroethene and CO2 (g), subsequent acetylation then results in 
89. Troc-protected dimer 87 was thus dissolved in THF and to this activated zinc (2.5 
equiv.) and acetic acid (20 equiv.) added. When no product formation was observed 
by TLC analysis after 8 h, additional portions of acetic acid (70 equiv.) and zinc (20 
equiv.) were added. Unfortunately, despite prolonged reactions times (48 h), none of 
the desired amine intermediate 88 was formed.  
 
 
 
 
Scheme 35. Zinc reduction of the 2,2,2-trichloroethoxycarbonyl. 
 
 
55 
 
Grozinger and co-workers have shown that the Troc protecting group could be 
removed under mildly basic conditions using ammonium acetate (pH 7.2), or mildly 
acidic conditions using disodium hydrogen phosphate (Na2HPO4, pH 6.5) or potassium 
dihydrogen phosphate (KH2PO4, pH 4.5), to give the desired amine products.93 Mildly 
basic conditions were preferred due to the potential liability of the α-L-fucose 
glycosidic bond and these conditions were thus attempted first. To this end, Troc 
protected dimer 87 was dissolved in THF and activated zinc and a solution of 1 M 
ammonium acetate in H2O was added. Though some product had been observed after 
48 h, there was still starting material present, as evidenced by TLC analysis, and all 
zinc had oxidised. Accordingly, additional portions of activated zinc and acid were 
added, but unfortunately, the reaction did not go to completion. Repeating the 
reaction with 1 M disodium hydrogen phosphate gave similar results, however, the 
use of 1 M potassium dihydrogen phosphate gave clean conversion (by TLC analysis) 
of Troc-protected dimer 87 into the corresponding amine. The reaction mixture was 
diluted with EtOAc, filtered over celite to remove the unreacted zinc, then 
concentrated in vacuo. Acetylation of the crude reaction mixture then gave acetamide 
89 in 64% overall yield following purification by gradient flash chromatography 
(Scheme 36). Along with the desired product, a side product containing acyl-groups at 
the 3’, 4’ and 6’-positions of the terminal glucose residue was also formed. As no 
baseline material was observed during the zinc reduction, it was believed that this 
side-product was formed during the work-up of the reaction. As both the PMB ether 
and benzylidine group are acid labile protecting groups, it was believed that the crude 
reaction mixture had become acidic when concentrated in vacuo and that this led to 
the formation of the triol which was subsequently acetylated. To overcome this 
problem, the crude reaction mixture can be co-concentrated with pyridine. 
 
 
Scheme 36. Reductive removal of the Troc protecting group. 
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Having successfully converted the Troc-protected disaccharide 87 to the N-acylated 
derivative 89 using zinc and disodium hydrogen phosphate for the reduction step, 
similar methodology was thus used for the conversion of trisaccharide 54a to the 
acetamide 90 (Scheme 37). Here, trisaccharide 54a was subject to 30 equivalents of 
zinc in a 5:1 solution of THF:1 M Na2HPO4 in H2O. After 24 h, TLC analysis revealed the 
formation of two products that could both be stained by ninhydrin on a TLC plate, 
thus suggesting the presence of an amine functional group in each product. Though 
initially confusing, the formation of the two products by TLC was later attributed to 
protonation/deprotonation of the product on silica, as is frequently observed when 
working with free amines. The crude reaction mixture was then diluted with EtOAc, 
filtered over celite, and pyridine added before concentrating so as to ensure the 
reaction did not become too acidic which would lead to a compromise in yield. The 
resultant oil was then subjected to pyridine:Ac2O (2:1) for 24 h. after which EtOAc was 
added and the organic layer was washed with with sat. aq. NaHCO3 to remove 
remaining Ac2O. The solvent was then removed in vacuo and the residue purified by 
silica gel gradient flash chromatography to give acetamide 90 in a good (87%) yield. 
 
 
 
Scheme 37. Conversion of the Troc protected amine to the N-acetate. 
 
Having established good conditions for the conversion of the Troc-protected amine to 
the acetamido functionality, attention was focused on converting the azide-protected 
amine to its acetamido counterpart for the more complex oligosaccharides. When 
considering methodology to achieve this transformation, it was noted that Block and 
co-workers successfully developed a strategy which enabled the Troc and azide 
functionalities of one molecule to both be converted to their corresponding amines by 
way of a zinc reduction with AcOH/Ac2O in THF.94 As illustrated above, the 
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methodology that allowed for the removal Troc group from disaccharide 87 was 
similar to that used by Block, and thus it was envisioned that these may also lead to 
the conversion of an azide into a protected amine. To explore this hypothesis and 
avoid experimentation on the more complex, and more difficult to synthesise, 
oligosaccharides, azide 91 (prepared by the candidate during his batchelor’s degree 
programme)95 was used as a model substrate. Accordingly, azide 91 was dissolved in 
THF and activated zinc was added, followed by 1 M aq. Na2HPO4. Gratifyingly, this 
resulted in the smooth transformation into amine 92 (Scheme 38). Acetylation of the 
crude reaction mixture under standard conditions then gave acetamide 93 (85% 
yield), thus illustrating the potential of this methodology for the dual reduction of 
both a Troc-protected amine and an azide.  
 
 
 
Scheme 38. Zinc-mediated azide reduction.  
 
With the successful conversion of azide 91 to its N-acylated counterpart using 
activated zinc and 1 M aq. Na2HPO4 and the use of similar methodology for the 
deprotection of Troc-protecting groups (e.g. 54a  90, Scheme 37, pg 56), attempts 
were then made to convert fucose hexasaccharide 49c to its N-acylated counterpart 
94. To this end, hexasaccharide 49c was dissolved in THF and activated zinc (30 
equiv.) and 1 M Na2HPO4 was added. Further equivalents of zinc and acid were then 
added after 3 h and again at 5 h and 7 h, at which point no further product formation 
was observed by TLC. The reaction was then filtered, the solvent reduced in vacuo, 
and the residue resubmitted to the reduction conditions (60 equiv. Zn, THF/ 1 M 
Na2HPO4, 5/1 v/v). This resulted in complete disappearance of the starting material 
and the subsequent subjection of the crude amide to standard acetylation conditions 
then gave hexasaccharide in 53% yield following purification by silica gel gradient 
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flash chromatography. As longer reaction times were needed, a variety of by-products 
were also formed which could not be resolved by NMR and HRMS. Accordingly, the 
reduction was repeated, though this time fucose hexasaccharide 49c was reacted with 
activated zinc (250 equiv.) as in previous reactions additional portions of zinc had to 
be added each time and rather than using 1 M Na2HPO4, 1 M KH2PO4 was used, as this 
reagent gave a faster conversion in the reaction of dimer 87 to 89 (Scheme 35, pg 54). 
The reaction was stirred for 2 h at room temperature, at which point TLC analysis 
revealed the complete disappearance of starting material, the solution was then 
filtered, the solvent removed in vacuo and the resulting crude oil subjected to 
pyridine/Ac2O (2/1). Using these conditions, acetamide 94 was obtained in 64% yield 
with still some of the unknown side product formed. Although this was not a big 
improvement in yield, the shortened reaction time meant that KH2PO4 was preferred 
choice of acid. 
 
 
 
Scheme 39. Acetamide formation. 
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Using the optimised reduction conditions, pentasaccharide 49d was then reacted with 
activated zinc in THF/1M KH2PO4 (5/1, v/v), which resulted in the complete 
disappearance of the starting material and the formation of one product by TLC 
analysis after 1.5 h (Scheme 40). Acetylation of the crude (pyridine/Ac2O, 2/1) then 
gave penta acetamide 95, albeit in a disappointing 29% yield. In addition to the 
desired N-acylated amine, a mixture of products was obtained though these could not 
be identified by NMR and/or HRMS analysis. The formation of side products can 
potentially be attributed to acidification of the crude upon concentration in vacuo as 
pyridine was not added at this stage. Although the yield of 95 was disappointing, 
sufficient material was obtained and due to the interests of time and the amount of 
starting materials available, a decision was made to forge ahead with the synthesis 
without further optimisation of this reaction. 
 
 
 
 
Scheme 40. Zinc reduction of Troc and azide to the acetamide of the core penta 
saccharide.  
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The next oligosaccharide to be converted to its N-acylated counterpart, was 
hexasaccharide 49b. As described previously (see Scheme 33, page 51), the [5+1] 
coupling resulted in an inseparable mixture of the - and - xylosylated 
hexasaccharide 49b. Given that conversion of the Troc and azide functionalities in 
49b to an N-acetylated amine would result in a more polar product, it was anticipated 
that better separation could be achieved after this transformation. To this end, the 
anomeric mixture 49b was converted to the corresponding acetamide by subjecting 
xylose hexasaccharide 49b to the zinc-mediated reduction with activated zinc in 
THF/1 M KH2PO4 (5/1, v/v) (Scheme 41). This resulted in the formation of two 
products by TLC analysis. Acetylation of the crude product mixture under standard 
conditions then gave an - and -mixture of 96 in 48% yield following silica gel 
gradient flash chromatography, and a higher running by-product, which unfortunately 
could not be identified. Having obtained 96, separation of the desired -anomer could 
now be achieved via careful silica gel chromatography using a long single gradient 
column (PE/EtOAc, 1/1 v/v).  
 
 
 
Scheme 41. Zinc-promoted reduction of the amine protecting groups. 
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The final substrate to undergo the zinc-mediated reduction was heptasaccharide 49a 
(Scheme 42). Using the standard conditions developed, [zinc in THF/1M KH2PO4 (5/1, 
v/v)], three products were observed by TLC analysis after 7 h, and the reaction was 
then diluted with EtOAc, filtered over celite, and concentrated in the presence of 
pyridine. Reaction of the resultant crude oil with pyridine/Ac2O (2/1) then gave 
heptasaccharide 97 together with a side product (product/byproduct, 4.3/1).  
 
 
 
Scheme 42. Zinc reduction of target hepta saccharide 49a.  
 
 
3.6.2 Global deprotection 
Having successfully prepared the N-aceylated oligosaccharides, the final step in the 
reaction sequence was global deprotection of each of the specific substrates. Here, it 
was envisioned that the aromatic protecting groups could be removed by a dissolving 
metal reduction and that by subsequently adding methanol to the reaction flask, 
sodium methoxide would be formed in situ, which would lead to the removal of the 
ester protecting groups (acetate or benzoate). Removal of the anomeric silane was 
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then thought to occur via the use of HF/pyridine (as previously discussed, e.g. see 
Scheme 26, pg 44). 
 
To this end, acetamide 89 was dissolved in THF and liquid ammonia was then added 
(via the use of a cold trap), followed by the addition of sodium until the blue colour of 
the solution remained (Scheme 43). The solution was then stirred for 45 min, at which 
point methanol was added and the solution allowed to warm to room temperature 
while stirring. To neutralise the reaction, DOWEX® H+ resin was added, and the 
solution was then filtered and concentrated under reduced pressure. To our surprise, 
analysis of the resulting oil by 1H NMR spectroscopy revealed that the fully 
deprotected disaccharide 43 had been formed. Here, the acidic DOWEX® H+ had 
unexpectedly cleaved the anomeric silane and as a result, the fully deprotected 
product was obtained in a highly efficient manner. Following purification by reverse 
phase (HyperSep C18 column), disaccharide 43 was obtained in an excellent (99%) 
yield.  
 
 
 
Scheme 43. One pot three step deprotection. 
 
With the global deprotection strategy in place, an attempt was then made at 
deprotecting xylose acetamide 90 (Scheme 44). The benzyl pprotecting groups of 
Xylose acetamide 90 were thus reductively cleaved, followed by the addition of 
methanol to the reaction vessel and then neutralisation with DOWEX® H+. This time, 
removal of the anomeric silane was incomplete and a 1/1 mixture of silane protected 
trisaccharide 100 and deprotected trimer 99 was observed. Separation could readily 
be achieved by reverse phase chromatography (HyperSep C8 column) with fully 
deprotected trimer 99 eluting first in H2O (52% yield), followed by silane protected 
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trimer 100 eluting in 50% methanol (48% yield). Removal of the tert-
butyldimethylsilane was then achieved by dissolving the silane-protected trimer in 
MeOH (0.3 mL) to which approximately 20 kernels of DOWEX® H+ resin were added.96 
The flask was then left to stand for two days, and following purification by (HyperSep 
C8 column), deprotected trimer 99 was obtained in an excellent (99%) yield. When 
combined with the 52% yield initially obtained for the synthesis of 99, this gives a 
quantitative yield for the global deprotection strategy. 
 
 
Scheme 44. Deprotection of trisaccharide 90. 
 
 
Acetamide 94 was then subjected to the global deprotection strategy using the 
general methodology previously highlighted (Scheme 43), though multiple additions 
of sodium were required to maintain the blue colour of the solution during the 
reduction (Scheme 45). Surprisingly, NMR analysis of the crude reaction mixture 
revealed multiple products, some of which contained aromatic groups, thus indicating 
incomplete reduction of the starting material. The crude reaction mixture was then 
resubmitted, though this time a flow of argon was applied over the reaction vessel to 
ensure that the reaction remained free from H2O. Following work-up, purification of 
the crude residue by C8 reverse phase chromatography revealed the formation of two 
major products, though these were not separable. Further purification of the products 
using a long C18 column however, enabled the products to be separated under the 
conditions tried. HRMS indicated that the product that eluted first was the 
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defucosylated pentamer 102 (35% yield), and that the second product to elute from 
the column was the desired fucose hexasaccharide 101 (37% yield). The formation of 
defucosylated product can be explained by the prolonged exposure to DOWEX® H+.  
 
 
Scheme 45. Deprotection of fucose hexasaccharide 94. 
 
 
The next oligosaccharide to be deprotected was pentasaccharide 95. To this end, 95 
was dissolved in THF and liquid ammonia added, followed by sodium (Scheme 46). 
The reaction was kept blue for 1.5 hour via the addition of sodium, when required, 
after which time methanol was added and the reaction left to stand for 15 min. The 
remaining ammonia was removed under vacuum, then the remaining solution was 
neutralised with DOWEX® H+ and concentrated. Purification of the crude residue by 
reverse phase (HyperSep C8 column) and Biorad P2 size exclusion gel then gave fully 
deprotected pentamer 102 in a good yield (70%).  
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Scheme 46. Global deprotection of the pentasaccharide. 
 
The next oligosaccharide to be deprotected was xylose hexasaccharide 96 (Scheme 
47). Therefore 96 was subjected to dissolving metal conditions for 1.5 hours, then 
quenched with MeOH and the resulting solution allowed to warm up to room 
temperature and the excess ammonia to evaporate. After 1.5 hours the solution was 
neutralised with DOWEX® H+ and left for an additional 30 min, then filtered and 
concentrated. NMR analysis of the crude product revealed what appeared to be the 
presence of silane remaining. Therefore the crude material was resubjected to 
DOWEX® H+ for an additional 30 min to remove the remaining silane. Purification of 
the crude residue by reverse phase Biorad P2 size exclusion and gel (HyperSep C8 
column) then gave fully deprotected hexasaccharide 103 in a 65% yield. 
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Scheme 47. Global deprotection of xylose hexasaccharide 
 
 
The final product to be fully deprotected was heptasaccharide 97 (Scheme 48). Here 
NMR also suggested the presence of two products with the same mass as the fully 
protected heptasaccharide. Acetamide 97 was thus subjected to the global 
deprotection strategy using Birch-reduction, followed by quenching with MeOH and 
left to warm up to room temperature to remove remaining ammonia. The solution 
was then neutralised with DOWEX® H+, as for hexasaccharide 61 (see Scheme 45, pg 
64) loss of the α-L-fucose was observed, the reaction was left for 10 min followed by 
filtration and concentration in vacuo. NMR analysis of the crude revealed some silane 
still present confirmed by HRMS [(ESI) m/z calcld. for [C51H90N2NaO34Si]+: 1325.5036, 
odsd.: 1325.5057] and therefore resubjected to DOWEX® H+ in MeOH for 20 min. 
Purification by Biorad P2 size exclusion an reverse phase (HyperSep C18 column) 
then gave heptasaccharide 104 in 65% yield. 
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Scheme 48. One pot global deprotection of heptasacchatride 97. 
 
3.7 Conclusion 
In summary, the five target structures have been synthesised, in a total of 20 steps in 
the longest linear sequence. Although some of the yields were moderate, this was 
nevertheless a notable achievement in itself. It was shown that the trifluoroimidate 
wasa good leaving group in the [4+1], [4+2], [5+1] and [5+2] coupling reactions. This 
approach allowed for the formation of the target structures in a more convergent 
manner than has been previously described in the literature for these type of 
structures. In addition, a highly efficient global deprotection strategy was developed 
whereby the target structures were fully deprotected, in only two steps, from their 
fully protected counterparts. Key in the deprotection was a dual reduction for the 
conversion of both the Troc- and azide-protected amines to the free amine in a one 
pot procedure. Second, a one pot global deprotection strategy for the removal of all 
aromatic protecting groups, ester protecting groups and the anomeric silane was 
found.  
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3.8 Future direction 
Future direction of this work could investigate whether the target structures do 
indeed stimulate the immune system towards the Th 2 immune response, as 
hypothesized. In order to do this, the glycans must be conjugated to a carrier protein. 
If these structures show good immunological activity further research into whether 
more truncated versions of the full structure also induce the allergy specific response 
would be warranted. Figure 9 shows potential targets for further study. 
 
 
Figure 9. Potential targets for future study.  
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Chapter 4: Introduction to azasugars 
4.1 Azasugars: an overview 
Since the isolation of nojirimycin (105, Figure 10) in 1966,97 there has been much 
interest in iminosugars (or azasugars) due to their broad biological activity.98,99 
Azasugars are structural analogues of normal sugars and contain a nitrogen atom in 
the ring rather than an oxygen atom. Nojirimycin, a six-membered azasugar (or 
piperidine), was first isolated from Streptomyces roseochromogenes and later from 
Streptomyces nojiriensis.100 It is a potent inhibitor of α- and β-glucosidases and has 
anti-microbial activity. It took another ten years, however, before the first five-
membered azasugar (or pyrrolidine) was isolated, this being 2,5-dihydroxymethyl-
3,4-dihydroxypyrrolidine (DMDP, 106) was isolated from the leaves of Derris 
elleptica.101 DMDP has shown good inhibitory activity towards several glycosidases 
including α- and β-glycosidases. In addition to the five- and six-membered azasugars, 
there are three more classes of naturally occurring azasugars: the pyrrolizidines (e.g. 
casuarine 107, isolated from Casuarina equisetifolia L.),102 the indolizidines (e.g. 
swainsonine 108, isolated from Swainsona canescens),103 and the nortropanes (e.g. 
calystegine A3 109, isolated from Calystegium sepium).104 All have interesting and 
varied glycosidase activities.98 
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Figure 10. Examples of the different classes of azasugars.  
4.1.1 Azasugars as glycosidase inhibitors 
Glycosyl hydrolases are an important class of enzymes that play a role in many 
processes in the human body, and, not surprisingly, are therefore implicated in a 
variety of diseases105,106 including cancer,21 Gaucher’s disease,22 viral and bacterial 
infection and diabeties.20 Glycosidases catalyse the hydrolysis of glycosidic bonds (I) 
to release smaller carbohydrate motifs (III) (Figure 11). Key in this hydrolysis is the 
formation of an oxocarbenium ion containing transition state (II). At physiological pH, 
azasugars are protonated and thus have an ability to mimic this positively charged 
oxonium ion intermediate and bind to the active site of the glycosidase.  
 
 
Figure 11. Cartoon representing the enzymatic hydrolysis of 
carbohydrates.  
71 
 
The therapeutic potential of azasugars is primarily due to their ability to mimic 
oxocarbenium ion transition states of glycosidase reactions.13 Glyset (110, Scheme 
49) and Zavesca (111, Scheme 49), which are deoxy-derivatives of nojirimycin, are 
used for the treatment of non-insulin-depended diabetes and function by inhibiting α-
glycosidase, thus slowing down the breakdown of starch into glucose during the 
digestion process.20 The naturally occurring 3,4-dihydroxy-2,5-dihydroxymethyl-
pyrrolidine (106, DMDP) and its analogues have also shown an ability to selectively 
inhibit glycosidases. This inhibitory activity has been attributed to a close 
conformational resemblance of 106 to the presumed half-chair conformation of the 
oxocarbenium transition state formed in certain glycosyl hydrolases (Figure 12).13,107 
In particular, DMDP shows strong inhibition against α- and β-glucosidases, and weak 
inhibition for α-L-fucosidase. In contrast, polyhydroxy-pyrrolidine 112 (Scheme 49) 
shows strong inhibition of α-L-fucosidase and only mild inhibition towards α- and β- 
glucosidases. It is this specific biological activity of each isomer that has lead to much 
interest in the synthesis and testing of pyrrolidines over recent years.99 
 
 
 
Scheme 49. Examples of potent azasugars. 
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Figure 12. Comparison of DMDP with the oxocarbenium transition 
state generated during the hydrolysis of α - and β-glycosides.108–110  
 
4.2 Previous syntheses of azasugars 
Given the therapeutic potential of azasugars, it is not surprising that a number of 
routes have been develop for their synthesis. Each strategy includes various key 
synthetic transformations such as radical reactions, aldol reactions, Michael additions, 
Wittig reactions, reductive amination, substitution reactions, ring-closing metathesis 
(RCM), and allylic alkylation. Details about these approaches can be found in a number 
of recent reviews on the subject matter.111–114 Of particular focus of this MSc thesis is 
the synthesis of 2,5-dihydroxymethyl-pyrrolidines via a protecting-group-free (PGF) 
approach. To place this work into context, a survey of some recent syntheses of 
related compounds is discussed below. 
 
4.2.1 The synthesis of pyrrolidines using protecting groups 
In 2006, Trost et al. illustrated the potential of a palladium catalysed asymmetric 
allylic alkylation for the synthesis of a variety of iminosugars including 2,5-
dihydroxymethyl-3,4-dihydroxypyrrolidine (+)-DMDP 106, (–)-bulgecinine 113 and 
(+)-broussonetine G 114 (Scheme 50).115 In this work a process known as dynamic 
kinetic asymmetric transformation (DYKAT) was used to convert a racemic compound 
into a single enantiomer. Here, the starting material exists in an equilibrium and only 
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one enantiomer reacts. This means that the racemic starting material can be 
converted into a single chiral product and, in theory, 100% conversion can be 
achieved.  
 
 
 
Scheme 50. The synthetic targets of Trost et al.115 
 
To achieve their target syntheses, Trost et al. used DYKAT to prepare the key synthetic 
precursor 121 (Scheme 51). In this work, a palladium catalysed DYKAT reaction of 
phthalimide 115 and butadiene monoxide (116), mediated by the addition of chiral 
ligand 122 was performed. This led to the generation of enantio-pure alcohol 117 in 
excellent yield and enantioselectivity (99% yield, 94% ee). Removal of the 
phthalimide protecting group and subsequent cyclisation with triphosgene then 
afforded oxazolidinone 118, which was subjected to a second palladium catalysed 
DYKAT reaction to yield diene 119, again in excellent yield and enantioselectivity. 
Diene 119 was then protected with a benzyl group to give 120, with this protection 
being necessary in order to achieve the subsequent ring closing metathesis (RCM). 
RCM of 120 was then achieved using Grubbs’ second-generation catalyst to form the 
key intermediate dihydropyrrole 121. 
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Scheme 51. i 0.4 mol-% [(η3-C3H5)PdCl]2, 1.2% (R,R)-122, 1% Na2CO3,CH2Cl2, 
room temp., 12 h, 99% (94% ee); ii ethylenediamine, EtOH; iii triphosgene, 
NaHCO3, 71% (2 steps); iv 1% [Pd2dba3], 3% (R,R)-11, 1% DBU,CH2Cl2, room 
temp., 8 h, 91% (dr = 93:7); v NaH, BnBr, TBAI; 84% vi 3x 0.4 mol-% Grubbs II 
cat., CH2Cl2, 91%. 
  
From key intermediate 121, (+)-DMDP was synthesised in 5-steps and in an overall 
yield of 22% (Scheme 52). Here, intermediate 121 was hydrolysed, followed by 
selective protection of the secondary amine as the benzylcarbamate to give 2,5-
dihydropyrrole 123. Epoxidation of 123 with methyltrioxorhenium (MTO) then gave 
124 as a single diastereomer due to hydroxyl direction, which was subsequently 
hydrolysed under acidic conditions to give the trans-diol, followed by palladium-
catalyzed hydrogenolysis of the CBz to afford (+)-DMDP 106.  
 
 
Scheme 52. i NaOH, EtOH/H2O 3:1, reflux; ii BnOCOCl, NaHCO3, Na2CO3, H2O, 0 
°C, 99% (2 steps); iii 0.4 mol-%MTO, urea∙H2O2, CH2Cl2, 40 °C, 91%; iv TFA, THF, 
H2O, 65 °C, 72%; v Pd/C, H2, HCl, MeOH, 96%. 
 
75 
 
(–)-Bulgecinine 113 was also readily obtained from common intermediate 121 
(Scheme 53). For this synthesis, selective hydroboration-oxidation of 121 with 9-
borabicyclo(3.3.1)nonane (9-BBN), sodium hydroxide and hydrogen peroxide gave 
125 as a single product due to the steric influence of the 6-O-benzyl. Sequential 
protection of the secondary hydroxyl with a benzyl group gave carbamate 126, which 
was hydrolysed, and the resulting amine subsequently protected to afford benzyl 
carbamate 127. The synthesis was completed by way of a TEMPO oxidation of the 
primary alcohol to the carboxylic acid followed using global deprotection by 
palladium-catalyzed hydrogenolysis to give 113 in a total of 12-steps and 18% overall 
yield.  
 
 
 
Scheme 53. i 9-BBN, NaOH, H2O2, 75%; ii NaH, BnBr, TBAI, THF 92%; iii NaOH, 
EtOH/H2O 3:1, reflux; iv BnOCOCl, NaHCO3, Na2CO3, H2O, 0 °C, 85% (2 steps); v 
TEMPO, NaOCl, KBr 75%; vi Pd/C, H2, MeOH 95% (2 steps). 
 
 
In 2006, Fernández and co-workers reported on an improved syntheses of DMDP 106 
and 2,5-dideoxy-2,5-imino-D-glucitol DGDP 128 by applying an effective 
intramolecular benzyl protection/delivery system (Scheme 54).116 The synthesis 
started by subjecting D-fructose-derived acetonide 129 to α,α’-dibromoxylene (130) 
to afford 3-O-(2- bromomethyl)benzyl ether 131 in excellent (91%) yield. Selective 
acid-catalyzed hydrolysis of the 4,5-O-isopropylidene group then provided diol 132, 
which was activated by treatment with NaH in N,N-dimethylformamide (DMF) to give 
alcohol 133 containing a fused eight-membered ring between the C-3 and C-4 
positions. Conversion of 133 into the iodide and subsequent treatment with sodium 
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azide then gave azide 134 with overall retention of stereochemistry. Removal of the 
acid labile protecting groups in 134 and catalytic hydrogenation then resulted in a 
one-pot reductive amination-cyclisation to yield DMDP 106 in a total of seven-steps 
and an impressive 61% overall yield. Formation of azide 135 with inverted 
stereochemistry at the 5-position, formed through azide substitution of the triflate 
derived from 133, led to the preparation of DGDP 128 in 6-steps and an overall yield 
of 55%.  
 
 
 
Scheme 54. i NaH, DMF 91%; ii 60% aq. AcOH, 45 °C, 87%; iii NaH, DMF 93%; 
iv I2, PPh3, imidazole, toluene 80 °C, 98%; v NaN3, DMF, 80 °C 91%; vi Tf2O, Py, 
CH2Cl2, rt; vii NaN3, DMF, rt, 83% (2 steps); viii Pd/C, H2, 4 bars, HCl, MeOH-H2O 
2:1, 95% for 106, 96% for 128.  
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4.2.2 The protect-group-free (PGF) synthesis of pyrrolidines: 
To date, two different approaches have been used for the synthesis of pyrrolidines 
without the need of protecting groups. In 2005, Lindström et al. devised an extremely 
efficient PGF asymmetric synthesis by applying a double epoxidation approach to give 
azasugars 136 (Scheme 55).117 Later, in 2009, the group of Stocker and Timmer 
developed a PGF I2-mediated carbamate annulation approach for the synthesis of a 
variety of pyrrolidines.118 
 
The asymmetric approach developed by Landström et al. provided pyrrolidine 136 in 
only 4-steps from cheap, commercially available 1,6-dibromodiene 137, and in an 
overall yield of 60% (Scheme 55). In this route, subjection of 137 to a modified 
Sharpless asymmetric dihydroxylation gave diol 138 in good yield and excellent 
enantioselectivity. The allylic position was then hydrolysed to yield triol 139. 
Formation of epoxide 140 proved more difficult and several attempts were made to 
obtain the desired product, when triol 139 was subjected to catalytic dinuclear 
peroxotungstate, epoxide 140 was obtained in excellent yield and selectivity (99%, 
92% ds). Finally, displacement of the bromide with ammonia by subjecting 140 to 
10% ammonia in water resulted in spontaneous cyclisation and gave pyrrolidine 136 
in 88% yield. Remarkably, all reactions were performed in water and showed 
excellent selectivity. 
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Scheme 55. I AD-mix α, NaHCO3, Me-SO2NH2, H2O/t-BuOH (1:1), 0 °C, 70% 
(97% ee); ii H2O, 50 °C, 98%; iii H2O2, cat.K2[W2O3(O2)4(H2O)2], H2O, rt, 99%, 
(92% ds); iv 10% NH3/H2O, 4 h, 88%. 
 
In the PGF synthesis of hydroxyl-pyrrolidines, the group of Stocker and Timmer 
developed two new reaction methodologies, the first being a reductive amination 
using ammonia as the nitrogen source, and the second involving an I2-mediated 
carbamate annulation.111,118–121 An illustrative example of this approach is given in 
scheme 57, whereby 1,4-dideoxy-1,4-imino-L-lyxitol 141 was prepared in five steps 
with an overall yield of 55%.118 Here, D-ribose 142 was subjected to Fisher 
glycosylation, followed by selective iodination of the primary hydroxyl to yield methyl 
iodoglycoside 143 in 67% over 2 steps. Applying the developed Vasella reductive 
ammination gave alkenylamine 144 in an excellent (91%) yield, and carbamate 145 
was then obtained via a halocyclization/carbonylation with iodine and NaHCO3 again 
in great stereoselectivity and excellent yield (93%). Finally, hydrolyses of 145 with 
NaOH in ethanol gave 1,4-dideoxy-1,4-imino-L-lyxitol 141. 
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Scheme 56. i AcCl, MeOH, 24h; ii PPh3, I2, imidazole, THF, reflux, 2 h, 67% (two 
steps); iii Zn, NH4OAc, NH3, NaCNBH3, EtOH, reflux 18 h, 91%; iv I2, NaHCO3, H2O, 
rt, 18 h, 93%; v NaOH, EtOH, reflux, 2 h, 97%. 
 
The exact mechanism of the key I2-mediated carbamate annulation has not yet been 
determined, however three possible pathways have been proposed. It is known that 
the primary iodine is a key intermediate en route to the formation of the carbamate,122 
and from this species, the target carbamate can be formed via an aziridine 
intermediate and subsequent ring opening by CO2 (route I, Scheme 57), via 
displacement of the iodide to give a carbamate which then undergoes ring closure 
(route II), or by the formation of carbamic acid (III). Results to date indicate that the 
aziridine is not an intermediate in the reaction as subjection of an aziridine to the I2-
intermediate annulation conditions does not yield the corresponding carbamate.122 
Investigation into the other two pathways is currently on-going.  
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Scheme 57. Three possible mechanisms for the formation of the carbamate 
product. 
 
4.2.3 The PGF synthesis of piperidines 
In addition to the synthesis of pyrrolidines, the Stocker-Timmer PGF methodology 
also has been used for the synthesis of piperidines.123,124 Key in this work was the 
optimisation of a carbamate annulation that favors the formation of six-membered 
carbamate containing piperidine over the five-membered counterpart. 
 
The PGF synthesis of 1-deoxygalactonojirimycin (DGJ) 146, currently in clinical trials 
for the treatment of fabry’s disease, is discussed below (Scheme 58). When 
commercially available methyl -D-galactopyranoside 147 was treated with 
triphenylphosphine, imidazole and iodine, only a modest yield of 149 (49%) was 
obtained in addition 45% of methyl 3,6-anhydro--D-galactopyranoside was formed 
preventing purification by crystallisation. Accordingly, another route was developed 
for the formation of 149, starting from acetonite 148 via iodination, then removal of 
the acetonites followed by methylation of the anomeric hydroxyl. This route was 
preferred when multigram quantities were required as all intermediates could be 
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purified by crystalisation or distillation. Glycoside 149 was then readily converted to 
the desired alkenylamine 150 with the developed Vasella reductive amination in good 
yield (85%). When alkenylamine 150 was subjected to the carbamate annulation 
along with the desired carbamate 151a, the trans product 151b and furan 151c were 
also obtained. The best ratio (151a:151b:151c, 3:1:1) was obtained when a large 
excess of iodine was used and the reaction was performed at 50°C. Hydrolyses of 
carbamate 151a with NaOH in refluxing ethanol then gave DGJ 146, providing the 
first example of an iodine mediated-carbamate annulation used in the formation of 
piperidines. 
 
 
 
Scheme 58. i I2, PPh3, imidazole, THF, reflux; 49%; ii I2, PPh3, imidazole, THF, 
reflux; 85%; iii MeOH, HCl aq, rt, 92%; iv Zn, NaCNBH3, NH3, NH4OAc, EtOH, 
reflux, 85%; v I2, NaHCO3, H2O, 50°C; vi NaOH, EtOH, reflux, 40% from 150. 
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4.3 PGF synthesis of 2,5-dimethylhydroxy-pyrrolidines 
The objective of this work is the PGF synthesis of 2,5-dimethylhydroxy-pyrrolidines. 
These compounds have important biological activities making them attractive 
synthetic targets, and moreover, provide an interesting chiral scaffold by which to 
explore the scope and limitation of the PGF reductive amination and carbamate 
annulation strategy previously developed for the synthesis of other azasugars. 
4.3.1 Why protecting-group-free synthesis? 
As illustrated, many elegant syntheses have been developed for the synthesis of 
pyrrolidines both with or without the use of protecting groups. Protecting groups are 
often incorporated into a synthesis to ‘mask’ competing reactive centres around a 
molecule, however the down-side of this approach is that the use of protecting groups 
inevitably leads to additional steps in the total synthesis. In addition, the introduction 
and removal of protecting groups leads to a loss of material (as quantitative recovery 
is not possible), and the generation of more waste.125 Another disadvantage of 
protecting groups is that organic solvents are typically required for the reaction, 
work-up and purification, again this also increases cost and waste. Thus, while many 
elegant syntheses incorporating the use of protecting groups have been reported over 
the years, there has been a growing interest in the development of PGF-
methodology.125–127 The development of a PGF synthetic strategy, however, requires 
the careful planning of reaction sequences to enable chemoselective reactions to occur 
when more than one potentially reactive functional group is present.125 
 
4.3.2 Retrosynthetic plan for the synthesis of 2,5-dihydroxymethyl-3,4-
dihydroxypyrrolidines 
The retrosynthetic plan for the PGF-synthesis of 2,5-dimethylhydroxypyrrolidines is 
presented (Scheme 59). Here, it is envisioned that the target pyrrolidine 152 can be 
obtained via the hydrolysis of carbamate 153 itself accessable by iodine-mediated 
carbamate annulation of alkenylamine 154. Whilst the stereochemistry of the newly 
formed chiral centre (C5) cannot be conclusively defined at this stage it is envisioned 
83 
 
that this will be cis to C4.120 Amine 154, in turn, is accessible through Vasella 
reductive amination of known methyl iodoglycoside 155 using ammonia as the 
nucleophile. The facial selectivity of the reductive amination will determine the 
stereochemistry at the C2 of the target pyrrolidine and it is anticipated that selectivity 
could be enhanced by the chirality at C3 and/or the use of chelating reagents. The 
required iodoglycoside 155 can readily be obtained from D-fructose 156 in 2-steps 
using known methodology.128  
 
 
 
Scheme 59. Proposed retrosynthesis of 2,5-dihydroxymethyl-pyrrolidines. 
 
As illustrated in the retrosynthetic analysis, the two key synthetic transformations 
required to prepare the target 2,5-dimethylhydroxypyrrolidine 152 are the reductive 
amination and the I2-mediated carbamate annulation. Though both methodologies 
have been previously used during the synthesis of less complex pyrrolidines,120,121 
there are a number of factors that should be considered when attempting to apply 
these methodologies to the synthesis of 2,5-sybstituted pyrrolidines and will be 
discussed below. 
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4.3.3 Reductive amination as a key step in the synthesis of 2,5-
dimethylhydroxy-3,4-dihydroxypyrrolidines 
The Vasella reductive amination developed by the Stocker/Timmer group allows for 
the synthesis of linear alkenyl amines from methyl iodoglycosides without the need 
for protecting groups. The reaction consists of two parts, the Vasella reaction to give 
the linear alkenal, followed by a reductive amination (with ammonia as the amine 
source) to give the primary amine (Scheme 60). Starting from methyl iodoglycoside 
143, the original application of this methodology can be illustrated. Here, the Vasella 
proceeds by oxidative insertion of zinc into the iodine-carbon bond to form 
intermediate 157, which undergoes reductive ring-opening to form the aldehyde 
product 158. Applying similar conditions, Madsen and co-workers were able to form 
ketone 160 from benzyl protected methyl iodoglycoside 159.128 It is envisioned that 
when applying similar conditions to known D-fructose derived methyl iodoglycoside 
155, the unsaturated ketone intermediate 161 can be formed. Both the aldehyde 158 
and ketone 161 can then be reduced via the agency of NaCNBH3 and NH3 to give the 
corresponding primary amines, 144 and 154, respectively. 
 
 
Scheme 60. The Vasella reductive amination. 
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In the reductive amination of aldehydes with ammonia, dimer formation is often 
observed (Scheme 61). Here, aldehyde 162 reacts with ammonia to form imine 163 
that is subsequently reduced to give primary amine 164. The more reactive primary 
amine 164 can then undergo another reductive amination sequence to give 165 
which is again reduced to give the undesired secondary (166) or tertiary (167) amine 
product. To avoid dimer formation, protected amines are traditionally used, which are 
subsequently removed in a later step. In 2004, Miriyala et al. had shown that a variety 
of aromatic and aliphatic ketones could be reductively aminated to the corresponding 
amine using a large excess of ammonia in ethanol as the nitrogen source. When 
applying this methodology to aldehydes only dimer products were observed.129 In 
2009, Dangerfield et al., however, were able to optimise the metal hydride/ammonia-
mediated reductive amination to give the primary amines selectively with no or 
minimal formation of the secondary amine by-product.119 This involved the use of a 
large excess of ammonia, a pH of approximately 12 and an aldehyde concentration of 
50 mM in sat. NH4OAc in ethanol.  
 
 
 
Scheme 61. Reductive amination with ammonia. 
 
While there is much precedent to suggest that the D-fructose derived methyl 
iodoglycoside 155 can be converted to the desired secondary amine without the need 
to use a protecting group, one key difference between this reductive amination and 
that used by the group of Stocker/Timmer to produce primary amines is the 
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generation of a chiral centre during the reduction of ketone 161 to amine 154. Two 
potential models to rationalise the stereoselective outcome of the reductive amination 
are the Cram chelating model,130 and the Felkin Anh model (Figure 13).131 In the Cram 
chelating model, the Zn2+ coordinates to the α-hydroxyl and imine, forming a five-
membered ring which fixes the conformation. Nucleophilic attack then takes place 
from the least hindered side (here from the top face) resulting in the formation of the 
syn-product. When applying the Felkin Anh model to the imine intermediate again the 
amine 154a is favoured. Though these models predict for α-hydroxyketones to be 
reduced anti to the chiral hydroxyl group, the presence of multiple free hydroxyls in 
155 (all of which could be involved in a chelation controlled reduction), makes it 
difficult to predict the stereochemistry at C2 at the onset of the synthesis.  
 
 
 
Figure 13. Cram-chelate and Felkin Anh model in the prediction of 
the stereochemical outcome of the reductive amination.  
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4.3.4 Carbamate annulation as a key step in the synthesis of 2,5-
dimethylhydroxypyrrolidines 
There are a number of factors to consider when applying the I2-mediated carbamate 
annulation to the synthesis of 2,5-dihydroxymethyl-3,4-dihydroxypyrrolidines. First, 
there is the stereochemistry of the annulation and in particular, how the presence of a 
substituent at C2 influences this. The second point to consider is the regiochemistry of 
the annulation and whether O- or N- cyclisation will be observed. 
 
To explain the preferred ‘cis’ stereochemistry of the annulation, a model has been 
proposed whereby the allylic hydroxyl exerts stereocontrol over the reaction.120 As 
mentioned previously (Scheme 56, pg 79), the formation of the intermediate iodide 
sets the stereochemistry of the newly formed bond, thus a model has been proposed 
whereby the iodine promoted cyclisation goes through a five-membered transition 
structure that allows the nitrogen to attack the I2-ethylene complex following a Sn2 
trajectory (Figure 14). In this envelope conformation, the hydroxyl substituent on the 
ring, depicted in blue, can be positioned in the plane of the double bond (A, O-in-
plane), or the hydrogen in the plane (B, H-in-plane). With the hydroxyl in the plane of 
the double bond there is minimal overlap between the electron-withdrawing     
  and 
reacting      orbitals. Whereas with H-in-plane conformer the electrons of the double 
bound      overlap with the hydroxyl     
 . This destabilises the I2-ethylene complex 
resulting in a higher energy transition state. As a result, in the absence of a substituent 
at the C2 possition the only product observed is the ‘cis’ product resulting from 
transition state A.  
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Figure 14. Proposed transition structure in the formation of the 
iodo-amine intermediate 
 
When the scope of this methodology was extended for the synthesis of 
aminoiminohexitols,132 however, sometimes minor amounts of the trans product were 
also observed (Scheme 62). As illustrated, treating syn-α-aminonitrile with I2 and 
NaHCO3 resulted in the smooth formation of the carbamate product with the cis-
carbamate as the only product observed (I, Scheme 62). When the anti-α-aminonitrile 
was cyclised, a slight loss in stereo-control was observed (6:1 cis:trans)(II). When 
applying the transition structure model to the cyclisation of α-aminonitriles, the 
influence that the dipole moment of the nitrile group has on the electron density of the 
amino nucleophile needs to be taken into consideration (Figure 15). For the syn-α-
aminonitriles, the transition structure with ‘O-in-plane’ results in an angle of nitrile 
dipole and the attacking lone pair of the electrons on the amine of approximately 90° 
(transition state C). Therefore the nitrile substituent does not greatly affect the 
electron density of the amine, and thus, the transition state with ‘O-in-plane’ (C) still 
dominates and exclusive formation of the cis-carbamate is observed. For the anti-α-
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aminonitrile however, the transition structure with ‘O-in-plane’ (D) places the dipole 
of the nitrile approximately 180° to the electrons of the amine. This time the nitrile 
does affect the lone pair of the attacking amine, withdrawing the electron density of 
the amine through overlap of n-σ*CCN with the amine electron pair raising the energy 
of the ‘O-in-plane’ transition state. This brings the energy of transition state with ‘O-
in-plane’ closer to that of H-in-plane, thus giving a 6:1 ratio of cis:trans.  
 
 
Scheme 62. Carbamate formation of syn- and anti- α-aminonitrile  
 
 
Figure 15. Transition state leading to the formation of carbamate  
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As illustrated, though formation of the 4,5-cis carbamate is favoured, the presence of a 
substituent at the 2-position can influence the stereochemical outcome. The theory to 
date indicates that this is due to the electronic nature of the substituent at the C-2. 
Thus, it will be interesting to see how the presence of a hydroxymethyl group, which is 
required for the synthesis of 2,5-dimethylhydroxypyrrolidines, will influence the 
annulation. In addition to stereochemical concern, the regioselectivity of the 
annulation en route to the synthesis of target 2,5-disubstituted pyrrolidine needs to be 
considered. As was illustrated in the synthesis of DGJ (Scheme 58, pg 81), competition 
between O- versus N-cyclisation resulted in the formation of the 5 and 6 membered 
rings, and similar outcome may also be observed upon attempted I2-mediated 
cyclisation of alkynalamine 154, with either pyrrolidine 167 (→ carbamate 168) or 
pyran 169 being formed (Scheme 63). Whilst it is expected that N-cyclisation to form 
the 5-membered ring would be favoured according to Baldwin’s rules,133 this outcome 
is not guaranteed and reaction conditions may need to be optimised to form the 
desired product. My finding on this will be reported in the following section. 
 
 
Scheme 63. Potential cyclisation products of the iodine promoted carbamate 
annulation. 
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Chapter 5: Results and discussion: Azasugars 
5.1 Synthesis of D-fructose derived methyl iodoglycoside 
In order to explore the PGF synthesis of 2,5-dihydroxymethylpyrrolidines, an efficient 
synthesis of the precursor methyl iodoglycoside 155 was first required. To this end, D-
fructose 156 was subjected to a Fisher glycosylation with methanol under kinetic 
conditions (Scheme 65).134 Here, a short reaction time was essential to minimise 
formation of the pyranose product and D-fructose was thus treated with sulfuric acid 
(0.9 equiv.) in methanol at room temperature for 45 min. This resulted in complete 
disappearance of starting marterial and the formation of two new products, as gauged 
by TLC analysis (Rf α/β = 0.68 and 0.54 6/4/1, EtOAc/isopropanol/H2O). To neutralise 
the reaction, DOWEX® OH- was then added,134 however after concentration, NMR 
analysis revealed a complex mixture of lower running products, none of which 
appeared to be the desired methylglycoside. This was surprising given the apparent 
clean conversion of the reaction as previously observed via TLC analysis. Accordingly, 
it was believed that the reaction was not fully neutralised upon work-up. To ensure 
the quality of the DOWEX® OH- resin used, the resin was activated overnight with 1M 
NaOH, however, when the reaction was repeated and again quenched with DOWEX® 
OH-, a similar result was observed. The choice of base for the neutralisation step was 
then altered and gratifyingly, it was found that when the reaction was quenched with 
triethylamine or co-concentrated with pyridine, the desired furanose methyl glycoside 
170 was obtained in a α/β mixture of 1:1, with only a minor amount of pyranose 171 
being the only other product observed (10/1). This product mixture was then used 
without further purification. 
 
Scheme 64. Fischer glycosylation to give methyl-α/β-D-fructofuranocide. 
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In 2006, Madson and co-workers illustrated that the 6-position of methyl glycoside 
170 could be selectively iodinated while the primary hydroxyl at the 1-position 
remained unreacted (Scheme 65).128 This selectivity arises from the steric congestion 
of the neopentylic position, making the hydroxyl at the 1 position less reactive. 
Accordingly, methyl glycoside 170 was subjected to 1.5 equivalents of iodine (1.5 
equiv.), triphenylphosphine (2.0 equiv.) and imidazole (2.0 equiv.) in refluxing THF 
for 2 h. TLC analysis revealed the formation of a single higher running product (Rf = 
0.75 CHCl3/MeOH, 5/1 v/v), which was unexpected when compared to the literature 
(Rf α = 0.67 and Rf β = 0.57, CHCl3/MeOH, 5/1 v/v). In addition, NMR analysis (1H and 
13C) did not reveal any of the desired product. With the presence of multiple free 
hydroxyls on methyl glycoside 170, it was thus thought that over iodination may have 
occurred and the reaction was therefore repeated, this time applying a shorter 
reaction time (1 h). Unfortunately, this also did not result in the formation of the 
desired product and only a higher running product (by TLC analysis) was observed. 
Madson and co-workers had reported that the iodine (in a solution of THF) was added 
drop-wise to the reaction mixture.128 Accordingly, this exact protocol was followed 
and a single product, with Rf similar to that reported, was obeserved by TLC analysis. 
Following work-up and purification by silca gel gradient flash chromatography, 
methyl iodoglycposide 155 was thus obtained in 65% yield over 2-steps  
 
 
 
 
Scheme 65. Selective iodination of methyl glycoside 170. 
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5.2 Synthesis of the alkenylamine  
Having established a good method to form the desired methyl iodoglycoside 155, 
attempts at the Vasella reduction, and the Vasella reductive amination were then 
made. In the initial Vasella reductive amination work presented by Dangerfield et al. 
(whereby an aldehyde was formed as a key intermediate),118 it was found that 
isolation of the aldehyde product was problematic and therefore formation of the 
primary amine was performed in situ.118 In the work presented herein, the 
fragmentation reaction of methyl iodoglycoside 155 with zinc under the Vasella 
conditions results in the formation of a potentially more stable ketone, and thus it was 
thought the ketone could indeed be isolated. Accordingly, methyl iodoglycoside 155 
was subjected to zinc in ethanol and a catalytic amount of acetic acid under reflux 
conditions (Scheme 66), and after two hours, complete disappearance of starting 
material was observed by TLC analysis (I). Though this result was initially 
encouraging, both high resolution mass spectrometry and NMR analysis did not reveal 
any of the desired product. In the formation of benzyl protected ketone 160 from 
protected methyl iodoglycoside 159, Madsen and co-workers performed the reaction 
at 40 °C to yield ketone 161 in 74% yield (II).128 To investigate how the temperature 
effects the reaction methyl iodoglycoside 155 was subjected to similar conditions 
starting at 40 °C, however, no conversion was observed until the temperature was 
raised to 78 °C (reflux). Again, none of the desired ketone product was observed and 
only a white insoluble solid was isolated. With no product detected from the Vasella 
reaction, the Vasella reaction with in situ reductive amination was then attempted.  
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Scheme 66. Formation of the ketone product from the fragmentation reaction 
of methyl iodoglycoside 155. I no product; II, work presented by Madson and co-
workers. 
 
5.2.1 Vasella reductive amination with Ph2CHNH2 
In the work presented by Dangerfield et al., diphenylmethylamine (Ph2CHNH2) was 
successfully used in the Vasella reductive amination to give the secondary amine. To 
investigate if the secondary amine could be formed in situ from the unprotected iodide 
glycoside 155, Ph2CHNH2 was therefore chosen as the amine source (I, Scheme 67). 
To this end, methyl iodoglycoside 155 was subjected to zinc, acetic acid, Ph2CHNH2 
(1.2 equiv), and NaCNBH3 (as the reducing agent) to yield secondary amines 172a and 
172b as a 1:1 mixture of diastereoisomers. Whilst it was difficult to determine the 
yield for this reaction due problems in removing the excess Ph2CHNH2, 172a and 
172b (Rf = 0.88 and 0.80 [(CH2Cl2/EtOH/MeOH/30% aqueous NH3, 5/2/2/1, 
v/v/v/v)/CH2Cl2 1/1 v/v] were the only products observed and the transformation 
appeared to occur smoothly. The only slightly disappointing aspect of this Vasella 
reduction amination, however, was the poor diastereoselectivity and it was hoped 
that some facial selectivity would be observed during the reductive amination. That 
said, these results are in accordance with work presented by Madson and co-workers 
who applied the reductive amination to the benzyl protected ketone 160 with 
NaCNBH3 as the reducing agent to form amine 173a and 173b (1:1, R:S)(II, Scheme 
67). In addition, Madson and co-workers illustrated that the use of 
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triacetoxyborohydride or L-selectride did not result in an improvement of the 
stereoselectivity and mainly reduction of the ketone was observed. When indium 
trichloride was used as a Lewis acid (III, Scheme 67), a slight improvement in 
stereoselectivity was observed (3:2 R:S).128 This modest improvement in 
diastereoselectivity, however, was not deemed sufficient to warrant investigation into 
similar indium-mediated reductive aminations of methyl iodoglycoside 155 at this 
stage of the synthesis. 
 
 
 
 
Scheme 67. The Vasella reductive amination.  
 
Having successfully prepared alkenes 172a and 172b, several attempts were then 
made to remove the excess amine (reverse phase HP20 column chromatography and 
silica gel gradient flash chromatography), however, this proved futile with the 
Ph2CHNH2 co-eluting with the desired product. Whilst the amount of Ph2CHNH2 used 
in the reaction could possibly be reduced to aid in this separation, it has been 
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previously observed that reductions in the amount of amine nucleophile used results 
in poorer reaction yields,135 and it was thus decided that the excess amine could be 
remove after removal of the diphenylmethyl protecting group. Removal of the 
diphenylmethyl protecting group can be achieved under acidic conditions in the 
presence of a reducing agent to quench the liberated carbocation. Accordingly, a 
mixture of 172a-b and Ph2CHNH2 were subjected to triethylsilane (Et3SiH) in 
refluxing trifluoroaceticacid (TFA).118 This resulted in the formation of the desired 
alkenylamine 154a-b in an initial 45% yield (following work-up and purification by 
flash silica gel column chromatography) together with a side-product (Fout! 
Verwijzingsbron niet gevonden.). Upon examination of the 1H NMR spectrum of this 
side-product, the presence of an internal alkene was observed, with signals at 6.01 
ppm and 5.71 ppm, each integrating for one proton. In addition, high resolution mass 
spectrometry gave a mass of 148.0897 [M+H+]. Taken together, these results suggest 
that alkene 174 was formed as a by-product during deprotection of amine 172a and 
172b. 
 
 
 
 
Scheme 68. Deprotection of diphenylmethyl protecting group. 
 
Formation of 174 can be explained by protonation of the hydroxyl at the 4-position of 
154a-b under the acidic conditions used, with subsequent Sn2’ substitution by 
nucleophilic attack of an hydroxyl at the allylic position I (175, Scheme 69). 
Alternatively, 174 can be formed via a Sn1 mechanism, whereby water leaves forming 
the allylic cation 176 which then undergoes nucleophilic attack by a hydroxyl to give 
alkene 174. When the reaction time was shortened to 3 hours, instead of overnight, 
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amines 154a (Rf = 0.30) and 154b (Rf = 0.30) could be obtained in an improved yield 
of 70% over 2-steps and formation of 174 was significantly reduced (ca. 5%). 
 
 
 
Scheme 69. Proposed reaction mechanism of (3R)-2-Amino-hex-4-ene-1,3,6-
triol 
 
 
5.2.2 Vasella reductive amination  
Having successfully illustrated that the desired amines 154a and 154b could indeed 
be prepared, a protecting group free approach for the synthesis of these substrates 
was then explored before attempts were made to separate the two diastereomers. In 
2009, the Stocker/Timmer group showed that aldehydes (e.g. 177), (I, Scheme 70) 
and acetals could be reductively aminated to give the corresponding primary amines 
178 with ammonia as the nitrogen source.119 Similar methodology was also applied in 
combination with the Vasella reaction to form the unsaturated primary amine product 
144 from methyl iodoglycoside 143 (II, Scheme 70).121 Accordingly, it was envisioned 
that applying these conditions to methyl iodoglycoside 155 could lead to the 
98 
 
formation of amine 154a and/or 154b without the need for a temporary amine 
protecting group. 
 
 
 
Scheme 70. Examples of the reductive amination and the Vasella reductive 
amination developed by the Stocker/Timmer group. 
 
As described in the introduction to this chapter (see Chapter 4, pg 85), it is important 
to use a large excess of ammonia in the Vasella reductive amination, to perform the 
reaction at a pH of ~12, and to use a low concentration (20 mL sat. NH4OAc per mmol 
substrate) to prevent dimer formation. In addition, NaCNBH3 was chosen as the 
reducing agent as it shows good chemoselectivity in reductive aminations,136 reducing 
the intermediate imine to the desired amine without reducing the carbonyl starting 
material (Scheme 71). Accordingly, these conditions were then applied to methyl 
iodoglycoside 155, however, unfortunately, it appeared as if none of the desired 
amine product was formed as observed by NMR analysis. Due to the large excess of 
salts used during the reaction, it was difficult to conclude with certainty, what 
products had been formed by NMR analysis of the crude reaction mixture. To remove 
the excess of ammonium salts, the crude product was thus passed through a DOWEX® 
H+ resin. The resin would bind the amine product and allow for the excess salts to be 
removed by washing the column with water. The desired product could be eluted via 
30% aq. ammonia.119 Applying the crude reaction mixture to this purification 
procedure, however, resulted in no observable material following elution of the 
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column with 15% → 30% aq ammonia. This suggests that no amine-containing 
product was formed.  
 
 
 
Scheme 71. Attempts at the reductive amination of the D-fructose derived 
methyl iodide 155 
 
 
A different purification procedure was then attempted in order to gain insight into 
what had happened during the treatment of methyl iodoglycoside 155 to the Vasella 
reductive amination conditions. To identify any potential non-aminated product 
(which would otherwise be eluted from the DOWEX® H+ resin along with the water-
soluble salts) a different ‘desalting’ purification procedure was used (Scheme 72). 
Thus, following treatment of 155 to the aforementioned Vasella reductive amination 
conditions, 1M aq. HCl was then added to the reaction vessel to convert the NH4OAc to 
NH4Cl and acetic acid, which was then removed under reduced pressure. The NH4Cl 
was then converted to NaCl by basifying with 1M NaOH (1 equiv. towards NH4OAc) 
and the remaining NaCl salt, which is less soluble in ethanol, this allows for a large 
excess of the salt to be removed by filtration. Though this ‘desalting’ strategy proved 
useful for removing much of the excess NH4OAc used during the course of the 
reaction, unfortunately, the complexity of the resulting 1H and 13C NMR spectra 
provided no further insight into what was formed during the reductive amination of 
155, only that a mixture of products was obtained of which no major product(s) could 
be identified. In 1971, Manning at. al applied the reductive amination to a selection of 
ketones in presence of ammonium acetate and NaCNBH3 at room temperature.136 
Since then this method has been successfully applied to a variety of ketone 
substrates.137–139 To investigate how temperature influences the reductive amination, 
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the Vasella reaction was performed (reflux 2 h, in presence of activated zinc and 
AcOH), then cooled to rt and the crude reaction mixture saturated with NH4OAc 
followed by the addition of NaCNBH3 and left for 42 hours. Unfortunately also this did 
not result in the desired product. 
 
 
 
 
Scheme 72. Removal of ammonium acetate by desalting 
 
5.3 The carbamate annulation 
Although the synthsis of alkenylamines 154a and 154b could not be achieved without 
the use of a temporary amine protecting group, due to the interests of time, efforts 
were made to forge ahead with the synthesis to reach the target 
dihydroxylpyrrolidines. To this end, alkenylamines 154a and 154b were subjected to 
the I2-mediatd carbamate annulation conditions to determine if the desired furanose 
(as compared to the pyranose) chiral skeleton would be formed, and whether the 
carbamate annulation would indeed be cis-selective, as has previously been 
suggested.120 
 
As separation of the alkenylamines 154a and 154b proved to be difficult by gradient 
flash chromatography, the diastereomeric mixture of 154a and 154b were subjected 
to iodine (1.5 equiv) in sat. aq. NaHCO3 (Scheme 73). This resulted in complete 
consumption of the starting material as gauged by TLC analysis, however, the 
carbamate products could not be visualised on TLC by staining (ninhydrin, 
permanganate, molybdenum, iodine in silica or 10% H2SO4 in EtOH). Given that a 
mixture of 154a and 154b was used and an additional chiral centre is formed in the 
reaction, four carbamate isomers can potentially be formed. Upon work-up (by 
101 
 
removal of the solvent under reduced pressure), analysis of the crude reaction 
mixture by 1H NMR, revealed three products, one major and two minor, in a 6:2:1 
ratio as determined by the integration of corresponding 1H NMR signals. As discussed 
in Chapter 4 pg 90 in the cyclisation both five- and six-membered rings can form, with 
the five-membered ring as the favoured product according to the Baldwin’s rules. To 
determine if a five- or six-membered ring is formed, HMBC long range correlation 
spectroscopy can be used, for five-membered rings a correlation between the 2-and 5-
position can be expected whereas in six-membered rings a correlation between the 1 
and 5 position can be observed. Indeed upon close examination of the HMBC NMR 
spectrum, for the major product, a correlation between the H-2 and C-5 was observed 
(Figure 16). However, for the two minor products the linkage could not be 
determined. 
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Figure 16. HMBC correlation spectrum showing the correlation 
between H-2 and C-5 indicating the desired 5 membered ring had 
formed 
 
 
 
Scheme 73. Potential products from the carbamate annulation. 
 
To understand more about the formation of the multiple products in the I2-promoted 
carbamate annulation, transition state models for the formation of the iodide 
intermediate need to be analysed. Iodocyclisation reactions are irreversible and 
accordingly, the relative stereochemistry of the carbamate product is determined by 
the relative energies of the transition states leading to the iodides.140 Here, two effects 
can be observed. First, the stabilising electronic effect from the allylic hydroxyl (as 
described in Chapter 4, pg 87-89) favours the formation of a 4,5-cis product. Second, 
the presence of a hydroxymethyl group at the 2-position, represents steric bulk and 
may favour the 2,5-trans product. Indeed, it should be noted that in the work by 
Davies et al.,141 the presence of a CH2CO2tBu group at the C-1 position appears to 
influence the stereochemical outcome of their I2-mediated iodoamination (with 
concomitant N-debenzylation). Though the 4,5-cis product is the major diastereomer 
(e.g. I, Scheme 74), the relative stereochemistry of the chiral-auxiliary and C-1 can 
reduce, or even reverse, this selectivity. This cis-selectivity is thought to occur via the 
rapid equilibrium of the two diastereomeric iodonium ions and subsequent 
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cyclisation as the rate-determining step. Surprisingly, halocyclisation or 
amidomercuration of a per-O-benzylated N-benzyloxylcarbonyl protected 
alkenylamine derived from D-arbinose, however, resulted in preferential formation of 
the 4,5-trans-diastereomer (II, Scheme 74).142 This trans-selectivity was attributed to 
the differential steric requirements in the transition states, and may reflect the added 
steric-considerations that need to be taken into account when both a C1-substituent 
and an N-protecting group are present.142,143 For example, O-cyclisation of a similar 
system (where NHCBz = OH) gives the cis-diastereomer preferentially (9:1; 
cis:trans)(III, Scheme 74).144 Studies within the Stocker/Timmer group, also indicate 
that the presence of a nitrile at the C-1 position also influences the diastereoselectivity 
of the carbamate annulation (see Chapter 4, pg 89), though this is thought to be due to 
electronic factors, as well as possible steric considerations.132 
 
 
 
Scheme 74. Examples of sterics influencing the stereoselective outcome of the 
halocyclisation 
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The transition states for all four possible carbamate diastereoisomers upon treatment 
of 154a/154b to the I2-mediated annulation are depicted in Figure 17. Here, 
alkenylamine 154a can form both the 4,5-cis carbamate 179, through transition state 
A, and the 4,5-trans carbamate 180 via transition state B. In transition state A, the 
allylic hydroxyl is positioned in the plane of the double bond stabilising the I2-
ethylene complex (O-in-plane), however the presence of the hydroxymethyl at the 2-
position leads to negative steric interactions across the five-membered ring. In 
transition state B, the allylic hydroxyl is positioned out of the plane of the double bond 
(H-in-plane), and although this leads to a less stable I2-ethylene complex, the steric 
interaction of the hydroxymethyl at the 2-position is minimal. Accordingly, it is likely 
the transition state energies of A and B will be close and that both products can be 
expected. For alkenylamine 154b, two diastereoisomers can also form the 4,5-cis 
carbamate 181 from transition state C, and the 4,5-trans carbamate 182 from 
transitionstate D. Transition state C leads to the favoured 4,5-cis product (O-in-plane), 
and in addition, there is no adverse steric interaction between the 2-hydroxymethyl 
and the CH2 on the 6-position of the furanose product. In comparision, transition state 
D would give the 4,5-trans product. This transition state would be expected to be high 
in energy due to the unfavourable ‘H-in-plane’ alignment and the steric hindrance 
between the hydroxymethyl and the newly formed methylene bond. Accordingly, the 
transition state energy of D relative to that of transition state C will be higher and as a 
result, only product 181 (and not 182) is expected. Taken as a whole, one would thus 
anticipate carbamate 181 to be the expected major diastereomer and carbamates 179 
and 180 to be the other two minor products. To determine this, the carbamates, 
however, need to be hydrolysed to give known azasugars as NOE (or similar) NMR 
studies cannot be used with certainty to predict configuration in five-membered 
rings.145 
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Figure 17.  Transition state models for the formation of the iodine 
intermediates 
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5.4 Hydrolysis of the carbamate product 
To allow for purification of the respective diastereomers and to determine the relative 
stereochemistry of each product, the carbamate products were hydrolysed. This was 
achieved by subjecting the mixture of carbamate products to NaOH in refluxing EtOH. 
From the possible four carbamate products (179, 180, 181 and 182), only three 
potential iminosugars can be formed as carbamates 179 and 182 both lead to the 
formation of imine DGDP 128 upon hydrolysis (Scheme 75). 
 
 
 
Scheme 75. Potential product after hydrolysis of the carbamate 
 
 
To this end, the carbamates were thus subjected to NaOH in refluxing EtOH which 
resulted in the formation of a ninhydrin positive product on TLC, indeed suggesting 
that the desired imine products were formed. The crude reaction mixture was then 
passed over a DOWEX® H+ column and the column washed with water (two column 
lengths) The column was then washed with ethanol, and the product removed from 
the resin via eluting with 30% aq. ammonia. A combination of 1H and 13C NMR 
analysis of the crude reaction mixture revealed that two products were formed in a 
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ratio of 3:1. Characteristic in the carbon spectrum was that for both products only 
three signals were observed which suggest a axes of symmetry present in both 
products (Figure 18). Of the three potential products only two contain a C2 axes, these 
are 2,5-dideoxy-2,5-imino-L-iditol 112 and DMDP (106) (Scheme 76). When the NMR 
spectra were compared to literature both products were in good agreement with the 
reported data. The major product could be identified as the 2,5-dideoxy-2,5-imino-L-
iditol 112,146 and the minor as 2,5-dideoxy-2,5-imino-D-manitol (DMDP) 106.147 
Although several attempts at separating the two diastereoisomers where made by 
carefully columning the products on a silica column [eluent 2/1 → 0/1 brew(5/2/2/1, 
CH2Cl2/EtOH/MeOH/30% aq. Ammonia) /CH2Cl2] separation could not be achieved. 
 
 
Figure 18. Carbon spectrum of the crude reaction mixture, identified 
as 2,5-dideoxy-2,5-imino-L-iditol 112,146 and the minor as 2,5-dideoxy-
2,5-imino-D-manitol (DMDP) 106. 147  
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Scheme 76. Imine products formed after hydrolysis of the carbamate product. 
 
4.5 Conclusion 
In summary, the scope of the I2-mediated carbamate annulation has been successfully 
extended for the synthesis of 2,5-dihydroxymethyl-3,4-dihydroxypyrrolidines. During 
this work, it was illustrated that the presence of steric bulk, in the form of a 
hydroxymethyl at the 2-position, can influence the stereoselective outcome of the 
carbamate annulation. All this was achieved with a minimal use of protecting groups 
and a total of six steps.  
 
4.6 Future directions 
Although several attempts at separating the two final products were made by silica 
gradient flash chromatography, due to time constraints, reverse phase (HP 20, C8 and 
C18) remain yet to be explored. In addition, separation of the alkenylamine products 
could be further attempted either at the protected (172a/172b) or deprotected stage 
(154a/154b). Furthermore, the conditions for the reductive amination can still be 
optimised to eliminate the use of a protected amine and ammonia can be used as a 
nitrogen source instead. Finally, it would be interesting to see if the developed 
methodology can be applied to other ketose substrates such as Tagatose, Sorbose and 
Psicose. 
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Experimental: N-glycans 
Unless otherwise stated all reactions were performed under atmospheric air. THF (Lab-Scan) was distilled 
from sodium wire prior to use. Triethylamine was distilled and stored over KOH pellets. Pyridine was distilled 
over KOH prior to use. EtOAc (Panreac), Toluene (Panreac), MeOH (Pure Science), and hexanes (Panreac). 
EtOH (absolute, Pure Science), AcOH (Lab Scam), Ac2O (Acros Organics), CH2Cl2 (LabServ), 30% aqueous NH3 
(Fisher Science), xylose (Sigma-Aldrich), triethylsilane (Fluka), NaCNBH3 (Aldrich), and NaOH (Pure Science) 
BzCl (Riedel de Haen), DMAP (Merck), DDQ (Merck) PhBCl2 (Aldrich), MgSO4 (Pure Science), Na2S2O4 (Pure 
Science), sodium (Aldrich), were used as received. TMSOTf and TfOH were distilled fresh prior to use. All 
solvents were removed by evaporation under reduced pressure (in vacuo). Reactions were monitored by 
TLC-analysis on Macherey-Nagel silica gel coated plastic sheets (0.20 mm, with fluorescent indicator UV254) 
with detection by UV-absorption (254 nm), by dipping in 10% H2SO4 in MeOH or 3% ninhydrin in EtOH 
followed by charring at ~150 °C. Column chromatography was performed on Pure Science silica gel (40-63 
micron). DOWEX® H
+
 50wx8-100 ion exchange resin was activated by overnight exposure to 1M HCl. Size 
exclusion column chromatography was performed on Sephadex® LH-20, bead size 25-100µ. C8 and C18 
reverse phase column were performed on thermo fisher scientific HyperSep Columns. High-resolution mass 
spectra were recorded on a Waters Q-TOF PremierTM Tandem Mass Spectrometer using positive electro-
spray ionisation. Optical rotations were recorded using a Perkin-Elmer 241 polarimeter at the sodium D-line. 
Infrared spectra were recorded as thin films using a Bruker Tensor 27 FTIR spectrometer, equipped with an 
Attenuated Total Reflectance (ATR) sampling accessory, and are reported in wave numbers (cm-1). Nuclear 
magnetic resonance spectra were recorded at 20 °C in chloroform using either a Varian Unity-INOVA 
operating at 300 MHz or a Varian Unity operating at 500 MHz. Chemical shifts are given in ppm (δ) and are 
relative to chloroform, all given 
13
C spectra are proton decoupled. NMR peak assignments were made using 
COSY, HSQC, TOCSY and HMBC experiments. Melting points (Mp) were obtained on a Gallenkamp Melting 
Point Apparatus.  
 
Tert-butyldimethylsilyloxy 4-O-(2-O-benzoyl-4,6-O-(R)-
benzylidene-3-O-para-methoxybenzyl-β-D-mannopyranosyl)-3,6-
di-O-benzyl-2-deoxy-2-(2,2,2-trichloroethyloxy)cabonylamido-β-
D-glucopyranoside (54b). ManGlc dimer 55 (1.04 g, 1.0 mmol, 1 equiv.) was co-evaporated with Tol. (3x), 
dissolved in pyridine (2.6 mL), and cooled down to (0°C), benzoylchloride (0.24 mL, 2.0 mmol, 2.0 equiv.) 
was added dropwise, followed by N,N-dimethylaminopyridine (DMAP) (12 mg, 0.017mmol, 0.02 equiv.). The 
resulting mixture was allowed to warm up to rt and left to react for 14h. The reaction was then diluted with 
EtOAc and the organic fraction washed with sat. aq. NaHCO3 (3x), brine, dried over MgSO4, filtered and 
concentrated in vacuo. Purification of the residue by column chromatography (PE/EtOAc, 10/1  EtOAc, 
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v/v) yielded the title compound 54b (1.05 gr, 0.94 mmol, 92%) as a colourless oil. Rf : 0.54 (PE/EtOAc, 1/1, 
v/v); [α]D
20
: -0.5 (c = 1.0 in CHCl3); IR (ν): 3351.2, 3033.1, 2929.9, 2858.0, 1724.0, 1585.4, 1513.5, 1453.5, 
1362.1, 1314.4, 1270.0, 1249.6, 1174.3, 1151.7, 1091.5, 1068.3, 1005.0, 910.8, 732.6, 671.6 cm
-1
; 
1
H NMR 
(500 MHz, CDCl3): δ 8.08 (dd, J = 2.0 Hz, J = 8.3, 2H, CHarom Bz), 7.53 (t, J = 7.5, 1H, CHarom Bz), 7.51 (dd, J = 1.9 
Hz, J = 8.0, 2H, CHarom Bz), 7.40-7.34 (m, 9H, CHarom), 7.27-7.24 (m, 8H, CHarom), 7.17-7.14 (m, 2H, CHarom), 6.82 
(m, Ja,b = 8.5 Hz, 2H, CHarom PMB), 5.70 (d, J1’,2’ = 2.9 Hz, 1H, H-2’), 5.60 (s, 1H, CHPh), 5.36 (d, Ja,b = 11.5 Hz, 
2H, CH-a 3-O-Bn, NH Troc), 4.81 (s, 1H, H-1’), 4.76 (d, J1,2 = 7.8 Hz, 1H, H-1), 4.72 (d, Ja,b = 11.9 Hz, CH-a 1H, 6-
O-Bn), 4.65 (d, Ja,b = 11.0 Hz, CH-a 1H, 3’-O-PMB), 4.57 (bdd, Ja,b = 11.7, Ja,b = 21.2, 2H, CH2 Troc), 4.52 (d, Ja,b = 
12.0 Hz, 1H, CH-b 3’-O-PMB), 4.49 (d, Ja,b = 12.2 Hz, 2H, CH-b 6-O-Bn), 4.43 (d, Ja,b = 11.4 Hz, 2H, CH-b 3-O-
Bn), 4.27 (dd, J6a,6b = 4.9 Hz, J5,6a = 10.5 Hz, 1H, H-6a), 4.07 (t, J3,4 = J4,5 = 9.1 Hz, 1H, H-4), 4.01 (t, J3’,4’ = J4’,5’ = 
9.4 Hz, 1H, H-4’), 3.79 (dd, J6a’,6b’ = 3.2 Hz, J5’,6’ = 11.2 Hz, 1H, H-6b’), 3.77 (s, 3H OMe, PMB), 3.77(t, J6a,6b = J5,6 
= 13.4, 1H, H-6a), 3.68 (dd, J6a,6b = 2.2 Hz, J5,6 = 11.3, 1H, H-6b) 3.65 (bt, J2,3 = J3,4 = 9.5 Hz, 1H, H-3), 3.61 (dd, 
J2’,3’ = 3.4 Hz, J3’,4’ = 9.7 Hz, 1H, H-3’), 3.41 (bd, J4,5 = J5,6 = 9.6 Hz, 1H, H-5), 3.25 (dt, J5’,6’ = 4.9 Hz, J5’,6’ = J4’,5’ = 
9.8 Hz, 1H, H-5’), 3.22 (1H, H-2), 0.86 (s, 9H, t-Bu, OTBDMS), 0.09 (s, 3H, Me, OTBDMS), 0.04 (s, 3H, Me, 
OTBDMS); 
13
C NMR (125MHz, CDCl3): δ 165.9 (C=O, Bz), 159.3 (C-p, PMB), 153.8 (C=O, Troc), 138.7 (C, 3-O-
Bn), 137.9 (C, 6-O-Bn), 137.6 (C Bn), 133.3, 130.2, 130.1, 129.9, 129.86, 129.3, 129.1, 128.7, 128.5, 128.3, 
128.3, 128.1, 128.07, 128.0, 127.6, 126.2 (16  Carom), 113.9 (Carom PhCH), 101.7 (PhCH), 99.4 (C-1’), 95.6 (C-
1), 78.4 (C-4’), 78.3 (C-4), 78.0 (C-3), 75.6 (C-3’), 74.5, 74.4 (CH2 Troc, C-5, 3-O-Bn), 73.7 (CH2 6-O-Bn), 71.4 
(CH2, 3’-O-PMB), 69.7 (C-2), 68.78, 68.76 (C-6, C-6’), 67.3 (C-5’), 59.7 (C-2), 55.4 (OMe, PMB), 25.7 (Me, t-Bu, 
OTBDMS), 18.0 (Cq, t-Bu, OTBDMS), -4.1, -5.1 (2  Me, TBDMS); HRMS(ESI) m/z calcld. for 
[C57H66O14NCl3Si+Na]
+
: 1144.3216, obsd.: 1144.3216. 
 
 Tert-butyldimethylsilyloxy  4-O-(2-O-benzoyl-4,6-O-(R)-
benzylidene-β-D-mannopyranosyl)-3,6-di-O-benzyl-2-deoxy-2-
(2,2,2-trichloroethyloxy)cabonylamido-β-D-glucopyranoside (71). 
Benzoylated dimer 54b (74 mg, 0.066 mmol, 1 equiv.) was dissolved in CH2Cl2/H2O (0.66 mL, 10/1, v/v), 
followed by the addition of 2,3-chloro-5,6-cyano-1,4-benzoquinone (16.4 mg, 0.077 mmol, 1.1 equiv.) and 
left to stir for 2 h after which the reaction was quenched by the addition of 10% aq. Na2S2O4. Then EtOAc 
was added and the organic fraction washed with 10% aq. Na2S2O4, sat. aq. NaHCO3 (2), and brine (1x). The 
organic phase was then dried over MgSO4, filtered and concentrated in vacuo. Purification of the residue by 
column chromatography (PE/EtOAc, 10/1  3/1, v/v) yielded the title compound 71 (51.2 mg, 0.051 mmol, 
77%) as a colourless oil. Rf : 0.34 (PE/EtOAc, 2/1, v/v); αD
20
: -0.4 (c = 1.0 in CHCl3); IR (ν): 3395.6, 3064.9, 
3033.1, 2929.4, 2858.1, 1720.3, 1602.3, 1525.8, 1453.3, 1361.6, 1315.2, 1272.9, 1217.9, 1174.9, 1090.2, 
1028.3, 995.0, 910.3, 838.8, 781.58, 731.1, 710.1, 698.3 cm
-1
; 
1
H NMR (500 MHz, CDCl3): δ 8.08 (dd, J = 1.9 
Hz, J = 8.0, 2H, CHarom Bz), 7.56 (t, J = 7.6, 1H, CHarom Bz), 7.54-7.49 (m, 2H, CHarom), 7.44-7.36 (m, 10H, 
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CHarom), 7.27-7.25 (m, 4H, CHarom), 7.17-7.16 (m, 4H, CHarom), 5.57 (s, 1H, CHPh), 5.56 (d, J1’,2’ = 2.2 Hz, 1H, H-
2’), 4.89 (s, 1H, H-1’), 4.88 (d, Ja,b = 11.4 Hz, 2H, CH-a 3-O-Bn, NH Troc), 4.759 (1H, H-1), 4.757 (d, Ja,b = 11.9 
Hz, 1H, CH-a 6-O-Bn), 4.59 (bdd, JNH,CH2 = 12.2 Hz, Ja,b = 21.0 Hz, 2H, CH2, Troc), 4.53 (d, Ja,b = 12.2 Hz, 1H, CH-b 
6-O-Bn), 4.45 (d, Ja,b = 11.7 Hz, CH-b 1H, 3-O-Bn), 4.27 (dd, J6a’,6b’ = 4.9 Hz, J5’,6’ = 10.4 Hz, 1H, H-6a’), 4.07 (t, 
J3,4 = J4,5 = 9.2 Hz, 1H, H-4), 3.88 (t, J3’,4’ = J4’,5’ = 9.8 Hz, 1H, H-4’), 3.82 (dd, J6a’,6b’ = 3.2 Hz, J5’,6’ = 10.5 Hz, 2H, 
H-6b’, H-3’), 3.74 (t, J6a’,6b’ = J5’,6’ = 10.2, 1H, H-6b’), 3.64 (bt, J2,3 = J3,4 = 9.2 Hz, 1H, H-3), 3.39 (bd, J4,5 = J5,6 = 
9.5 Hz, 1H, H-5), 3.28 (dt, J5’,6’ = 4.9 Hz, J5’,6’ = J4’,5’ = 9.7 Hz, 1H, H-5’), 3.24 (1H, H-2), 0.86 (s, 9H, t-Bu, 
OTBDMS), 0.10 (s, 3H, Me OTBDMS), 0.04 (s, 3H, Me OTBDMS); 
13
C NMR (125MHz, CDCl3): δ 166.0 (C=O, Bz), 
153.7 (C=O, Troc), 138.6 (C, 3-O-Bn), 137.9 (C, 6-O-Bn), 137.0 (C Bn), 129.9, 129.6, 129.4, 128.6, 128.5, 128.4, 
128.2, 128.04, 128.02, 127.9, 127.5, 126.3 (12  Carom) 102.2 (PhCH), 99.3 (C-1’), 95.5 (C-1, CCl3, Troc), 79.0 
(C-4), 78.6 (C-4’), 77.9 (C-3), 74.3 (CH2, Troc, 3-O-Bn, C-5), 73.7 (CH2, 6-O-Bn), 71.7 (C-2’), 70.0 (C-3’), 68.62, 
68.57 (C-6, C-6’), 66.8 (C-5’), 59.6 (C-2), 25.6 (Me, t-Bu, OTBDMS), 17.9 (Cq, t-Bu, OTBDMS), -4.2, -5.3 (2  
Me, TBDMS); HRMS(ESI) m/z calcld. for [C57H66O14NCl3Si+Na]
+
: 1024.2641, obsd.: 1024.2641. 
 
 Tert-butyldimethylsilyloxy 4-O-(2-O-benzoyl-4-O-benzyl-β-D-
mannopyranosyl)-3,6-di-O-benzyl-2-deoxy-2-(2,2,2-
trichloroethyloxy)cabonylamido-β-D-glucopyranoside (72). Dimer 71 
(651 mg, 0.0.65 mmol) was co-evaporated with toluene (3x), then dissolved in dry CH2Cl2 (6.5 mL). Activated 
molecular sieves (4Å) were added and the resulting suspension was stirred for 75 min at 0°C, after which the 
reaction mixture was cooled down to -78°C and Et3SiH (0.30 mL, 1.95 mmol) was added. After stirring for 15 
min, PhBCl2 (0.29 mL, 2.2mmol) was added, and the reaction was stirred until TLC analysis showed complete 
disappearance of the starting material (15 min). The reaction was quenched by the addition of sat. aq. 
NaHCO3 (3 mL) and EtOAc, and the organic phase washed with sat. aq. NaHCO3 (2) and brine (1x), dried 
over MgSO4, filtered and concentrated in vacuo. Purification of the residue by column chromatography 
(silica gel, PE/EtOAc, 10/1  3/1, v/v) yielded the title compound 72 (530 mg, 0.53 mmol, 81%) as a 
colourless oil. Rf : 0.56 (PE/EtOAc, 1/1, v/v); [α]D
20
: 0.2 (c = 1.0 in CHCl3); IR (ν): 3393.7, 3063.7, 3032.0, 
2928.8, 2857.4, 1718.7, 1523.6, 1497.0, 1453.4, 1360.9, 1315.2, 1273.4, 1169.1, 1067.9, 1028.4, 941.4, 
910.3, 838.8, 782.1, 732.8, 708.0 cm
-1
; 
1
H NMR (500 MHz, CDCl3): δ 8.07-8.05 (m, 2H, CHarom Bz), 7.57-7.55 
(m, 1H, CHarom Bz), 7.44-7.40 (m, 2H, CHarom Bz), 7.40-7.25 (m, 14H, CHarom), 7.13-7.12 (m, 2H, CHarom), 5.44 
(d, J1’,2’ = 2.7 Hz, 1H, H-2’), 4.89 (d, Ja,b = 11.8 Hz, 1H, CH-a 3-O-Bn), 4.86 (d, JNH,2’ = 7.4, 1H, NH Troc), 4.81 (s, 
1H, H-1), 4.76 (d, Ja,b = 11.5 Hz, 1H, CH-a 4’-O-Bn), 7.26 (d, 1H, H-1), 4.69 (d, Ja,b = 11.5 Hz, 1H, CH-a 6-O-Bn), 
4.67 (d, Ja,b = 11.0 Hz, 1H, CH-a 4’-O-Bn), 4.57 (bdd, Ja,b = 12.3 Hz, Ja,b = 25.2 Hz, 2H, CH2 Troc), 4.52 (d, Ja,b = 
12.2 Hz, 1H, CH-b 6-O-Bn), 4.46 (d, Ja,b = 12.0 Hz, CH-b 1H, 3-O-Bn), 4.02 (t, J3,4 = J4,5 = 9.3 Hz, 1H, H-4), 3.80 
(d, J6a’,6b’ = J5’,6’ = 9.0 Hz, 1H, H-6a’), 3.76 (dd, J6a,6b = 3.4 Hz, J5’,6’ = 11.4 Hz, 1H, H-6a), 3.72-3.69 (m, 2H, H-3’, 
H-4’), 3.66 (dd, J6a,6b = 2.5 Hz, J5’,6’ = 11.5 Hz, 1H, H-6b), 3.63 (dd, J6a’,6b’ = 4.6 Hz, J5,6 = 12.0, 1H, H-6b’), 3.60 
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(1H, H-3), 3.40 (dt, J5,6b = 2.5, J5,6b = 11.4 Hz, 1H, H-5), 3.27 (bdd, J = 8.1 Hz, 1H, H-2), 3.25-3.22 (m, 1H, H-5’), 
0.85 (s, 9H, t-Bu, OTBDMS), 0.09 (s, 3H, Me OTBDMS), 0.03 (s, 3H, Me OTBDMS); 
13
C NMR (125MHz, CDCl3): 
δ 166.4 (C=O, Bz), 154.0 (C=O, Troc), 137.8 (C, 3-O-Bn), 138.2 (C, 6-O-Bn), 138.0, 133.5, 130.1, 130.0, 128.74, 
128.72, 128.7, 128.5, 128.18, 128.16, 128.10, 128.06, 127.7, 127.5 (14  Carom), 98.8 (C-1’), 95.8 (C-1), 95.5 
(CCl3, Troc), 78.3 (C-4, C-3), 75.79 (C-4’), 75.75 (C-5’), 75.1 (CH2, 4’-O-Bn), 74.6 (CH2, Troc, C-5), 74.2 (CH2, 3-
O-Bn), 73.9 (CH2, 6-O-Bn), 73.4 (C-3’), 72.4 (C-2), 68.87 (C-6, C-6’), 25.8 (Me, t-Bu, OTBDMS), 18.1 (Cq, t-Bu, 
OTBDMS), -4.0, -5.1 (2  Me, TBDMS). HRMS(ESI) m/z calcld. for [C57H66O14NCl3Si+Na]
+
: 1026.2797, obsd.: 
1026.2797. 
 
 Tert-butyldimethylsilyloxy  4-O-(2-O-(2,3,4-tri-O-acetyl-β-D-
xylopyranosyl)-4,6-O-(R)-benzylidene-3-O-para-methoxybenzyl-β-
D-mannopyranosyl)-3,6-di-O-benzyl-2-deoxy-2-(2,2,2-
trichloroethyloxy)cabonylamido-β-D-glucopyranoside (54a). 
ManGlc acceptor 55 (1.15 g, 1.1 mmol) and xylose imidate 69 (1.66 g, 4.0 mmol), were co-evaporated 
together, and dissolved in dry CH2Cl2 (5 mL). Activated molecular sieves (4Å) were added and the resulting 
suspension was stirred for 1h at 0°C, after which TMSOTf (28.3 µL, 1M in CH2Cl2), and the reaction was 
stirred for 4h and until TLC analysis showed complete consumption of the xylose donor 69. The reaction was 
quenched by the addition of sat. aq. NaHCO3, diluted with EtOAc and the organic phase washed with sat. aq. 
NaHCO3 (2x), and brine (1x), dried over MgSO4, filtered and concentrated in vacuo. Purification of the 
residue by column chromatography (PE/EtOAc, 6/1→4/1, v/v), yielded the title compound 54a (1.03 g, 0.70 
mmol, 72%) as a colourless oil. Rf : 0.51 (tol/EtOAc, 3/1, v/v); [α]D
20
: +3.6 (c = 10.0 in CHCl3); IR (ν): 3349, 
3030, 2935, 1740, 1612, 1369, 1303, 1285, 1247, 1222, 1174, 1156, 1085, 1051, 1037, 970, 911, 883, 838, 
820, 782, 732, 698, 676 cm
-1
; 
1
H NMR (500 MHz, CDCl3): δ 7.48.7.47 (m, 2H, CHarom), 7.40-7.23 (m, 16H, 
CHarom), 6.85 (d, Ja,b = 8.8 Hz, 2H, CHarom PMB), 5.45 (s, 1H, CHPh), 5.02-5.00 (m, 5H, NH Troc, H-1’’, H-2’’, H-
3’’, CH2 3-O-Bn), 4.81 (bd, J1,2 = 7.9 Hz, 1H, H-1), 4.79 (bs, 1H, H-4’’), 4.68 (d, Ja,b = 12.7 Hz, 1H, CH-a 3’-O-
PMB), 4.68 (s, 2H, CH2 Troc), 4.61 (d, Ja,b = 12.2 Hz, 1H, CH2 6-O-Bn) , 4.60 (d, Ja,b = 12.5 Hz, CH-b 1H, 3’-O-
PMB), 4.59 (H-5a) 4.57 (s, 1H, H-1’), 4.54 (d, Ja,b = 11.3 Hz, 1H, CH-b 3-O-Bn), 4.45 (d, Ja,b = 12.2 Hz, 1H, CH-b 
6-O-Bn), 4.10 (dd, J6a’,6b’ = 4.4 Hz, J5’,6’ = 10.5 Hz, 1H, H-6a’), 4.00 (s, 1H, H-2’), 3.93 (t, J3’,4’ = J4’,5’ = 9.1 Hz, 1H, 
H-4’), 3.86 (t, J3,4 = J4,5 = 9.5, 1H, H-4), 3.83 (t, J2,3 = J3,4 = 9.8, 1H, H-3), 3.78 (s, 3H, OMe PMB) 3.64 (m, 2H, H-
6a, H-6b), 3.44-3.38 (m, 4H, 3’, 5, 5b’’, 6b’), 3.80 (dd, 1H, H-2), 3.13 (dt, J5’,6’ = 4.6 Hz, J4’,5’ = J5’,6’ = 9.5 Hz, 1H, 
H-5’), 2.11, 2.06, 1.98 (3x s, 3H, Me Ac), 0.88 (s, 9H, t-Bu, OTBDMS), 0.12 (s, 3H, Me OTBDMS), 0.09 (s, 3H, 
Me OTBDMS); 
13
C NMR (125MHz, CDCl3): δ 170.0, 169.4, 169.2 (C=O Ac), 159.7 (C-p, PMB), 154.1 (C=O, 
Troc), 139.2 (Carom) 138.0 (C, 3-O-Bn), 137.6 (C, 6-O-Bn), 130.4, 129.3, 129.1, 128.7, 128.32, 128.26, 128.1, 
127.9, 127.6, 127.5, 126.3 (11  Carom), 113.9 (Carom) 101.9 (C-1’), 101.7 (PhCH), 99.1 (C-1’’), 96.1 (C-1), 95.7 
(CCl3 Troc),79.8 (C-4’), 79.3 (C-3), 78.6 (C-4), 76.8 (C-5), 75.8 (C-2’), 74.8, 74.7 (CH2 Troc, 3-O-Bn), 74.5 (C-3’), 
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73.9 (CH2 6-O-Bn), 72.1 (CH2 3’-O-PMB), 69.4 (C-6), 68.8 (C-6’), 68.5 (C-2’’), 68.3 (C3’’), 68.1 (C-4’’), 67.5 (C-
5’), 59.9 (C-5’’), 59.7 (C-2), 55.4 (OMe, PMB), 25.8 (Me, t-Bu, OTBDMS), 21.10, 21.08, 20.9 (Me Ac), 18.1 (Cq, 
t-Bu, OTBDMS), -4.0, -5.0 (2  Me, TBDMS); HRMS(ESI) m/z calcld. for [C61H76Cl3NNaO20Si]
+
: 1298.3688, 
obsd.: 1298.3687. 
 
 
 Tert-butyldimethylsilyloxy  4-O-(2-O-(2,3,4-tri-O-acetyl-β-D-
xylopyranosyl)-4,6-O-(R)-benzylidene-β-D-mannopyranosyl)-3,6-
di-O-benzyl-2-deoxy-2-(2,2,2-trichloroethyloxy)cabonylamido-β-D-
glucopyranoside (73). Xylose trimer 54a (59.2 mg, 0.046 mmol, 1 
equiv.) was dissolved in CH2Cl2/MeOH (0.5 mL, 10/1, v/v), followed by the addition of 2,3-chloro-5,6-cyano-
1,4-benzoquinone (16.4 mg, 0.077 mmol, 1.2 equiv.). After stirring for 2h the reaction was quenched by the 
addition of 10% aq. Na2S2O4 and diluted with EtOAc. The organic layer was washed with 10% aq. Na2S2O4, 
sat. aq. NaHCO3 (2) and brine. The organic phase was then dried over MgSO4, filtered and concentrated in 
vacuo. Purification of the residue by column chromatography (PE/EtOAc, 10/1  3/1, v/v) yielded the title 
compound (73) (51.2 mg, 0.051 mmol, 77%) as a colourless oil. Rf : 0.31, debenzylated product Rf : 0.23, 
(PE/EtOAc, 1/1, v/v);[α]D
20
: -12.0 (c = 1.0 in CHCl3); IR (ν): 3348.4, 3033.3, 2930.0, 2858.6, 1742.4, 1531.7, 
1454.8, 1369.4, 1249.2, 1221.9, 1173.0, 1069.5, 911.8, 839.1, 783.0, 734.0, 698.8 cm
-1
; 
1
H NMR (500 MHz, 
CDCl3): δ 7.47-7.45 (m, 2H, CHarom), 7.40-7.31 (m, 8H, CHarom), 5.45 (s, 1H, CHPh), 5.19 (t, J2’’,3’’ = J3’’,4’’ = 7.8 Hz, 
1H, H-3’’), 5.16 (bs, 1H, NH Troc), 4.97 (dd, J1,2 = 6.1 Hz, J2,3 = 7.9 Hz, 1H, H-2), 4.95-4.93 (m, J3’’,4’’ = 7.8 Hz, 
1H, H-4’’), 4.92 (H-1), 4.91 (d, Ja,b = 11.2 Hz, 1H, CH-a 3-O-Bn), 4.85 (d, J1’’,2’’ = 6.1 Hz, 1H, H-1’’), 4.72 (d, Ja,b = 
12.2 Hz, 1H, CH-a 6-O-Bn), 4.66 (s-1H, H-1’), 4.65 (m, J = 12.0, Hz, J = 22.0 Hz, 2H, CH2 Troc), 4.55 (d, Ja,b = 
11.2 Hz, 1H, CH-b 3-O-Bn), 4.51 (d, Ja,b = 12.0 Hz, 1H, CH-b 6-O-Bn), 4.23 (dd, J5a’’,5b’’ = 4.9 Hz, J4’’,5’’ = 12.0 Hz, 
1H, H-5’’), 4.02 (dd, J5’,6’ = 4.9 Hz, J6a’,6b’ = 10.2 Hz, 1H, H-6a’), 3.96-3.91 (m, 3H, H-2’ , H-3 and H-4), 3.70-3.67 
(m, 2H, H-6a and H-6b), 3.60 (t, J3’,4’ = J4’,5’ = 9.8 Hz, 1H, H-4’), 3.56 (bs, 1H, H-3’), 3.47 (t, J5,6 = J6a’ ,6b’ = 10.3 
Hz, 1H, H-6b’), 3.44 (1H, H-5), 3.38 (dd, J4’’,5’’ = 8.1 Hz, J5a’’,5b’’ = 12.0 Hz, 1H, H-5b’’), 3.28 (bs, 1H, H-2), 3.14 
(dt, J5’,6’ = 4.8 Hz, J4’,5’ = J5’,6’ = 9.5 Hz, 1H, H-5’), 2.89 (s, 1H, 3’-OH), 2.07, 2.04, 2.00 (3x s, 9H, Me Ac), 0.89 (s, 
9H, t-Bu, OTBDMS), 0.13 (s, 3H, Me OTBDMS), 0.09 (s, 3H, Me OTBDMS); 
13
C NMR (125MHz, CDCl3): δ 169.9, 
169.8, 169.5 (3 x C=O Ac), 154.0 (C=O, Troc), 138.9 (C, 3-O-Bn), 137.9 (C, 6-O-Bn), 137.4, (11  Carom), 113.9 
(Carom) 102.3 (PhCH), 102.0 (C-1’), 100.3 (C-1’’), 95.6 (C-1), 94.0 (CCl3 Troc), 80.0 (C-4), 79.1 (C-4’), 78.7 (C-2’), 
77.9 (C-3), 74.8 (C-5), 74.7 (CH2 Troc), 74.0 (CH2 3-O-Bn, 6-O-Bn), 70.7 (C-2’’), 70.6 (C-3’’), 70.4 (C-3’), 69.2 (C-
6), 68.6 (C-6’, C-4’’), 67.6 (C-5’), 61.9 (C-5’’), 59.8 (C-2), 25.8 (Me, t-Bu, OTBDMS), 21.1, 20.9, 20.8 (3 x Me 
OAc), 18.1 (Cq, t-Bu, OTBDMS), -4.0, -5.0 (2  Me, TBDMS); HRMS(ESI) m/z calcld. for [C53H68O19NCl3Si+Na]
+
: 
1178.3118, obsd.: 1178.3118. 
 
114 
 
 
 
Tert-butyldimethylsilyloxy  4-O-[2-O-(2,3,4-O-acetyl-β-D-
xylopyranosyl)-4-O-benzyl-β-D-mannopyranosyl]-3,6-di-O-benzyl-2-
deoxy-2-(2,2,2-trichloroethyloxy)carbonylamido- β-D-
glucopyranoside (74). Trimer (73) (536 mg, 0.46 mmol) was co-
evaporated 3 x with toluene, and dissolved in dry CH2Cl2 (5 mL). Activated molecular sieves (4Å) were added 
and the resulting suspension was stirred for 1h at 0°C, after which the reaction mixture was cooled down to 
-78°C and Et3SiH (0.37 mL 2.32 mmol)was added. After stirring for 15 min, PhBCl2 (1.57 mL, 1M in CH2Cl2) 
was added, and the reaction was stirred until TLC analysis showed complete disappearance of the starting 
material. The reaction was quenched by the addition of sat. aq. NaHCO3 (3 mL) and EtOAc, and the organic 
phase washed with sat. aq. NaHCO3 (2) and brine (1x), dried over MgSO4, filtered and concentrated in 
vacuo. Purification of the residue by column chromatography (silica gel, PE/EtOAc, 3/1  1/1, v/v) yielded 
the title compound (74) (438 mg, 0.36 mmol, 82%) as a colourless oil. Rf: 0.54 (Pe/EtOAc, 1/1, v/v); []D
18.0
 = 
-14.4 (c 1.0, CHCl3); IR (ν): 3363, 3065, 3031, 2954, 2928, 2858, 1742, 1537, 1498, 1498, 1455, 1370, 1222, 
1168, 1066, 839, 755, 699 cm
-1
; 
1
H NMR (500 MHz, CDCl3): δ 7.40-7.26 (m, 15H, CHarom), 5.20 (t, J2’’,3’’ = J3’’,4’’ = 
8.0 Hz, 1H, H-3’’), 5.18 (bs, 1H, NH Troc), 4.98 (dd, J2’’,3’’ = 8.0 Hz, J1’’,2’’ = 6.2 Hz, 1H, H-2’’), 4.95 (dd, J3’’,4’’ = 8.1 
Hz, J4’’,5’’ = 3.4 Hz, 1H, H-4’’), 4.93 (s, 1H, H-1), 4.92 (d, Ja,b = 11.1 Hz, 1H, CH-a 3-O-Bn), 4.85 (d, Ja,b = 11.2 Hz, 
1H, CH-a 4’-O-Bn), 4.79 (d, J1’’,2’’ = 6.0 Hz, 1H, H-1’’), 4.67-4.61 (m, 2H, CH2 Troc), 4.66 (d, Ja,b = 13.3 Hz, 1H, 
CH-a 6-O-Bn), 4.63 (d, Ja,b = 12.1 Hz, 1H, CH-b 3-O-Bn), 4.60 (1H, H-1’), 4.59 (d, Ja,b = 10.6 Hz, 1H, CH-b 4’-O-
Bn), 4.53 (d, Ja,b = 12.1 Hz, 1H, CH-b 6-O-Bn), 4.21 (dd, J4’’,5a’’ = 4.8 Hz, J5a’’,5b’’ = 11.9 Hz, 1H, H-5a’’), 3.93 (bd, J 
=7.9 Hz, 1H, H-3), 3.87 (t, J3,4 = J3,4 = 9.1 Hz, 1H, H-4), 3.83 (d, J1,2 = 2.4 Hz, 1H, H-2’), 3.72 (d, J6a,6b = 10.0 Hz, 
1H, H-6a), 3.66 (dd, J5,6b = 3.6 Hz, J6a,6b = 11.0 Hz, 1H, H-6b), 3.61 (d, J6a’,6b’ = 9.9 Hz, 1H, H-6a’), 3.53-3.48 (m, 
2H, H-3’ and H-5), 3.43 (t, J3’,4’ = J4’,5’ = 9.1 Hz, 1H, H-4’), 3.41 (dd, J5’,6b’ = 5.0 Hz, 1H, H-6b’), 3.36 (dd, J4’’,5b’’ = 
8.2 Hz J5a’’,5b’’ = 11.9 Hz, 1H, H-5b’’), 3.28 (bd, J2,3 = 9.4 Hz, 1H, H-2), 3.13-3.10 (m, 1H, H-5’), 2.09, 2.06, 2.02 
(3 x s, 9H, Me Ac), 0.89 (s, 9H, Me OTBDMS), 0.13, 0.10 (2 x s, 6H, Me OTBDMS); 
13
C NMR (125 MHz, CDCl3): 
δ 170.0, 169.9, 169.6 (3x C=O Ac), 154.0 (C=O Troc), 138.7 (C, 3-O-Bn), 138.3 (C, 4’-O-Bn), 137.7 (C, 6-O-Bn), 
128.7, 128.57, 128.56, 128.2, 128.1, 128.0, 127.8, 127.2 (7x Carom), 100.5 (C-1’, C1’’), 95.5 (CCl3 Troc), 95.3 (C-
1), 79.1 (C-4), 78.2 (C-2), 78.1 (C-3), 76.0 (C-4’), 75.9 (C-5’), 75.0 (CH2 4’-O-Bn), 74.7 (C-5), 74.5 (CH2 Troc), 
73.9 (CH2 3-O-Bn, 6-O-Bn), 73.7 (C-3’), 70.52, 70.46 (C-2’’ and C-3’’), 69.0 (C-6), 68.4 (C-4’’), 62.1 (C-6’), 61.7 
(C-5’’), 59.7 (C-2), 25.7 (Me t-Bu, OTBDMS), 21.1, 20.9, 20.8 (3 x Me Ac), 18.1 (Cq t-Bu, OTBDMS), -4.1, -5.1 (2 
x Me, OTBDMS); HRMS (ESI) m/z calcld. for [C53H70Cl3NNaO19Si]
+
: 1180.3269, odsd.: 1180.3270. 
 
Tert-butyldimethylsilyloxy   2-acetamido-2-deoxy-4-O-[2-O-
(2,3,4-tri-O-acetyl-β-D-xylopyranosyl)-4,6-O-(R)-benzylidene-3-O-
115 
 
para-methoxybenzyl-β-D-mannopyranosyl]-3,6-O-bynzyl-β-D-glucopyranoside (90). Troc protected trimer 
(54a) (128.7 mg, 0.104 mmol) was dissolved in THF (0.4 mL), followed by the addition of activated zinc 
(350.0 mg, 5.35 mmol) and aq. Na2HPO4 (0.1 mL, 1M). The suspension was stirred vigorously until TLC 
analysis showed complete disappearance of the starting material. The reaction mixture was then diluted 
with EtOAc, filtered over celite to remove unreacted zinc, and co-concentrated with pyridine. The residue 
was dissolved in pyridine/Ac2O (1 mL, 2/1) and left to stir until TLC analysis, [Rf: 0.08, (Pe/EtOAc, 2/1, v/v, 
ninhydrin stain)], showed complete disappearance of the amine. The reaction mixture was diluted with 
EtOAc, washed with sat. aq. NaHCO3 (4x) until no further gas was formed. The organic fraction was then 
washed with brine (1x), dried over MgSO4, filtered and concentrated. Purification of the residue by column 
chromatography (silica gel, PE/EtOAc, 2/1, v/v) yielded the title compound (90) (100 mg, 0.087 mmol, 84%) 
as a colourless oil. Rf: 0.42 (Pe/EtOAc, 2/1, v/v ) ; []D
17.7
 = -33 (c 1.0 CHCl3); IR (ν): 3294, 3065, 3034, 2955, 
2929, 2858, 1749, 1658, 1613, 1558, 1514, 1455, 1371, 1303, 1249, 1223, 1175, 1086, 1053, 839 cm
-1
; 
1
H 
NMR (500 MHz, CDCl3): δ 7.51-7.49 (m, 2H, CHarom), 7.41-7.36 (m, 3H, CHarom), 7.35-7.25 (m, 13H, CHarom), 
6.86 (d, J = 8.8 Hz, J = 7.5 Hz, 2H, CHarom OPMB), 5.47 (s, 1H, CHPh), 5.45 (bd, J2,NH = 8.0 Hz, 1H, NHAc), 5.05 
(d, J1’’,2’’ = 6.6 Hz, 1H, H-1’’), 5.04-5.00 (m, 2H, H-2’’ and H-4’’), 4.99 (d, J1,2 = 7.6 Hz, 1H, H-1), 4.94 (d, Ja,b = 
11.5 Hz, 1H, CH-a 3-O-Bn), 4.80 (dd, J =3.4 Hz, J =7.3 Hz, 1H, H-3’’), 4.53 (dd, Ja,b =12.0 Hz, Ja,b =21.9 Hz, 2H, 
CH2 4’-O-PMB), 4.62 (d, Ja,b = 12.0 Hz, 1H, CH-a 6-O-Bn), 4.568 (s, 1H, 1’), 4.567 (dd, J4’’,5a’’ = 3.4 Hz, J5a’’,5b’’ = 
12.9 Hz, 1H, H-5a’’), 4.51 (d, Ja,b = 11.7 Hz, 1H, CH-b 3-O-Bn), 4.46 (d, Ja,b = 12.0 Hz, 1H, CH-b 6-O-Bn),4.13 
(dd, J5’,6a’ = 4.9 Hz, J6a’,6b’ = 10.5 Hz, 1H, H-6a’), 4.04 (d, J1’,2’ = 3.1 Hz, 1H, H-2’), 4.00 (dd, J3,4 = 8.5 Hz, J2,3 = 9.8 
Hz, 1H, H-3), 3.883 (t, J = 8.3 Hz, 1H, H-4), 3.879 (t, J = 9.8 Hz, 1H, H-4’), 3.79 (s, 3H, OMe OPMB), 3.47 (m, 
2H, H-5 and H-6b’), 3.43 (dd, J4’’,5b’’ = 3.1 Hz, J5a’’,5b’’ = 12.9 Hz, 2H, H-5b’’ and H-3), 3.40 (m, J2,3 = 9.5 Hz, 1H, 
H-2), 3.14 (dt, J5’,6a’ = 4.9 Hz, J5’,6b’ = J4’,5’ = 9.8 Hz, 1H, H-5’), 2.12, 2.07, 2.00 (3 x s, 9H, Me O-Ac), 1.82 (s, 3H, 
Me NHAc), 0.89 (s, 9H, Me t-Bu OTBDMS), 0.12, 0.09 (2 x s, 6H, Me OTBDMS); 
13
C NMR (125 MHz, CDCl3): δ 
169.95, 169.93, 169.3, 169.2 (4 x C=O O-Ac and N-Ac), 159.2 (C, 3’-O-PMB), 139.3 (C, 3-O-Bn), 137.9 (C, 6-O-
Bn), 137.4 130.2, 129.2, 128.9, 128.5, 128.21, 128.19, 128.1, 127.9, 127.7, 127.6, 127.3, 126.1 (13x CHarom), 
113.7 (CHarom PMB), 101.9 (C-1’), 101.5 (C-CHPh), 99.0 (C-1’’), 95.2 (C-1), 79.9 (C-4), 78.36, 78.32 (C-3 and C-
4’), 76.4 (C-3’), 75.3 (C-2’), 74.4 (C-5), 74.2, 73.6 (CH2 6-O-Bn and CH2 4-O-Bn), 71.8 (CH2 PMB), 69.3 (C-6), 
68.6 (C-6’), 68.4, 68.2 (C-2’’ and C-4’’), 68.0 (C-3’’), 67.3 (C-5’), 59.8 (C-5’’), 58.4 (C-2), 55.3 (OMe PMB), 25.6 
(Me t-Bu, OTBDMS), 23.5 (Me N-Ac), 21.0, 21.0, 20.8 (3 x Me O-Ac), 17.9 (Cq t-Bu, OTBDMS), -4.2, -5.2 (2 x 
Me, OTBDMS); HRMS (ESI) m/z calcld. for [C60H77NNaO19Si]
+
: 1166.4751, odsd.: 1166.4763. 
 
2-N-acetamido-2-deoxy-4-O-(2-O-β-D-xylopyranosyl-β-D-mannopyranosyl)-
β-glucopyranose (99). Acetamido trimer (90) (81.9 mg, 0.072 mmol) was 
dissolved in dry THF (0.5 mL), NH3 (l)(15 mL) was added followed by the 
carful addition of sodium (s) (200 mg) until the blue colour remained. The 
116 
 
solution was stirred for 1.5 h under refluxing NH3, then MeOH was added (4 mL) and resulting solution 
allowed to warm up to rt and the NH3 was evaporated. The solution was neutralized by the addition of 
activated DOWEX® H
+
, after 15 min the organic phase was filtered and concentrated under reduced 
pressure. Purification by reverse phase column chromatography (HyperSep C8 Column, 050% MeOH/H2O) 
yielded title compound (99) as a white foam (21.9 mg, 0.042 mmol, 59%) and TBDMS protected trimer (100) 
as a collerless oil (18.9 mg, 0.30 mmol, 41%); Rf: 0.05 (EtOAc/ isopropanol/H2O, 6/4/1 v/v ) ;[]D
19.8
 = -20 (C 
0.1 CHCl3); ratio α/β = 2/1 IR (ν): 3295, 2923, 2853, 1636, 1557, 1427, 1375, 1318, 1245, 1155, 1032, 897, 
807 cm
-1
;
1
H NMR (500 MHz, CDCl3): δ 5.18 (d, J1,2 = 3.2 Hz, 1H, H-1α), 4.82 (s, 1H, H-1’ α), 4.81 (s, 1H, H-1’ β), 
4.69 (d, J1,2 = 7.6 Hz, 1H, H-1β), 4.48 (d, J1’’,2’’ = 7.8 Hz, 1H, H-1’’α), 4.45 (d, J1’’,2’’ = 7.6 Hz, 1H, H-1’’β), 4.23 (d, 
J2’,3’ = 3.4 Hz, 1H, H-2’α), 4.21 (d, J2’,3’ = 3.5 Hz, 1H, H-2’β), 3.96-3.82 (m, 8H), 3.81-3.79 (m, 1.4H), 3.78-3.68 
(m), 3.66-3.53 (m, 7H, H-2, H-3, H-3’, H-3’’, H-4, H-4’, H-4’’, H-5, H-5’, H-6 and H-6’), 3.35 (d, J1’’,2’’ = 7.8 Hz, H-
2’’α), 3.34 (d, J1’’,2’’ = 7.6 Hz, H-2’’β), 3.23 (t, J = 11.5 Hz, H-5b’’α), 3.22 (t, J = 11.2 Hz, H-5b’’β), 2.02 (s, 6H, Me 
NHAc); 
13
C NMR (125 MHz, CDCl3): δ 174.6, 174.3 (2x C=O, NHAc), 104.0, 103.9 (2x C-1’’), 100.1 (C-1’), 94.8 
(C-1β), 90.4 (C-1α), 79.1, 78.8, 77.77, 77.69, 76.27, 74.6, 73.11, 73.06, 72.2, 71.7, 70.0, 69.2, 69.1, 66.7 (C-2’, 
C-2’’, C-3, C3’, C-3’’, C-4, C-4’, C-4’’, C-5, C-5’), 64.9 (C-5’’), 60.3, 60.2, 60.1 (C-6, C-6’), 56.1 (C-2β), 53.6 (C-
2α), 22.0, 21.7 (2 x Me NHAc); HRMS (ESI) m/z calcld. for [C19H33NNaO15]
+
: 538.1742, odsd.: 538.1738. 
 
Tert-Butyldimethylsilyloxy   2-N-acetamido-2-deoxy-4-O-(2-O-β-
D-xylopyranosyl-β-D-mannopyranosyl)-β-D-glucopyranoside (100). 
1
H 
NMR (500 MHz, CDCl3): δ 4.82 (s, 1H, H-1’), 4.72 (d, J1,2 = 7.6 Hz, 1H, H-
1), 4.45 (d, J1’’,2’’ = 7.6 Hz, 1H, H-1’’), 4.22 (s, 1H, H-2’), 3.93 (dd, J4’’,5’’ = 
5.7 Hz, J5a’’,5b’’ = 12.0 Hz, 1H, H-5a’’), 3.88 (t, J = 12.7 Hz, 2H, H-6a and H-6a’), 3.76-3.53 (m, 9H, H-2, H-3, H-3’, 
H-4, H-4’, H-4’’, H-5, H-6b, H-6b’), 3.42 (t, J = 7.8 Hz, 2H, H-3’’, H-5’), 3.35 (t, J1’’,2’’ = J2’’,3’’ = 7.8 Hz, 1H, H-2’’), 
3.23 (t, J4’’,5’’ = J5a’’,5b’’ = 11.2 Hz, 1H, H-5b’’), 2.01 (s, 3H, Me NHAc), 0.86 (s, 9H, t-Bu, OTBDMS), 0.12, 0.11 (2x 
6H Me, OTBDMS); 
13
C NMR (125 MHz, CDCl3): δ 174.2 (C=O, NHAc), 104.1 (C-1’’), 100.2 (C-1’), 95.9 (C-1), 
79.2 (C-4), 77.9 (C-2), 76.3 (C-5’), 75.3, (C-3’’), 74.5 (C-5), 73.1 (C-2’’), 72.1 (C-3), 71.7 (C-3’), 69.2 (C-4’’), 66.7 
(C-4’), 64.9 (C-5’’), 60.3 (C-6 and C-6’), 56.9 (C-2), 24.6 (Me, t-Bu, OTBDMS), 22.2 (Cq, t-Bu, OTBDMS), -5.4, -
6.4 (2x Me, OTBDMS); HRMS (ESI) m/z calcld. for [C25H47NNaO15Si]
+
: 652.2607, odsd.: 652.2607. 
 
 
2-N-acetamido-2-deoxy-4-O-(2-O-β-D-xylopyranosyl-β-D-mannopyranosyl)- 
β-glucopyranose (99). Silane protected trimer (100) (14.6 mg, 0.023 mmol) 
was dissolved in MeOH (0.3mL), activated DOWEX® H
+
 added (20 granules) 
and left for 2 days. The DOWEX® H
+
 was then filtered of and the organic 
fraction concentrated. Purification by reverse phase column chromatography (HyperSep C8 column, H2O) 
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yielded title compound (99) as a white foam (11.3 mg, 0.023 mmol, 96%); Data matched those reported 
above. 
 
Tert-butyldimethylsilyloxy   2-N-acetamido-2-deoxy-4-O-(2-
O-acetyl-4,6-O-[R]-benzylidene-3-O-para-methoxybenzyl-β-D-
glucopyranosyl)-3,6-O-bynzyl-β-D-glucopyranoside (89). Troc 
protected dimer (87) (41.8 mg, 0.039 mmol) was dissolved in THF (0.15 mL), followed by the addition of 
activated zinc (60 mg, 0.92 mmol) and aq. Na2HPO4 (0.03 mL, 1M). The suspension was stirred vigorously 
until TLC analysis showed complete disappearance of the starting material (1.5 h). The reaction mixture was 
then diluted with EtOAc, filtered over celite to remove unreacted zinc. The residue was dissolved in 
pyridine/Ac2O (1 mL, 2/1) and left to stir until TLC analysis, [Rf :0.34 (1/1, Pe/EtOAc, v/v, ninhydrine stain)], 
showed complete disappearance of the amine. The reaction mixture was diluted with EtOAc, washed with 
sat. aq. NaHCO3 (3x) until no further gas was formed. The organic fraction was then washed with brine (1x), 
dried over MgSO4, filtered and concentrated. Purification by flash chromatography (silica gel, 33% EtoAc in 
PE) gave the title compound (89) as a collerless oil (23.1mg, 0.025 mmol, 64%); TLC Rf: 0.23 (Pe/EtOAc, 2/1, 
v/v); []D
23.3
 = -15 (c 0.1, CHCl3); IR (ν): 3281, 3066, 3033, 2956, 2930, 2857, 1751, 1654, 1559, 13.72, 1246, 
1231, 1095, 1063, 839, 752, 698 cm
-1
;
 1
H NMR (500 MHz, CDCl3): δ 7.52-7.48 (m, 2H, CHarom), 7.44-7.38 (m, 
3H, CHarom), 7.36-7.28 (m, 10H, CHarom), 7.21-7.19 (m, 2H, CHarom 3’-O-PMB), 6.88-6.85 (m, 2H, CHarom 3’-O-
PMB), 5.79 (d, JNH,2 = 8.6 Hz, 1H, NH NHAc), 5.53 (s, 1H, CHPh), 4.95 (d, J2’,3’ = 6.1 Hz, 1H, H-2’), 4.94 (d, J1,2 
=8.9 Hz, 1H, H-1), 4.78 (d, Ja,b = 11.6 Hz, 1H, CH-a 3’-O-Bn), 4.75 (d, Ja,b = 11.8 Hz, 1H, CH-a 3-O-Bn), 4.64 (d, 
Ja,b = 12.1 Hz, 1H, CH-a 6-O-Bn), 4.63 (d, Ja,b = 11.9 Hz, 1H, CH-b 3-O-Bn), 4.60 (d, Ja,b = 11.8 Hz, 1H, CH-b 3’-O-
Bn), 4.55 (d, J1’, 2’ = 7.9 Hz, 1H, H-1’), 4.48 (d, Ja,b = 12.0 Hz, 1H, CH-b 6-O-Bn), 4.26 (dd, J5’,6’ = 5.1 Hz, J6a’,6b’ = 
10.5 Hz, 1H, H-6a’), 3.97 (t, J3,4 = J4,5 = 6.7 Hz, 1H, H-4), 3.88 (t, J2,3 = J3,4 = 7.0 Hz, 1H, H-3), 3.83-3.80 (m, 1H, 
H-6a), 3.81 (s, 3H, OMe OPMB), 3.69 (t, J = 9.7 Hz, 2H, H-4’ and H-6b), 3.65-3.54 (m, 4H, H-2, H-3’, H-5, H-
6b’), 3.29 (dt, J = 5.1 Hz, J = 9.7 Hz, 1H, H-5’), 2.00 (s, 3H, Me, OAc), 1.90 (s, 3H, Me, NHAc), 0.89 (s, 9H, t-Bu, 
OTBDMS), 0.09, 0.08 (2x Me, OTBDMS); 
13
C NMR (125 MHz, CDCl3): δ 170.1 (C=O NHAc), 169.7 (C=O OAc), 
159.3 (C-OPMB), 138.7, 138.1, 137.2 (3x C-OBn), 130.3, 129.5, 129.1, 128.5, 128.29, 128.26, 127.8, 127.7, 
127.5, 126.0, 113.7 (11x CHarom), 101.2 (CHPh), 100.3 (C-1’), 94.7 (C-1), 81.6 (C-4’), 77.8 (C-3’), 77.2 (C-3), 
75.6 (C-4), 74.3 (C-5), 73.8 (CH2 3’-O-Bn), 73.6 (CH2 3-O-Bn, CH2 6-O-Bn), 73.3 (C-2’), 68.9 (C-6), 68.6 (C-6’), 
66.1 (C-5’), 55.5 (C-2), 55.3 (Me OPMB), 25.6 (Me, t-Bu, OTBDMS), 23.4 (Me NHAc), 20.9 (Me OAc), 17.9 (Cq, 
t-Bu, OTBDMS), -4.4, -5.3 (2 x Me, OTBDMS); HRMS (ESI) m/z calcld. for [C51H65NNaO13Si]
+
: 950.4117, odsd.: 
950.4124. 
 
2-N-acetamido-2-deoxy-4-O-β-D-mannopyranosyl-β-D-glucopyranose (98). 
Acetamido dimer (89) (27.8 mg, 0.030 mmol) was dissolved in dry THF (0.3 
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mL), NH3 (l)(15 mL) was added followed by the carful addition of sodium (s) until the blue colour remained. 
The solution was stirred for 45 min under refluxing NH3, then MeOH was added (4 mL) and resulting solution 
allowed to warm up to rt and the NH3 was evaporated. The solution was neutralized by the addition of 
activated DOWEX® H
+
, after 15 min the organic phase was filtered and concentrated under reduced 
pressure. Purification by column chromatography (HyperSep C18 column, H2O) yielded title compound (98) 
as a white foam (10.8 mg, 0.028 mmol, 94%). 
1
H NMR (500 MHz, CDCl3): δ 5.18 (s, 1H, H-1α), 4.69 (d, J1,2 = 
7.8 Hz, 1H, H-1β), 4.51 (d, J1,2 = 8.1 Hz, 1H, H-1’’), 3.96-3.78 (m, 8H), 3.73-3.64 (m, 7H), 3.51-3.44 (m, 4H), 
3.41-3.37 (m, 2H), 3.34-3.27 (m, 2H), 2.02 (s, 5H, Me NHAc); 
13
C NMR (125 MHz, CDCl3): δ 174.6, 174.4 (2x 
Cq NHAc), 102.4, 94.7, 90.4 (C-1α, C-1β, C-1’), 79.0, 78.6, 75.91, 75.88, 75.4, 74.7, 73.1, 72.3, 10.2, 69.3, 
69.1, 62.4, 60.5, 59.9, 59.8, 56.2, 53.7, 48.8 (C-2, C-2’, C-3, C-3’, C-4, C-4’, C-5, C-5’, C-6, C-6’), 22.1, 21.8 (2 x 
Me NHAc); HRMS (ESI) m/z calcld. for [C14H25NNaO11]
+
: 406.1320, odsd.: 406.1319. 
 
 
 
4-O-(2-O-benzoyl-3,6-di-O-(2-O-benzoyl-3,4,6-tri-O-benzyl-α-D-
mannopyranosyl)-4-O-benzyl-β-D-mannopyranosyl)-3,6-di-O-
benzyl-2-deoxy-2-(2,2,2-trichloroethoxy)carbonylamido-α/β-D-
glucopyranose (77). Compound 58b (233.1 mg , 0.112 mmol) 
was transferred to a Falcon tube (25 mL) then dissolved in THF 
(0.33mL) and treated with HF∙ pyridene (70%, 133µL) for 6h. The 
reaction was then diluted with EtOAc and the organic layer washed with saturated aq. NaHCO3 (3x) and 
Brine (1x). The organic layer was then dried over MgSO4, Filtered, and concentrated in vacuo. Purification by 
flash chromatography (silica gel, 33% EtOAc in PE) yielded the title compound 77 as an amorphous white 
solid (103mg, 103mmol, 92%, α/β = 10/1); TLC Rf: 0.05 (Pe/EtOAc, 2/1, v/v); D
19.8
 = 1.3 (c 0.1, CHCl3); IR (ν): 
3419, 3088, 3064, 3031, 2926, 2865, 1724, 1453, 1268, 1097, 1028, 736, 711, 698 cm
-1
; 
1
H NMR (500 MHz, 
CDCl3): δ 8.14-8.13 (m, 2H, CHarom OBz), 8.05-8.03 (m, 4H, CHarom OBz), 7.58-7.53 (m, 3H, CHarom), 7.50-7.47 
(m, 2H, CHarom), 7.39-7.21 (m, 36H, CHarom), 7.19-7.06 (m, 12H, CHarom), 5.72 (s, 1H, H-2’’’), 5.67 (s, 1H, H-2’), 
5.59 (s, 1H, H-2’’), 5.25 (s, 1H, H-1’’), 4.98 (s, 1H, H-1’’’), 4.87-4.65 (m, 10H, CH2 O-Bn), 4.85 (s, H-1), 4.81 (s, 
H-1’), 4.59-4.41 (m, 9H, CH2 O-Bn), 4.35-4.32 (m, 2H, CH2 O-Bn), 4.19-4.00 (m, 5H, H-3, H-3’’, H-4’’, H-4’’’, H-
5’’), 3.96 (dd, J =2.9 Hz, J =9.5 Hz, 1H, H-3’’’), 3.88-3.70 (m, 7H, H-2, H-3’, H-4’, H-5, H-5’’’, H-6’), 3.64-3.63 
(m, 1H, CH-a H-6), 3.57 (d, J = 11.2 Hz, 1H, CH-b H-6), 3.35 (dd, J = 5.4 Hz, J =8.5 Hz, 1H, H-5’); 
13
C NMR (125 
MHz, CDCl3): δ 165.6, 165.5, 165.4 (3x C=O Bz), 154.2 (C=O Troc), 138.7, 138.6, 138.5, 138.2, 138.1, 138.0, 
137.9, 137.8, 137.4 (9x CHarom), 133.4, 133.2, 133.1 (3x CHarom OBz), 129.99, 129.97, 129.94, 129.8 (4x CHarom 
OBz), 128.7, 128.5, 128.4, 128.35, 128.28, 128.18, 128.15, 128.1, 128.0, 127.9, 127.82, 127.77, 127.73, 
127.65, 127.54, 127.48, 127.44, 127.36 (18x CHarom), 99.7 (C-1’’), 98.2 (C-1’’’), 97.2 (C-1’), 95.4 (CCl3 Troc), 
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91.8 (C-1), 79.0 (C-3’), 77.8 (C-3’’), 77.5 (C-3’’’), 76.0 (C-3), 75.5, 75.3 (2x CH2 Bn), 74.7 (C-4’), 74.6 (3x CH2 
Bn), 74.5 (C-4), 74.3 (C-4’’’), 73.9 (C-4’’), 73.4, 73.3 (2x CH2 Bn), 72.7 (C-5’’), 71.8 (C-5’’’), 71.7 (C-2’), 71.5, 
71.2 (2x CH2 Bn), 70.1 (C-5), 69.4 (C-2’’), 68.9, 68.8 (C-6, C-6’’, C-6’’’), 68.5 (C-2’’’), 66.9 (C-6’), 54.3 (C-2); 
HRMS (ESI) m/z calcld. for [C111H110Cl3NNaO25]
+
: 1984.6325, odsd.:1984.6325 
 
4-O-(-2-O-benzoyl-3,6-di-O-[2-O-benzoyl-3,4,6-tri-O-
benzyl-α-D-mannopyranosyl]-4-O-benzyl-β-D-
mannopyranosyl)-3,6-di-O-benzyl-2-deoxy-2-(2,2,2-
trichloroethoxy)carbonylamido-1-O-(N-[phenyl]trifluoro-
acetimidoyl)-α/β-D-glucopyranoside (82). Lactol (77) 
(125.7 mg, 0.064 mmol) was dissolved in dry acetone (0.7 
mL), N-(phenyl)trifluoroacetimidoyl chloride (26 µL, 0.19 mmol) was at 0°C followed by the addition of 
Cs2CO3 ( 31 mg, 0.096 mmol). The resulting suspension was allowed to warm up to rt and stirred for 2 h and 
until side product formation was observed [Rf side: 0.63 (toluene/EtOAc, 6/1, v/v)]. The reaction was diluted 
with EtOAc, then filtered over celite to remove the unreacted Cs2CO3 and concentrated in vacuo. Purification 
using flash chromatography (silica gel, 3%  6% EtOAc in toluene) yielded title compound 82 as a colourless 
oil. (108.7 mg, 0.051 mmol, 80%); α/β = 2/1; TLC α Rf: 0.57, β Rf: 0.50 (toluene/EtOAc, 6/1, v/v); IR (ν): 3050, 
3030, 2930, 2873, 1560, 1728, 1355, 1268, 1108, 1042, 752 cm
-1
; 
1
H NMR (500 MHz, CDCl3): δ 8.19-8.18 (m, 
2H, CHarom Bz), 8.06-8.04 (m, 2H, CHarom Bz), 7.96-7.94 (m, 2H, CHarom Bz), 7.58-7.49 (m, 5H,3x CHarom Bz, 2x 
CHarom Bn), 7.40-7.05 (m, 50H, CHarom), 6.87 (m, 2H, CHarom Bn), 6.70-6.69 (m, 2H, CHarom Bn), 5.76 (s, 1H, H-
2’’’), 5.67 (d, J1’,2’ = 3.0 Hz, 1H, H-2’), 5.62 (t, J1’’,2’’ = 2.2 Hz, 1H, H-2’’), 5.26 (d, J1’’,2’’ = 1.5 Hz, 1H, H-1’’), 5.10 
(d, J1’’’,2’’’ = 1.4 Hz, 1H, H-1’’’), 4.87-4.81 (m, 4H, 3x CH2 Bn, NH Troc), 4.76-4.59 (m, 6H, 6x CH2 Bn, H-1’), 4.69 
(bs, 1H, H-1’), 4.59-4.46 (m, 8H, 6x CH2 Bn, 2 x CH2 Troc), 4.41 (d, Ja,b = 12.2 Hz, 2H, CH2 Bn), 4.33 (d, Ja,b = 
11.4 Hz, 2H, CH2 Bn), 4.19-4.07 (m, 6H, H-3, H-3’’’, H-4, H-4’’ H-4’’’), 4.00-3.98 (m, 1H, H-3’’), 3.96 (t, J = 10 
Hz, 1H, H-4’), 3.92 (dd, J5’,6a’ = 11.7 Hz, 1H, H-6a’), 3.87-3.77 (m, 6H, H-2, H-3’, H-5’’, 2 x H-6, H-6b’), 3.72-3.57 
(m, 5H, H-5’’, 4x H-6), 3.46-3.41 (m, 1H, H5), 3.24-3.22 (m, 1H, H5); 
13
C NMR (125 MHz, CDCl3): δ 165.7, 
165.5, 165.3 (3x C=O Bz), 153.9 (C=O Troc), 146.6, 143.2, 140.2, 138.7, 138.6, 138.5, 137.9, 137.8, 137.7, 
137.6 (10 x CHarom), 133.4, 133.2, 133.0 (3x CHarom Bz), 129.97, 129.95, 129.9, 129.83, 129.79, 129.7, 128.9, 
128.73, 128.69, 128.50, 128.47, 128.39, 128.36, 128.3, 128.23, 128.18, 128.17, 128.1, 128.0, 128.0, 127.8, 
127.74, 127.69, 127.64, 127.56, 127.52, 127.47, 127.446, 127.36 (29x CHarom), 119.3 (CHarom), 99.7 (C-1’’), 
99.0 (C-1’), 98.3 (C-1’’’), 95.3 (CCl3 Troc), 79.0 (C-3’), 78.0 (C-3’’’), 77.9 (C-3’’), 77.3 (C-3), 75.3, 75.2 (2x CH2 
Bn), 74.7, 74.61, 74.56, 74.5, 74.4 (C-4 or C-4’’’, C-4’, C-5, C-5’, CH2 Bn), 74.2, 74.1 (2x CH2 Bn), 73.9 (C-4’’), 
73.5, 73.41, 74.37, 72.9 (4x (CH2 Bn), 72.6 (C-4 or C-4’’’, C-5’’), 71.7 (CH2 Bn), 71.6 (C-2’), 71.3 (CH2 Bn), 69.3 
(C-2’’), 69.1, 68.9 (2x C-6), 68.5 (C-2’’’), 67.7 (C-6), 65.7 (C-6’), 53.9 (C-2); HRMS (ESI) m/z calcld. for 
[C119H114Cl3F3N2NaO25]
+
: 2155.6621, odsd.: 2155.6626 
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 Tert-butyldimethylsilyloxy  4-O-(2-O-benzoyl-3,6-di-O-[2-O-
benzoyl-3,4,6-tri-O-benzyl-α-d-mannopyranosyl]-4-O-benzyl-
β-d-mannopyranosyl)-3,6-di-O-benzyl-2-deoxy-2-(2,2,2-
trichloroethyloxy)cabonylamido-β-D-glucopyranoside (58b). 
Diol acceptor (72) (628 mg, 0.63 mmol) and mannose donor 
(53) (1.68 g, 2.4 mmol), were co-evaporated with toluene (3x), dissolved in dry CH2Cl2 (12 mL) and activated 
molecular sieves (4Å) added. The resulting suspension was left to stir at 0°C for 45 min after which TMSOTf 
(328 µL, 1M in CH2Cl2) was added. The reaction was then allowed to warm up to rt. After 4h a second 
portion of mannose donor (53) (407 mg, 0.58 mmol) was added in CH2Cl2 (1 mL) and left an additional 1.5h. 
the reaction was diluted with CH2Cl2 and the organic phase washed with sat. aq NaHCO3 (2x) and Brine (1x), 
dried over MgSO4, filtered and concentrated in vacuo. Purification of the residue by column chromatography 
(silica gel, 0% 5% EtOAc in CH2Cl2) and size exclusion chromatography (Sephadex® LH-20, bead size 25-
100µ, CH2Cl2/MeOH, 1/1, v/v) yielded the title compound (58b) (1178.2 mg, 0.567 mmol, 91 %) as a 
colourless oil. Rf : 0.60 (CH2Cl2/EtOAc, 20/1, v/v); αD
16.0
: -0.6 (c = 1.0 in CHCl3); IR (ν): 3064, 3031, 2928, 2859, 
1724, 1602, 1515, 1497, 1453, 1362, 1316, 1267, 1097, 1070, 1028, 839, 737, 711, 698 cm
-1
; 
1
H NMR (500 
MHz, CDCl3): δ 8.15-8.13 (m, 2H, CHarom Bz), 8.09-8.06 (m, 2H, CHarom Bz), 8.05-8.03 (m, 2H, CHarom Bz), 8.0-
7.98 (m, 2H, CHarom Bz), 7.58-7.40 (m, 3H, CHarom), 7.38-7.23 (m, 33H, CHarom), 7.19-7.14 (m, 8H, CHarom), 7.10 
(s, 6H, CHarom), 6.91-6.90 (m, 2H, CHarom), 5.68 (s, 2H, H-2’ and H-2’’), 5.59 (t, J1’’’,2’’’ = J2’’’,3’’’ = 2.2 Hz, 1H, H-
2’’’), 5.24 (d, J1’’’,2’’’ = 1.5 Hz, 1H, H-1’’’), 5.06 (s, 1H, H-1’’), 4.82 (s, 1H, H-1’), 4.81 (d, Ja,b = 10.9 Hz, 1H, CH2 
Bn), 4.77 (d, Ja,b = 12.2 Hz, 1H, CH2 Bn), 4.75 (d, Ja,b = 11.0 Hz, 1H, CH2 Bn), 4.73 (d, Ja,b = 12.2 Hz, 1H, CH2 Bn), 
4.68 (bs, 1H, H-1), 4.65 (d, Ja,b = 11.7 Hz, 1H, CH2 Bn), 4.63 (d, Ja,b = 10.9 Hz, 1H, CH2 Bn), 5.54 (d, Ja,b = 11.3 
Hz, 1H, CH2 Bn), 4.53 (d, Ja,b = 11.5 Hz, 1H, CH2 Bn), 4.50 (d, Ja,b = 11.9 Hz, 2H, CH2 Troc), 4.46 (d, Ja,b = 12.2 Hz, 
1H, CH2 Bn), 4.42 (d, Ja,b = 11.5 Hz, 1H, CH2 Bn), 4.39 (d, Ja,b = 11.0 Hz, 1H, CH2 Bn), 4.36 (d, Ja,b = 11.2 Hz, 1H, 
CH2 Bn), 4.31 (d, Ja,b = 11.2 Hz, 1H, CH2 Bn), 4.12 (t, J3’’’,4’’’’ = J4’’’,5’’’ = 9.5 Hz, 1H, H-4’’’), 4.07-4.05 (m, 3H, H-
5’’’, H-3’’, H-4’ or H-4’’), 4.01 (t, J3,4 = J4,5 = 9.3 Hz, 1H, H-4), 3.95 (dd, J2’’’,3’’’’ = 3.0 Hz, J3’’’,4’’’ = 9.2 Hz, 1H, H-
3’’’), 3.86 (dd, J6a’,6b’ = 5.1 Hz J5’,6’ = 11.2 Hz, 1H, H-6a’), 3.85 (s, 3H, H-3’, H-5’’, H-4’ or H-4’’), 3.82 (dd, J6a’’’,6b’’’ 
= 2.9 Hz, J5’’’,6’’’ = 11.2 Hz, 1H, H-6a’’’), 3.79 (t, J6a’,6b’ J6a’’’,6b’’’ = 11.1 Hz, 2H, H-6b’ and H-6b’’’), 3.66 (dd, J6a’’,6b’’ = 
3.4 Hz, J5’’,6’’ = 11.0 Hz, 1H, H-6a’’), 3.69 (dd, J6a,6b = 2.9 Hz, J5,6 = 11.7 Hz, 1H, H-6a), 3.58 (dd, J6a,6b = 0.8 Hz, J5,6 
= 11.0, 1H, H-6b), 3.57 (bt J2,3 = J3,4 = 9.2 Hz, 1H, H-3), 3.52 (t, J5,6 =, J6a’’,6b’’ = 12.7 Hz, 1H, H-6b’’), 3.34-3.30 
(m, 2H, H-5 and H-5’), 3.02 (bdd, J1,2 = 7.2 Hz, 1H, H-2), 0.82 (s, 9H, Me t-Bu OTBDMS), 0.04, -0.01 (2x s, 3H, 
Me OTBDMS); 
13
C NMR (125 MHz, CDCl3): δ 165.8, 165.7, 165.6 (3 x C=O, OBz), 153.6 (C=O, Troc), 138.94, 
138.86, 138.3, 138.2, 138.1, 137.8, 133.4, 133.2, 133.1, 130.1, 128.9, 128.7, 128.62, 128.59, 128.57, 128.52, 
128.50, 128.47, 128.44, 128.43, 128.37, 128.29, 128.28, 128.2, 128.13, 128.09, 128.03, 127.98, 127.96, 
127.91, 127.83, 127.78, 127.7, 127.64, 127.61, 127.59, 127.57, 127.54, 127.52, 127.45, 127.3 (41  CHarom), 
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100.0 (C-1’’’), 98.8 (C-1’), 98.2 (C-1’’), 95.6 (C-1), 95.5 (CCl3, Troc), 79.6 (C-3’), 78.4 (C-3’’), 78.2 (C-4), 78.0 (C-
3’’’), 77.4 (C-3), 75.4, 75.2 (CH2, Bn), 74.8, 74.6 (C-5, C-5’, C-4’,C-4’’), 74.1 (C-4’’’), 74.0, 73.61, 73.59, 73.5 
(CH2, Bn), 72.8 (C-5’’’), 72.3 (CH2 Bn), 71.9 (C-2’), 71.6 (CH2 Bn), 69.6 (C-2’’’), 69.3, 69.13, 69.07, 68.9 (C-2’’, C-
6, C-6’’, C-6’’’), 66.5 (C-6’), 59.6 (C-2), 25.8 (Me, t-Bu, OTBDMS), 18.1 (Cq, t-Bu, OTBDMS), -4.1, -5.1 (2 x Me, 
TBDMS). HRMS(ESI) m/z calcld. for [C57H66O14NCl3Si+Na]
+
: 2098.7195, obsd.: 2098.7184. 
 
Tert-butyldimethylsilyloxy   4-O-(2-O-[2,3,4-tri-O-
acetyl-β-D-xylopyranosyl]-3,6-di-O-[2-O-benzoyl-3,4,6-tri-O-
benzyl-α-D-mannopyranosyl]-4-O-benzyl-β-D-
mannopyranosyl)-3,6-di-O-benzyl-2-deoxy-2-(2,2,2-
trichloroethoxy)carbonylamido-β-D-glucopyranoside (58a). 
Trimer acceptor (74) (438 mg, 0.38 mmol) and mannose 
imidate donor (53) (1.01 g, 1.5 mmol) were co-evaporated together with toluene (3x), dissolved in CH2Cl2 
(7.5 mL) and activated molecular sieves (4 Å) were added. The resulting suspension was stirred at 0C for 45 
min after which TMSOTf (205 µl, 1M in CH2Cl2) was added. the resulting mixture was kept at 0C until TLC 
analysis indicated compete disappearance of donor (1h), after which an additional portion of mannose 
donor (53)was added (132mg, 0.19 mmol) and left for another 1.5h. the reaction was then diluted with 
EtOAc, the organic fraction washed with sat aq. NaHCO3 (2x), Brine (1x), dried over MgSO4, filtered and 
concentrated in vacuo. Purification of the residue by column chromatography (silica gel, PE/EtOAc, 5/1  
4/1EtOAc, v/v) yielded the title compound (58a) (559 mg, 0.25 mmol, 66%) as a colourless oil and 6-
mannosilated tetramer (76) (153 mg, 0.090 mmol, 24%) as a colourless oil.  
 
 
Tert-butyldimethylsilyloxy   4-O-(2-O-[2,3,4-tri-O-
acetyl-β-D-xylopyranosyl]-6-O-[2-O-benzoyl-3,4,6-tri-O-
benzyl-α-D-mannopyranosyl]-4-O-benzyl-β-D-
mannopyranosyl)-3,6-di-O-benzyl-2-deoxy-2-(2,2,2-
trichloroethoxy)carbonylamido-β-D-glucopyranoside (76). Rf: 
0.26 (toluene/EtOAc, 6/1, v/v) 
1
H NMR (500 MHz, CDCl3): δ 8.09-8.07 (m, 2H, CHarom OBz), 7.57-7.54 (m, 1H, 
CHarom Bz), 7.38-7.14 (m, 37H, CHarom),5.25 (t, J2’’,3’’ = 3’’,4’’ = 8.8 Hz, 1H, H-3’’), 5.00-4.93 (m, 3H, H-2’’, H-4’’, 
CH2 Bn), 4.94 (s, 1H, H-1’’’), 4.90-4.82 (m, 4H, 3x CH2 Bn, NH Troc), 4.88 (1H, H-1), 4.83 (1H, H-1’’), 4.73-4.47 
(m, 11H, 2x CH2 Troc, 9x CH2 Bn), 4.64 (1H, H-1’), 4.38 (d, Ja,b = 12.0 Hz, 1H, CH2 Bn), 4.15 (dd, J4’’,5a’’ = 5.1 Hz, 
J5a’’,5b’’ = 12.0 Hz 1H, H-5a’’), 4.07-4.05 (m, 2H, H-2’, H-3), 3.96 (t, J3,4 = 4,5 = 8.3 Hz, 1H, H-4), 3.90-3.85 (m, 2H, 
H-2’ and H-3), 3.77-3.69 (m, 3H, H-4’’’, H-6a’’’, H-6b’’’), 3.67-3.58 (m, 3H, H-6a, H-6a’, H-6b’), 3.51-3.44 (m, 
3H, H-3’, H-4’, H-6b), 3.38-3.29 (m, 3H, H-5, H-5’, H-5b’’), 3.20-3.15 (m, 1H, H-2), 3.00 (bd, J3’’,OH = 9.8 Hz, 1H, 
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3’’-OH), 2.07, 2.04, 1.97 (3x s, 9H, Me OAc), 0.87 (s, 9H, Me t-Bu OTBDMS), 0.10, 0.06 (2 x s, 6H, Me 
OTBDMS); 
13
C NMR (125 MHz, CDCl3): δ 169.87, 169.86, 169.3 (3x C=O OAc), 165.8 (C=O Bz), 153.7 (C=O 
Troc), 138.7, 138.5, 138.31, 138.29, 137.9 (5x CHarom), 133.1 (CHarom Bz), 130.0, 128.5. 128.4, 128.32, 128.30, 
128.29, 128.24, 128.23, 128.03, 127.97, 127.8, 127.7, 127.6, 127.54, 127.50, 127.46, 127.4 (17x CHarom), 
100.6 (C-1’), 100.3 (C-1’’), 97.0 (C-1’’’), 95.4 (CCl3 Troc), 95.1 (C-1), 78.6 (C-4), 78.0 (C-3’’’, C-3), 77.3 (C-2’), 
76.0 (C-5 or C-5’), 75.1 (CH2 Bn), 74.6, 74.4, 74.3, 74.0, 73.8 (C-3’, C-4’, C-5’’’, C-5 or C-5’, CH2 Bn), 73.6, 73.3, 
73.1 (CH2 Bn), 71.6 (C-4’’’), 71.3 (CH2 Bn), 70.9 (C-3’’), 70.7 (C-2’’), 69.12, 69.06 (C-4’’ and C-6’’’), 68.8 (C-2’’’ 
and C-6), 66.5 (C-6’), 62.1 (C-6’), 59.3 (C-2), 25.6 (Me t-Bu OTBDMS), 20.8, 20.74, 20.73 (3 x Me Ac), -4.2, -5.2 
(2x Me OTBDMS);  
Tert-butyldimethylsilyloxy   4-O-[2-O-(2,3,4-tri-O-acetyl-β-D-xylopyranosyl)-3,6-di-O-(2-O-benzoyl-
3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-4-O-benzyl-β-D-mannopyranosyl]-3,6-di-O-benzyl-2-deoxy-2-
(2,2,2-trichloroethoxy)carbonylamido-β-D-glucopyranoside (58a). Rf: 0.50 (toluene/EtOAc, 6/1, v/v) αD
16.0
: -
1.2 (c = 1.0 in CHCl3); IR (ν): 3064, 3031, 2931, 2859, 1756, 1725, 1454, 1267, 1250, 1220, 1097, 1071, 839, 
752, 698 cm
-1
; 
1
H NMR (500 MHz, CDCl3): δ 8.10-8.05 (m, 4H, CHarom OBz), 7.58-7.54 (m, 2H, CHarom OBz), 
7.42-7.14 (m, 49H, CHarom), 5.73 (s, 1H, H-2’’’), 5.66 (s, 1H, H-2’’’’), 5.22 (s, 1H, H-1’’’), 5.17 (t, J2’’,3’’ = J3’’,4’’ = 
9.0 Hz, 1H, H-3’’), 5.07-5.04 (m, J1’’,2’’ = 7.1 Hz, J2’’,3’’ = 9.0 Hz, 2H, H-2’’ and NH Troc), 4.93-4.82 (m, 5H, 4 x CH2 
Bn, H-4’’), 4.92 (1H, H-1’’’’), 4.89 (1H, H-1’’), 4.84 (1H, H-1), 4.79-4.40 (m, 16H, CH2 Bn), 4.65 (1H, H-1’), 4.26-
4.21 (m, 2H, H-3’’’ and H-5’’’’), 4.13 (bs, 1H, H-2’), 4.09-4.02 (m, 4H, H-3’’’’, H-4’’’, H-4’’’’, H-5a’’), 3.94 (t, J3,4 
= J4,5 = 9.0 Hz, 1H, H-4), 3.85-3.82 (m, 1H, H-3), 3.79-3.64 (m, 3H, H-3’, H-4’, H-5’’’), 3.58-3.47 (m, 3H, H-5, H-
6a’, H-6b’), 3.85-3.82, 3.79-3.64, 3.58-3.47 (m, 6H, H-6a, H-6b, H-6a’’’, H-6b’’’, H-6a’’’’, H-6b’’’’), 3.36-3.30 
(m, 1H, H-2), 3.28-3.22 (m, 1H, H-5’), 3.19-3.14 (m, 1H, H-5b’’), 2.03, 2.00, 1.95 (3 x s, 9H, Me Ac), 0.87 (s, 
9H, t-Bu OTBDMS), 0.10, 0.06 (2 x s, 6H, Me OTBDMS); 
13
C NMR (125 MHz, CDCl3): δ 170.0, 169.5, 169.4 (3 x 
C=O Ac), 165.9, 165.4 (C=O Bz), 153.8 (C=O Troc), 138.7, 138.61, 138.57, 138.5, 138.4, 138.2, 138.1, 137.0, 
137.6 (9x CHarom), 133.14, 133.06 (2x CHarom Bz), 130.00, 129.96, 129.9, 128.44, 128.41, 128.36, 128.34, 
128.31, 128.24, 128.16, 128.03, 127.97, 127.92, 127.87, 127.6, 127.53, 127.50, 127.47, 127.42, 127.39, 
127.35 (24x CHarom), 100.3 (C-1’’), 100.0 (C-1’), 99.7 (C-1’’’), 96.8 (C-1’’’’), 95.5 (CCl3 Troc), 95.3 (C-1), 79.0 (C-
3’), 77.7, 77.6, 77.43, 77.40 (C-3, C-3’’’, C-3’’’’, C-4), 75.6 (C-2’), 75.1 (CH2 Bn), 74.43, 74.38, 74.1, 73.8, 73.5 
(C-4’, C-4’’’, C-4’’’’, C-5, C-5’), 73.4, 73.34, 73.31 (CH2 Bn), 72.4 (C-5’’’’), 72.3, 72.0 (CH2 Bn), 71.8 (C-5’’’), 71.6 
(C-3’’), 71.1 (CH2 Bn), 71.0 (C-2’’), 69.5, 69.3, 69.18, 69.15, 68.8 (C-2’’’, C-2’’’’, C-4’’, C-6, C-6’’’, C-6’’’’), 66.3 
(C-6’), 61.8 (C-5’’), 58.8 (C-2), 25.6 (Me t-Bu OTBDMS), 20.80, 20.78, 20.76 (3 x Me OAc), 17.9 (Cq t-Bu 
OTBDMS), -4.2, -5.2 (2 x Me OTBDMS); HRMS (ESI) m/z calcld. for [C121H134Cl3NNaO31Si]
+
: 2252.7667, odsd.: 
2252.7673. 
 
4-O-[2-O-(2,3,4-tri-O-acetyl-β-D-xylopyranosyl)-3,6-di-O-(2-O-
benzoyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-4-O-benzyl-β-D-
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mannopyranosyl]-3,6-di-O-benzyl-2-deoxy-2-(2,2,2-trichloroethoxy)carbonylamido-α/β-D-glucopyranose 
(84). Pentasaccharide (58a) (208 mg, 0.093 mmol) was transferred to a falcon tube, dissolved in THF (0.9 mL) 
and treated with HF∙pyridene (70%, 110 µL) for 4.5h after which EtOAc was added and the organic layer was 
washed with saturated aq. NaHCO3 until no gas erupted (3x) and Brine (1x). The organic layer was dried over 
MgSO4, Filtered, and concentrated in vacuo. Purification by flash chromatography (silica gel, 33% EtoAc in 
PE) yielded the title compound (84) as colourless oil (185 mg, 0.087 mmol, 94%, α/β = 3/1); TLC Rf: 0.26 
(PE/EtOAc, 1/1, v/v); IR(ν): 3064, 3031, 2924, 1754, 1724, 1602, 1514, 1497, 1453, 1365, 1266, 1220, 1097, 
1070, 1044, 909, 818, 733, 711, 698 cm
-1
; 
1
H NMR (500 MHz, CDCl3): δ 8.10-8.07 (m, 4H, CHarom OBz),7.59-
7.55 (m, 2H, CHarom OBz), 7.43-7.15 (m, 50H,4x CHarom Bz, 46x CHarom Bn), 5.66 (s, 2H, H-2’’’, H-2’’’’), 5.21 (s, 
1H, H-1’’’), 5.11 (t, J2’’,3’’ = J3’’,4’’ = 8.3 Hz, 2H, H-3’’, NH Troc), 5.02 (t, J1’’,2’’ = J2’’,3’’ = 8.8 Hz, 1H, H-2’’), 4.95-4.88 
(m, 3H, H-1’’ and H-4’’, CH2 Bn), 4.84-4.76 (m, 5H, 4x CH2 Bn, CH2 Troc), 4.76 (s, 1H, H-1’’’’), 4.71-4.55 (m, 
11H, 10x CH2 Bn, CH2 Troc), 4.69 (s, 1H, H-1’), 4.49-4.46 (m, 2H, 2x CH2 Bn), 4.47 (bs,1H, H-1), 4.40 (d, Ja,b = 
12 Hz, 1H, CH-b Bn), 4.33 (d, Ja,b = 12 Hz, 1H, CH-b Bn), 4.24-3.95 (m, 11H, H-2, H-2’ H-3, H-3’’’, H-3’’’’, H-4, H-
4’, H-4’’’, H4’’’’, H-5a’’), 3.85-3.73, 3.61-3.58, 3.50-3.41 (m, 11H, H-3’, H-5 or H-5’, H-5’’’, CH2 H-6, CH2 H-6’, 
CH2 H-6’’’, CH2 H-6’’’’), 3.33 (t, J = 8.8 Hz, 1H, H-5 or H-5’), 3.11 (dd, J =9.3 Hz, J =11.5 Hz, 1H, H-5b’’), 2.08, 
2.02, 2.00 (3x s, 9H, Me OAc); 
13
C NMR (125 MHz, CDCl3): δ 171.2, 169.9, 169.5 (3x C=O OAc), 165.7, 165.5 
(3x C=O Bz), 154.1 (C=O Troc), 138.8, 138.7, 138.6, 138.2, 137.93, 137.90, 137.8, 137.31, 137.28 (9x CHarom) 
133.3, 133.1 (CHarom Bz), 130.2, 130.0 (2x CHarom Bz), 129.9, 129.7, 128.60, 128.56, 128.49, 128.45, 128.404, 
128.397, 128.36, 128.34, 128.32, 128.27, 128.2, 128.1, 127.9, 127.8, 127.8, 127.6, 127.50, 127.46, 127.40, 
127.37, 127.2 (23 x CHarom), 99.9 (C-1’’’), 99.6 (C-1’’), 97.8 (C-1’’’’), 96.7 (C-1’), 95.4 (CCl3 Troc), 91.5 (C-1), 
79.7 (C-3’), 77.3 (C-3’’’), 76.5 (C-3’’’’), 75.8 (CH2 Bn), 75.3 (CH2 Bn), 75.0 (CH2 Bn), 74.7 (C-2’, C-5 or C-5’), 74.6 
(CH2 Bn), 74.34, 74.29, 74.2, 73.8 (C-4, C-4’, C-4’’’’, C-5 or C-5’), 73.4, 73.3, 73.2 (CH2 Bn), 72.9 (C-5’’’), 72.4 
(C-4’’’), 71.8 (CH2 Bn), 71.42, 71.36 (C-3’’, C-2’’), 71.1 (C-2’’), 71.0 (CH2 Bn), 70.2 (C-3), 69.4, 69.3, 68.2, 69.21, 
68.9, 68.6, 68.44, 68.40 (C-2’’’, C-4’’, C-2’’’’, C-6, C-6’, C-6’’’, C6’’’’), 61.7 (C-5’’), 54.3 (C-2), 20.9, 20.84, 20.77 
(3 x Me Ac); HRMS (ESI) m/z calcld. for [C115H120Cl3NNaO31]
+
: 2138.6802, odsd.: 2138.6807 
 
 
4-O-[2-O-(2,3,4-tri-O-acetyl-β-D-xylopyranosyl)-3,6-di-O-(2-
O-benzoyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-4-O-
benzyl-β-D-mannopyranosyl]-3,6-di-O-benzyl-2-deoxy-2-
(2,2,2-trichloroethoxy)carbonylamido-1-O-(N-
(phenyl)trifluoro-acetimidoyl)-α/β-D-glucopyranoside (85). 
Lactol Pentasaccharide (84) (185 mg, 0.087 mmol) was dissolved in acetone (0.7 mL), N-
(phenyl)trifluoroacetimidoyl chloride (36 µL, 0.26 mmol) was added. The resulting solution was cooled to 
0C and Cs2CO3 (43 mg, 0.131 mmol) added. The resulting suspension was stirred for 2 h at rt after which 
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EtOAc was added and the unreacted Cs2CO3 filtered off over celite. The organic phase was then 
concentrated in vacuo. Purification using flash chromatography (silica gel, 4%  7% EtOAc in toluene) 
yielded title compound (85) as a colourless oil. (161 mg, 0.070 mmol, 80%), α/β = 5/1); TLC Rf: 0.54 
(toluene/EtOAc, 6/1, v/v); IR(ν): 3064, 3030, 2927, 2866, 1755, 1724, 1600, 1497, 1454, 1267, 1219, 1099, 
1047, 752, 698 cm
-1
; 
1
H NMR (600 MHz, CDCl3): δ 8.08-8.03 (m, 4H, CHarom OBz), 7.58-7.52 (m, 2H, CHarom 
OBz), 7.42-7.10 (m, 52H, CHarom), 6.76-6.75 (m, 2H, CHarom), 5.76 (s, 1H, H-2’’’), 5.73 (s, 1H, H-2’’’’), 5.25 (s, 
1H, H-1’’’), 5.13 (t, J2’’,3’’ = 7.6 Hz, 1H, H-3’’), 5.06 (t, J2’’,3’’ = 7.4 Hz, 1H, H-2’’), 4.95-4.40 (m, 22H, NH Troc, CH2 
Troc, H-4’’, 9x CH2 Bn), 4.91 (s, 1H, H-1’’’’), 4.88 (1H, H-1’’), 4.56 (1H, H-1’) 4.23-4.21 (m, 2H), 4.14 (dd, J4’’,5a’’ 
= 4.7 Hz, J5a’’,5b’’ = 11.7 Hz, 1H, H-5a’’), 4.08-3.95 (m, 6H), 3.84-3.57 (m, 10H), 3.54-3.52 (m, 2H), 3.22 (dd, 
J4’’,5b’’ = 7.4 Hz, J5a’’,5b’’ = 11.8 Hz, H-5b’’), 3.19-3.16 (m,1H, H-5’), 2.01, 1.99, 1.98 (3 x s, 3H, Me Ac); 
13
C NMR 
(150 MHz, CDCl3): δ 169.9, 169.6, 169.2 (3 x C=O Ac), 165.6, 165.5 (3x C=O Bz), 154.2 (C=O Troc), 143.3 
(C=NPh), 138.73, 138.71, 138.63, 138.61, 138.5, 138.3, 138.23, 138.17, 138.04, 138.00, 137.8, 137.7, 133.4, 
133.2, 133.1, 130.14, 130.10, 130.0, 129.5, 128.9, 128.8, 128.72, 128.68, 128.63, 128.56, 128.54, 128.51, 
128.49, 128.46, 128.44, 128.41, 128.39, 128.37, 128.31, 128.29, 128.2, 128.1, 128.04, 128.01, 128.00, 
127.95, 127.91, 127.89, 127.85, 127.8, 127.74, 127.69, 127.62, 127.59, 127.58, 127.53, 127.51, 127.48, 
127.3, 126.5, 124.6, 120.5, 119.4 (58x CHarom), 101.1 (C-1’), 100.4 (C-1’’), 99.9 (C-1’’’), 97.7 (C-1’’’’), 95.4 
(CCl3), 79.0, 77.74, 77.72, 77.4, 77.2, 76.9, 76.8, 75.3, 75.23, 75.20, 75.18, 75.16, 74.7, 74.6, 74.5, 74.4, 74.1, 
73.6, 73.52, 73.50, 73.47, 73.44, 73.39, 72.5, 72.0, 71.1, 70.7, 70.2, 69.7, 69.4, 69.34, 69.26, 69.1, 69.0, 68.9, 
68.8, 68.3, 66.4, 53.6, 20.9, 20.8 (3x Me Ac); HRMS (ESI) m/z calcld. for [C123H124Cl3F3N2NaO31]
+
: 2309.7098, 
odsd.: 2309.7104 
Tert-butyldimethylsilyloxy  2-azido-4-O-[4-O-(2-
O-{2,3,4-tri-O-acetyl-β-D-xylopyranosyl}-3,6-di-
O-{2-O-benzoyl-3,4,6-tri-O-benzyl-α-D-
mannopyranosyl}-4-O-benzyl-β-D-
mannopyranosyl)-3,6-di-O-benzyl-2-deoxy-2-
(2,2,2-trichloroethoxy)carbonylamido-α/β-D-glucopyranosyl]-3,6-di-O-benzyl-deoxy-α/β-D-
glucopyranoside (49b). Traces of water were removed from Penta imidate (85) (38.1 mg, 0.0166 mmol) and 
acceptor (52) (24.6 mg, 0.0499 mmol), by co-evaporation with toluene (3x), then dissolved in dry toluene 
and activated molecular sieves (4 Å) were added. The resulting suspension was left to stir at rt. for 1h, then 
cooled to -40°C followed by the careful addition of TfOH (8.3µL, 0.1M in toluene). The reaction was then 
allowed to warm up to rt (3h), then diluted with EtOAc, filtered over cotton wool, and the organic fraction 
was washed with sat. aq. NaHCO3 (2x), Brine (1x). the organic phase was dried over MgSO4, filtered and 
concentrated in vacuo. Purification using flash chromatography (silica gel, 4%  7% EtOAc in toluene) 
yielded title compound (49b) as a colourless oil. (28.7 mg, 0.0116 mmol, 70%), α/β = 1/1); TLC Rf: 0.34 
(toluene/EtOAc, 6/1, v/v); αD
16
: -1.2 (c = 1.0 in CHCl3); IR (ν): 3060, 3032, 2926, 2867, 1754, 1723, 1600, 
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1499, 1454, 1266, 1220, 1097, 1047, 752 cm
-1
; 
1
H NMR (500 MHz, CDCl3): δ 8.11-8.05 (m, 8H, α/β CHarom 
OBz), 7.59-7.54 (m, 4H α/β CHarom Bz), 7.44-7.05 (m, 118H, α/β CHarom), 6.10 (d, J α2’,αNH = 9.8 Hz, 1H, α-NH 
Troc), 5.89, 5.80(s, 4H, α/β H-2’’’’ and H-2’’’’’), 5.75 (s, 4H, α/β H-2’’’’, H-2’’’’’), 5.28 (d, Jα1’, α2’ = 3.4 Hz, 1H, α-
H-1’), 5.26, 5.22 (s, 2H, 2x α/β H-1’’’’ and/or H-1’’’’’), 5.20-5.16 (m, 2H, α/β H-2’’’ or H-3’’’), 5.12-5.08 (m, 2H, 
α/β H-2’’’ or H-3’’’), 5.03 (d, Ja,b = 11.7 Hz, 1H, CH-a Bn), 4.99 (d, Ja,b = 11.4 Hz, 1H, CH-a Bn), 4.96-4.38 (m, 
26H, α/β CH2 Bn, CH2 Troc), 4.88, 4.81, 4.57, 4.45 (9H, α/β H-1, βH-1’, α/β H-1’’, α/β H-1’’’, α/β H-1’’’’ and/or 
H-1’’’’’), 4.32 (dd, J = 2.9 Hz, J = 9.3 Hz, 1H), 4.26 (dd, J = 2.9 Hz, J = 9.3 Hz, 1H), 4.23-4.20 (m, 2H), 4.17-4.02 
(m, 8H), 3.96 (t, J = 9.3 Hz, 1H), 3.92-3.81 (m, 5H), 3.76-3.39 (m, 20H), 3.38-3.17 (m, 5H, α or β H-5b’’’), 3.11-
3.02 (m, 5H, α or β H-5b’’’), 2.10, 2.036, 2.025, 2.02 (4x s, 12H, Me Ac), 1.99 (2x s, 6H, Me Ac), 0.97, 0.96 (2x 
s, 18H, Me t-Bu OTBDMS), 0.20, 0.184, 0.175, 0.16 (4x s, 12H, Me OTBDMS); 
13
C NMR (125 MHz, CDCl3): δ 
171.2, 170.3, 170.0, 169.5, 169.4, 169.30, 169.27 (6x C=O Ac), 165.7, 165.39, 165.35 (4x C=O Bz), 154.3, 
153.9 (2x C=O Troc), 138.8, 138.73, 138.70, 138.67, 138.6, 138.52, 138.49, 138.3, 138.24, 138.19, 138.1, 
138.02, 137.97, 137.95, 137.90, 137.85, 137.8, 137.7, 137.3 (18x CHarom) 133.09, 133.05 (CHarom Bz), 130.1, 
130.00, 129.97, 129.9, 129.1, 128.9, 128.7, 128.63, 128.61, 128.54, 128.50, 128.47, 128.46, 128.39, 128.37, 
128.34, 128.33, 128.31, 128.30, 128.26, 128.23, 128.21, 128.18, 128.16, 128.14, 128.11, 128.05, 128.03, 
127.98, 127.9, 127.81, 127.79, 127.77, 127.73, 127.67, 127.6, 127.5, 127.446, 127.43, 127.41, 127.36, 
127.33, 127.30, 127.2, 126.5, 125.3 (48x CHarom), 101.3, 100.9, 100.5, 99.7, 99.5, 98.1, 97.4, 97.3, 97.1 (α/β 
C-1, β C-1’, α/β C-1’’, α/β C-1’’’, α/β C-1’’’’, α/β C-1’’’’’ ), 99.0 (α C-1’), 95.5 2x (α/β CCl3 NHTroc), 82.3, 81.2, 
81.1, 78.8, 78.3, 78.0, 77.8, 77.5, 76.2, 75.9, 75.2, 75.14, 75.06, 75.0, 74.9, 74.7, 74.6, 74.3, 74.3, 74.2, 74.02, 
73.98, 73.9, 73.7, 73.5, 73.4, 73.30, 73.28, 73.2, 72.5, 72.4, 72.1, 72.02, 71.98, 71.9, 71.8, 71.5, 71.2, 71.0, 
70.7, 70.4, 69.3, 69.2, 69.1, 68.84, 68.76, 68.7, 68.5, 68.2, 68.1, 66.3, 61.8, 61.6, 60.4, 57.2, 54.9, 25.62, 
25.60 (6x Me t-Bu OTBDMS), ), 21.5, 21.1, 20.93, 20.86, 20.84, 20.80, 20.77 (6x Me O-Ac), 18.00 17.98 (2x Cq 
t-Bu, OTBDMS), -4.2, -4.3, -5.16, -5.19 (4x Me, OTBDMS); HRMS (ESI) m/z calcld. for [C141H155Cl3N4NaO35Si]
+
: 
2619.9199, odsd.: 2619.9204. 
 
 
Tert-butyldimethylsilyloxy  2-azido-4-O-[4-O-(2-
O-benzoyl-3,6-di-O-{2-O-benzoyl-3,4,6-tri-O-
benzyl-α-D-mannopyranosyl}-4-O-benzyl-β-D-
mannopyranosyl)-3,6-di-O-benzyl-2-deoxy-2-
(2,2,2-trichloroethoxy)carbonylamido-α/β-D-glucopyranosyl]-3,6-di-O-benzyl-2-deoxy-β-D-
glucopyranoside (49d). Tetra imidate (82 (109 mg, 0.051 mmol) and acceptor (52) (78 mg, 0.15 mmol), were 
co-evaporated together with toluene (3x), dissolved in dry toluene, activated molecular sieves (4 Å) added 
and the resulting suspension stirred at rt for 1h. The solution was then cooled to 0°C followed by the careful 
addition of TfOH (10µL, 1M in toluene) after which the reaction was allowed to warm up to rt. Two 
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additional portions of TfOH (50µL, 1M in toluene) were added over 5h at 0°C and the resulting mixture was 
left to stir for a total 14h. The reaction was diluted with EtOAc, filtered over cotton wool, and the organic 
fraction was washed with sat. aq. NaHCO3 (2x), Brine (1x), dried over MgSO4, Filtered and concentrated in 
vacuo. Purification using flash chromatography (silica gel, 4%  7% EtOAc in toluene) yielded title 
compound (49d)as a colourless oil. (77.4 mg, 0.032 mmol, 63%), α/β = 1/1); TLC Rf α: 0.47, Rf β: 0.53 
(toluene/EtOAc, 6/1, v/v); IR (ν): 3062, 3034, 2928, 2864, 1750, 1602, 1498, 1266, 1096, 1047, 752cm
-1
; αD
16
: 
-1.2 (c = 1.0 in CHCl3); Spectroscopic data alpha: 
1
H NMR (500 MHz, CDCl3): δ 8.18-8.16 (m, 2H, CHarom OBz), 
8.06-8.03 (m, 2H, CHarom OBz), 8.00-7.88 (m, 2H, CHarom OBz), 7.57-7.52 (m, 5H, CHarom), 7.37-7.09 (m, 54H, 
CHarom), 7.01-6.98 (m, 2H, CHarom), 6.94-6.91 (m, 3H, CHarom), 5.72 (s, 1H, H-2’’’’), 5.62-5.61 (m, 2H, H-2’’, H-
2’’’), 5.41 (d, JNH,2 = 9.8 Hz, 1H, NH’ Troc), 5.25 (d, J1’,2’ = 3.4 Hz, 1H, H-1’), 5.18 (s, 1H, H-1’’’), 4.88 (s, 1H, H-
1’’’’), 4.87-4.81 (m, 3H, CH2 Bn), 4.76-4.65 (m, 6H), 4.66 (H-1’’), 4.60-4.41 (m, 17H), 4.46 (H-1), 4.33-4.26 (m, 
3H), 4.16 (t, J = 9.5 Hz, 1H), 4.07-4.04 (m, 3H), 4.00-3.52 (m, 17H), 3.41 (d, J = 10.5 Hz), 3.32-3.15 (m, 5H), 
0.91 (s, 9H, Me t-Bu OTBDMS), 0.14, 0.12 (2x s, 6H, Me OTBDMS); 
13
C NMR (125 MHz, CDCl3): δ 165.8, 165.6, 
165.4 (3x C=O Bz), 154.2 (C=O NHTroc), 138.8, 138.73, 138.68, 138.6, 138.3, 138.0, 137.9, 137.4, 133.6, 
133.3, 133.2, 130.3, 130.1, 130.04, 129.98, 129.9, 129.0, 128.8, 128.6, 128.54, 128.49, 128.46, 128.44, 
128.43, 128.33, 128.3, 128.27, 128.25, 128.09, 128.05, 128.0, 127.91, 127.88, 127.8, 127.7, 127.59, 127.56, 
127.53, 127.50, 127.48, 127.3, 127.1 (41x CHarom), 99.8 (C-1’’’), 99.5 (C-1’’), 98.5 (C-1’), 98.4 (C-1’’’’), 97.4 (C-
1), 95.5 (CCl3 NHTroc), 82.0, 79.9, 78.1, 78.01, 77.97, 77.7, 75.3, 75.2, 74.9, 74.8, 74.5, 74.2, 74.1, 74.0, 
73.50, 73.47, 73.2, 72.8, 72.2, 71.9, 71.7,71.32, 71.28, 69.3, 69.0, 68.8, 68.4, 68.2, 65.9, 55.1 25.7 (Me, t-Bu 
OTBDMS), 18.1 (Cq t-Bu OTBDMS), -4.2, -5.1 (2x Me OTBDMS); Coupling constants; 99.8 (C-1’’’, J = 173.4 Hz), 
99.5 (C-1’’, J = 159.8 Hz), 98.5 (C-1’, J = 176.5 Hz), 98.4 (C-1’’’’, J = 175.6 Hz), 97.4 (C-1, J = 159.6 Hz); 
Spectroscopic data Beta: 
1
H NMR (500 MHz, CDCl3): δ 8.23-8.21 (m, 2H, CHarom OBz), 8.07-8.03 (m, 2H, CHarom 
OBz), 8.00-7.88 (m, 2H, CHarom OBz), 7.58-7.55, 7.40-6.88 (m, 64H, CHarom), 5.72 (s, 1H, H-2’’’), 5.62 (d, J = 3.6 
Hz, 1H, H-2’’), 5.61 (s, 1H, H-2’’’’), 5.15 (s, 1H, H-1’’’), 4.99 (d, Ja,b = 11.7 Hz, 1H, CH-a Bn), 4.92 (bs, 1H, H-
1’’’’), 4.90-4.82, 4.77-4.64, 4.62-4.38, 4.34-4.27 (m, 27H, NHTroc, CH2 Troc, CH2 Bn), 4.69 (H-1’’), 4.40 (H-1), 
4.22 (d, , Ja,b = 12.0 Hz, 1H, CH-b Bn), 4.18-4.12, 4.07-3.52 (m, 19H), 4.12 (H-1’), 3.45 (bd, J = 10.2 Hz, 1H), 
3.34 (bd, J2’,3’ = 8.5 Hz, JNH,2’ = 16.4 Hz, 1H, H-2’), 3.26-3.15 (M, 4H), 3.09 (bd, J = 9.3 Hz, 1H), 2.94 (bt, J = 8.5 
Hz, 1H, H-3’), 0.92 (s, 9H, Me t-Bu OTBDMS), 0.14, 0.12 (2x s 6H, Me OTBDMS); 
13
C NMR (125 MHz, CDCl3): δ 
165.8, 165.6, 165.4 (3x C=O Bz), 153.8 (C=O NHTroc), 139.0, 1387, 138.6, 138.0, 137.9, 137.8, 133.6, 133.3, 
133.2, 130.14, 130.10, 130.02, 129.98, 129.94, 129.89, 129.21, 129.17, 129.1, 129.0, 128.9, 128.81, 128.76, 
128.6, 128.54, 128.49, 128.47, 128.43, 128.35, 128.31, 128.27, 128.23, 128.21, 128.16, 128.1, 128.0, 127.94, 
127.90, 127.89, 127.86, 127.84, 127.81, 127.76, 127.7, 127.64, 127.6, 127.53, 127.48, 127.4, 125.4 (50x 
CHarom), 100.8 (C-1’), 99.9 (C-1’’’), 98.7 (C-1’’), 98.3 (C-1’’’’), 97.2 (C-1), 95.7 (CCl3 NHTroc), 81.1, 80.2, 79.3, 
78.1, 78.0, 77.8, 75.4, 75.2, 74.9, 74.6, 74.4, 74.2, 74.0, 73.6, 73.5, 73.5, 73.3, 72.8, 72.1, 71.9, 71.8, 71.7, 
71.4, 69.3, 68.9, 68.7, 68.5, 68.4, 67.8, 53.6, 25.7 (Me, t-Bu OTBDMS), 18.1 (Cq t-Bu OTBDMS), -4.2, -5.1 (2x 
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Me OTBDMS); Coupling constants; 100.8 (C-1’, J = 160.0 Hz), 99.9 (C-1’’’, J = 173.6 Hz), 98.7 (C-1’’, J = 159.7 
Hz), 98.3 (C-1’’’’, J = 176.3 Hz), 97.2 (C-1, J = 164.5 Hz); HRMS (ESI) m/z calcld. for [C137H145Cl3N4NaO29Si]
+
: 
2465.8722, odsd.: 2465.8728. 
 
Tert-butyldimethylsilyloxy  2-acetamido-2-
deoxy-4-O-(2-acetamido-2-deoxy-4-O-(2-O-
benzoyl-3,6-di-O-(2-O-benzoyl-3,4,6-tri-O-benzyl-
α-D-mannopyranosyl)-4-O-benzyl-β-D-
mannopyranosyl)-3,6-di-O-benzyl-β-D-
glucopyranosyl)-3,6-di-O-benzyl-β-D-glucopyranoside (95). Pentamer (49d) (21.4 mg, 0.0087 mmol) was 
dissolved in THF (0.2 mL), activated zinc was added (110 mg, 1.68 mmol) followed by aq. KH2PO4 (0.04 mL, 
1M) after which the suspension was stirred vigorously for 2h. The suspension was then diluted with EtOAc, 
filtered over celite to remove unreacted zinc, and co-concentrated in presence of pyridine. The resulting 
yellow oil was dissolved in pyridine/Ac2O (0.3mL, 2/1) and left to stir until ninhydrin stain showed complete 
disappearance of amine product (1 h). The reaction was diluted with EtOA, and organic fraction washed with 
sat. aq. NaHCO3 (3x) and until no further gas was formed and brine (1x).The organic phase was dried over 
MgSO4 , filtered and concentrated. Purification of the residue by column chromatography (silica gel, 
PE/EtOAc, 2/11/1, v/v) yielded the title compound (95) (6 mg, 0.0258 mmol, 30%) as a yellow oil. Rf: 0.42 
(Pe/EtOAc, 1/2, v/v) ;αD
17
: -0.03 (c = 1.0 in CHCl3); 
1
H NMR (500 MHz, (CD3)2CO): δ 8.27-8.23 (m, 2H, CHarom 
Bz), 8.08-8.03 (m, 4H, CHarom Bz), 7.68-7.60 (m, 5H, CHarom), 7.47-7.02 (m, 60H, 59x CHarom, NHAc), 6.66 (bd, 
JNH’,2’ = 7.8 Hz, 1H, NHAc’), 5.84 (s, 1H, H-2’’), 5.81 (s, 1H, H-2’’’’), 5.66 (s, 1H, H-2’’’), 5.29 (s, 1H, H-1’’’), 5.03-
5.00 (m, 3H, H-1’’, H-1’’’’, CH2 Bn), 4.95 (d, Ja,b = 11.7Hz, 1H, CH2 Bn), 4.90-4.80 (m, 3H, H-1, 2x CH2 Bn), 4.78-
4.44 (m, 17H, 17x CH2 Bn), 4.70 (1H, H-1’), 4.34 (d, Ja,b = 11.4 Hz, 1H, CH-b Bn), 4.21-3.95 (m, 10H, H-3’’, H-
3’’’, H-3’’’’, H-4, H-4’, H-4’’, H-4’’’, H-4’’’’, H-5’’’ or H-5’’’’, H-6a’’), 3.90-3.61 (m, 14H, H-2, H-2’, H-3, H-3’, H-
5’’’ or H-5’’’’, 2x H-6, 2x H-6’, H-6b’’, 2x H-6’’’, 2x H-6’’’’), 3.53-3.50 (m, 1H, H-5), 3.46-3.41 (m, 1H, H-5’’), 
3.28-3.24 (m, 1H, H-5’), 1.82 (s, 3H, Me NHAc), 1.69 (s, 3H, Me NHAc), 0.87 (s, 9H,Me t-Bu OTBDMS), 0.10, 
0.09 (2x s, 6H, Me OTBDMS); 
13
C NMR (125 MHz, CDCl3): δ 169.3 (C=O NHAc’), 168.8 (C=O NHAc), 165.4, 
165.1, 165.0 (3 x C=O Bz), 139.8, 139.6, 139.1, 139.0, 138.94, 138.87, 138.8, 138.4, 138.2, 138.1, 133.33, 
133.27, 133.2, 130.5, 130.1, 130.0, 129.8, 129.7, 129.6, 128.9, 128.61, 128.57, 128.4, 128.3, 128.24, 128.20, 
128.19, 128.11, 128.09, 128.07, 128.05, 127.88, 127.87, 127.8, 127.63, 127.58, 127.56, 127.5, 127.41, 
127.37, 127.34, 127.31, 127.28, 127.24, 127.19, 126.8, 126.7 (47x CHarom), 100.1 (C-1’’), 99.4 (C-1’’’), 98.7 (C-
1’’), 98.0 (C-1’’’’), 96.1 (C-1), 80.3 (C-3), 80.0 (C-3’), 79.4 (C-3’’), 78.2 (C-4’), 78.0 (C-3’’’), 77.6 (C-3’’’’), 75.3 (C-
4), 74.9, 74.84, 74.82, 74.44, 74.39, 74.3, 74.1, 73.7 (C-4’’, C-4’’’, C-4’’’’, C-5, C-5’, C-5’’, CH2 Bn), 73.1, 73.0, 
72.9, 72.8, 72.7, 72.5 (C-5’’’, C-5’’’’, CH2 Bn), 72.3, 72.2 (C-2’’, CH2 Bn), 71.3, 70.7 (2x CH2 Bn), 69.4 (C-2’’’’), 
69.1, 69.0, 68.7 (C-6, C-6’, C-6’’’, C-6’’’’), 68.6 (C-2’’’), 66.0 (C-6’’), 56.5 (C-2), 55.9 (C-2’), 25.1 (Me t-Bu 
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OTBDMS), 22.62, 22.57 (2x Me NHAc), 17.6 (Cq t-Bu OTBDMS), -4.8, -5.9 (2x Me OTBDMS); HRMS (ESI) m/z 
calcld. for [C138H150N2NaO29Si]
+
: 2349.9986, odsd.: 2349.9990 
 
Tert-butyldimethylsilyloxy  2-acetamido-4-O-(2-
acetamido-4-O-[2-O-{2,3,4-tri-O-acetyl-β-D-
xylopyranosyl}-3,6-di-O-{2-O-benzoyl-3,4,6-tri-
O-benzyl-α-D-mannopyranosyl}-4-O-benzyl-β-D-
mannopyranosyl]-3,6-di-O-benzyl-2-deoxy-β-D-
glucopyranosyl)-3,6-di-O-benzyl-2-deoxy-β-D-glucopyranoside (96). A 1/1 α/β mixture of xylose 
hexasaccharide (49b) (18.1mg, 0.0070 mmol) was dissolved in THF (0.2 mL), then activated zinc (110 mg, 
1.68 mmol) was added, followed by aq. KH2PO4 (0.04 mL, 1M). The resulting suspension was stirred 
vigorously for 3h and then diluted with EtOAc, filtered over celite to remove the unreacted zinc and 
concentrated in presence of pyridine under reduced pressure. The resulting yellow oil was taken up in 
pyridine/Ac2O (0.3 mL, 2/1) and left to stir until ninhydrin stain showed complete disappearance of amine 
product (2.5 h). the reaction was diluted with EtOAc, and organic fraction washed with sat. aq. NaHCO3 (3x) 
and until no further gas was formed, and brine (1x).The organic phase was then dried over MgSO4, filtered 
and concentrated in vacuo. Purification of the residue by column chromatography (silica gel, PE/EtOAc, 1/1, 
v/v) yielded the title compound (X) (8.4 mg, α/β, 0.0338 mmol, 48%) of which the beta product could be 
separated by a long silica column (silica gel, PE/EtOAc, 1/1, v/v). Rf α: 0.10 Rf β: 0.15 (PE/EtOAc, 1/1, v/v): 
αD
20
: -0.6 (c = 1.0 in CHCl3); IR (ν): 2925, 2855, 1726, 1662, 1454, 1366, 1251, 1218, 1074, 843, 753, 698 cm
-1
; 
1
H NMR (500 MHz, (CDCl3): δ 8.05-8.00 (m, 4H, CHarom OBz), 7.57-7.51 (m, 2H, CHarom OBz), 7.38-7.08 (m, 
59H, CHarom), 6.08 (bs, 1H, NH’ NHAc), 5.72 (s, 1H, H-2’’’’), 5.70 (s, 1H, H-2’’’’’), 5.20 (s, 1H, H-1’’’’), 5.41 (t, 
J2’’’,3’’’ = J2’’’,3’’’ = 8.2 Hz, 1H, H-3’’’), 5.05 (dd, J1’’’,2’’’ = 6.3 Hz J2’’’,3’’’ = 8.2 Hz, 1H, H-2’’’), 5.00 (bd, JNH,2 = 2.6 Hz, 
1H, NH NHAc), 4.91-4.81 (m, 4H, CH2 Bn), 4.90 (1H, H-1’’’), 4.88 (2H, H-4’’’ and H-1’’’’), 4.81 (H, H-1’), 4.74-
4.38 (m, 18H, CH2 Bn), 4.57 (1H, H-1’’), 4.46 (1H, H-1), 4.22-4.18 (m, 2H, H-3’’’’ and H-5’’’’ or H-5’’’’’), 4.12-
4.09 (m, 1H, H-5a’’’), 4.07-4.00 (m, 4H, H-2’’, H3’’’’’, H-4’’’’, H-4’’’’’), 3.95-3.93 (m, 1H, H-4), 3.89-3.88 (m, 1H, 
4’), 3.83-3.76, 3.71-3.63, 3.62-3.57, 3.54-3.51 (m, 18H, H-2, H-2’, H-3, H-3’, H-3’’, H-4’’, H-5, H-5’’’’ or H-5’’’’’, 
H-6, H-6’, H-6’’, H-6’’’’, H-6’’’’’), 3.26 (bd, J = 10.9 Hz, 1H, H-5’), 3.12 (dd, J = 7.8 Hz, J = 10.9 Hz, 1H, H-5b’’’), 
3.16-3.13 (m, 1H, H-5’’), 2.00, 1.92 (3x s, 9H, Me OAc), 1.61, 1.25 (2x s, 6H, Me NHAc), 0.83 (s, 9H,Me t-Bu 
OTBDMS), 0.05 (s, 6H, Me OTBDMS); 
13
C NMR (125 MHz, CDCl3): δ 170.7, 170.0, 169.6, 169.4 (5x C=O, NHAc, 
OAc), 165.7, 165.5 (2x C=O OBz), 138.9, 138.8, 138.75, 138.71, 138.6, 138.4, 138.3, 138.0, 137.3, 137.7, 
133.21, 133.18, 130.07, 130.05, 129.97, 128.7, 128.6, 128.54, 128.51, 128.48, 128.42, 128.39, 128.32, 
128.28, 128.06, 127.34, 127.90, 127.87, 127.34, 127.78, 127.76, 127.69, 127.65, 127.6, 127.54, 127.50, 127.4 
(37x CHarom), 101.4 (C-1’’, JCH = 157.3 Hz), 100.2 (C-1’’’, JCH = 168.8 Hz), 100.0 (C-1’, JCH = 162.2 Hz), 99.9 (C-
1’’’’, JCH = 174.5 Hz), 97.7 (C-1’’’’’, JCH = 173.7 Hz), 95.0 (C-1, JCH = 163.9 Hz), 79.2 (C-3’’), 79.0 (C-4’), 78.7 (C-
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3’), 77.8 (C-3, C-3’’’’, C-3’’’’’), 76.3 (C-2’’), 75.2, 75.1, 74.9 (C-5’, CH2 Bn), 74.62, 74.57, 74.4, 74.3, 74.2 (C-4’’, 
C-4’’’’, C-4’’’’’, C-5, C-5’’), 73.51, 73.48, 73.47, 73.4, 73.0, 72.7 (CH2 Bn), 72.5, 72.0 (C-5’’’’, C-5’’’’’, CH2 Bn), 
71.2, 71.0, (CH2 Bn), 70.5 (C-3’’’), 69.8 (C-2’’’), 69.5, 69.3, 69.0, 68.9 (C-2’’’’, C-2’’’’’, C-4’’’, C-6, C-6’, C-6’’’’, C-
6’’’’’), 66.6 (C-6’’), 61.5 (C-5’’’), 55.3 (C-2’), 54.5 (C-2), 25.7 (Me t-Bu OTBDMS), 23.5, 23.1 (2x Me NHAc), 20.9 
(3x Me OAc), 18.0 (Cq t-Bu OTBDMS), -4.3, -5.2 (2x Me OTBDMS); HRMS (ESI) m/z calcld. for 
[C142H160N2NaO35Si]
+
: 2504.0463, odsd.: 2504.0469. 
 
Tert-butyldimethylsilyloxy  2-azido-4-O-(4-O-[2-
O-Benzoyl-3,6-di-O-{2-O-benzoyl-3,4,6-tri-O-
benzyl-α-D-mannopyranosyl}-4-O-benzyl-β-D-
mannopyranosyl]-3,6-di-O-benzyl-2-deoxy-2-
[2,2,2-trichloroethoxycarbonylamido]-β-D-
glucopyranosyl)-6-O-benzyl-3-O-(2,3,4-tri-O-
benzyl-α-L-fucopyranosyl)-2-deoxy-β-D-glucopyranoside (49c). Traces of water were removed from tetra 
imidate (82) (63.1 mg, 0.030 mmol) and acceptor (52) (24.6 mg, 0.044 mmol), by co-evaporated with 
toluene (3x), then dissolved in dry toluene and activated molecular sieves (4 Å) were added. The resulting 
suspension was left to stir at rt for 1h and then cooled to 0°C followed by the careful addition of TfOH (75 
µL, 0.1M in toluene). The resulting mixture was then kept at 0°C for 3h, after which 5 drups of triethylamine 
were added, then diluted with EtOAc, filtered over cotton wool, and the organic fraction was washed with 
sat. aq. NaHCO3 (2x), Brine (1x), dried over MgSO4, filtered and concentrated in vacuo. Purification using 
flash chromatography (silica gel, 20% EtOAc in CH2Cl2) and size exclusion to yield title compound (49c) as a 
colourless oil. (26.8 mg, 0.0092 mmol, 31%); Rf:0.73 (toluene/EtOAc, 6/1, v/v); αD
19
: -0.5 (c = 1.0 in CHCl3); 
1
H 
NMR (500 MHz, (CDCl3): δ 8.25-8.22 (m, 2H, CHarom OBz), 8.06-8.04 (m, 2H, CHarom OBz), 7.99-7.97 (m, 2H, 
CHarom OBz), 7.58-7.51 (m, 5H, CHarom), 7.36-7.13, 7.11-7.03, 7.0-6.98 (m, 69 H, CHarom), 5.75 (s, 1H, H-2’’’’), 
5.52 (t, J1’’’’’,2’’’’’ = J2’’’’’,3’’’’’ = 2.3 Hz, 1H, H-2’’’’’), 5.50 (d, J = 2.6 Hz, 1H, H-2’’’), 5.45 (d, J1’,2’ = 3.3 Hz, 1H, H-1’), 
4.97 (s, 1H, H-1’’’’’), 4.85-4.76 (m, 5H, CH2 Bn), 4.79 (H-1’’’’), 4.72-4.61 (m, 5H), 4.58 (dd, J = 6.8 Hz, J = 13.2 
Hz, 1H, H-5’), 4.54 (s, 1H, H-1’’’), 4.53-4.39 (m, 17H), 4.49 (H-1, H-1’’), 4.23 (d, Ja,b = 11.4 Hz, CH2 Bn), 4.14-
4.11, 4.07-4.03, 4.01-3.88, 3.86-3.80, 3.75-3.49 (m, 25H), 3.46 (dd, J = 2.7 Hz, J = 9.6 Hz, 1H H-3’’’), 3.34 (dd, J 
= 7.7 Hz, J = 10.1 Hz, 1H, H-2), 3.34 (s, 1H), 3.26 (d, J = 9.9 Hz, 1H), 3.12 (bs, 1H), 3.04 (bd, J = 9.6 Hz, 1H), 
1.15 (bd, J5’,6’ = 4.9 Hz, 3H, H-6’), 0.90 (s, 9H, Me t-Bu OTBDMS), 0.11, 0.10 (2x s 6H, Me OTBDMS); 
13
C NMR 
(125 MHz, CDCl3): δ 166.5, 165.5 (3x C=O Bz), 154.0 (C=O NHTroc), 139.2, 139.1, 138.63, 138.56, 138.48, 
138.45, 138.4, 138.2, 138.1, 137.8, 137.8, 137.7, 133.6, 133.2, 133.1, 130.2, 130.0, 129.77, 129.76, 128.8, 
128.7, 128.54, 128.48, 128.4, 128.34, 128.27, 128.24, 128.23, 128.17, 128.11, 128.07, 128.01, 127.97, 127.8, 
127.7, 127.64, 127.62, 127.57, 127.51, 127.48, 127.46, 127.44, 127.40, 127.31, 127.27, 127.2, 127.1, 127.0 
(48 CHarom), 100.2 (C-1 or C-1’’), 99.7 (C-1’’’’), 98.4 (C-1’’’’’), 97.4 (C-1 or C-1’’ and C-1’’’), 96.9 (C-1’), 95.8 
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(CCl3 NHTroc), 80.8, 80.4, 79.5, 78.9, 78.0, 77.8, 75.8, 75.3, 75.1, 74.9, 74.8, 74.6, 74.3, 74.1, 73.8, 73.7, 73.6, 
73.4, 73.3, 73.2, 73.0, 72.8, 72.6, 72.0, 71.9, 71.4, 71.3, 69.5, 69.0, 68.8, 68.7, 68.5, 68.5, 68.4, 66.3, 65.8, 
56.2, 25.6 (Me t-Bu OTBDMS), 18.0 (Cq t-Bu OTBDMS), 16.6 (C-6’), -4.3, -5.0 (2x Me OTBDMS); Coupling 
constant: (C-1 or C-1’’, C-1’’’ J = 158.0 Hz, J = 160.0 Hz, J = 163.0 Hz,), (C-1’’’’, J = 173.8 Hz,), (C-1’’’’’, J = 174.8 
Hz), (C-1’, J = 177.4 Hz) HRMS (ESI) m/z calcld. for [C157H167Cl3N4NaO33Si]
+
: 2792.0240, odsd.: 2792.0244. 
 
Tert-butyldimethylsilyloxy  2-acetamido-2-
deoxy-4-O-(2-acetamido-2-deoxy--4-O-[2-O-
benzoyl-3,6-di-O-(2-O-benzoyl-3,4,6-tri-O-
benzyl-α-D-mannopyranosyl)-4-O-benzyl-β-D-
mannopyranosyl)-3,6-di-O-benzyl-β-D-
glucopyranosyl)-6-O-benzyl-3-O-(2,3,4-tri-O-
benzyl-α-L-fucopyranosyl)-β-D-glucopyranoside (94). Fucose hexamer (49c) (17.2 mg, 0.0062 mmol) was 
dissolved in THF (0.2 mL), activated zinc was added (93.3 mg, 1.43 mmol) followed by aq. KH2PO4 (0.04 mL, 
1M), the resulting suspension was stirred vigorously for 2 h and until complete disappearance of starting 
material by TLC analysis. The suspension was diluted with EtOAc, filtered over celite, and co-concentrated 
with pyridine. The resulting oil was taken up in pyridine/Ac2O (0.3mL, 2/1) and left to stir until ninhydrin 
stain showed complete disappearance of amine product (2 h). Then EtOAc was added, and organic fraction 
washed with sat. aq. NaHCO3 (3x) until no further gas was formed and brine (1x).The organic phase was 
dried over MgSO4 , filtered and concentrated. Purification of the residue by column chromatography (silica 
gel, PE/EtOAc, 2/11/1, v/v) yielded the title compound (94) (10.1 mg, 0.0038 mmol, 62%) as a collerless 
oil. Rf: 0.11 (Pe/EtOAc, 1/1, v/v ) ; αD
19
: -0.3 (c = 1.0 in CHCl3); IR (ν): 3060, 3030, 2926, 2857, 1724, 1670, 
1454, 1362, 1268, 1099, 773, 698 cm
-1
; 
1
H NMR (600 MHz, (CDCl3): δ 8.15-8.12 (m, 2H, CHarom Bz), 7.94-7.91 
(m, 4H, CHarom OBz), 7.52-7.49 (m, 5H CHarom), 7.23-6.88 (m, 68H, CHarom), 6.94-6.90 (m, 2H, CHarom, NHAc), 
6.67 (bd, JNH,2 = 9.1 Hz, NH NHAc), 5.70 (s, 2H, H-2’’’ and H-2’’’’’), 5.52 (s, 1H, H-2’’’’), 5.14 (s, 1H, H-1’), 5.11 
(s, 1H, H-1’’’’), 4.91 (s, 1H, H-1’’’’’), 4.88 (s, 1H, H-1’’’), 4.86 (d, Ja,b =12.3 Hz, 1H, CH-a Bn), 4.76-4.35 (m, 21H, 
CH2 Bn), 4.66 (H-1), 4.45 (H-1’’), 4.22 (d, Ja,b =11.5 Hz, 1H, CH-b Bn), 4.20 (d, Ja,b =11.5 Hz, 1H, CH-b Bn), 4.11 
(bd, J = 5.9 Hz, 1H, H-5’), 4.06 (t, J3’’’’,4’’’’ = J4’’’’,5’’’’ = 9.6 Hz, 1H, H-4’’’’), 4.03-3.91 (m, 7H), J2’’’’,3’’’’ = 3.0 Hz, 
J3’’’’,4’’’’’ = 9.4 Hz, 1H, H-3’’’’), 3.85-3.79 (m, 5H), 3.74-3.58 (m, 10H), 3.56-3.52 (m, 2H), 3.49-3.45 (m, 2H), 
3.25-3.22 (m, 2H), 1.75 (s, 3H, Me NHAc), 1.63 (s, 3H, Me NHAc), 0.98 (d, J5’,6’ = 6.4 Hz, 3H, H-6’), 0.75 (s, 9H, 
Me t-Bu OTBDMS), -0.04, -0.05 (2x s, 6H, Me OTBDMS); 
13
C NMR (150 MHz, ((CD3)2CO): δ 169.7, 169.0 (2x 
C=O NHAc), 165.6, 165.1 (3x C=O Bz), 139.60, 139.56, 139.4, 139.3, 139.1, 139.02, 139.00, 139, 138.7, 138.6, 
138.4, 138.2, 138.0, 133.34, 133.26, 130.5, 130.0, 129.9, 129.8, 129.7, 129.6, 129.0, 128.61, 128.58, 128.4, 
128.31, 128.30, 128.25, 128.2, 128.14. 128.10, 128.09, 128.05, 127.9, 127.92, 127.86, 127.8, 127.7, 127.62, 
127.56, 127.54, 127.50, 127.48, 127.41, 127.38, 127.34, 127.33, 127.29, 127.28, 127.24, 127.23, 127.19, 
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127.1, 127.0, 126.9 (55x CHarom), 99.4 (C-1’’’’), 99.3 (C-1’’), 98.7 (C-1’’’), 98.0 (C-1’’’’’), 96.4 (C-1’), 95.8 (C-1), 
80.0, 79.6, 78.8, 78.6, 78.3, 78.1, 77.94, 77.92, 77.5, 76.2, 75.7, 75.4, 74.9, 74.8, 74.6, 74.53, 74.46, 74.4, 
74.33, 74.28, 74.0, 73.4, 73.1, 72.9, 72.80, 72.77, 72.6, 72.4, 72.29, 72.25, 71.4, 71.2, 70.7, 69.6, 69.3, 69.11, 
69.06, 68.9, 68.5, 66.4, 65.8, 56.7, 55.1, 25.2 (Me t-Bu OTBDMS), 22.7, 22.5 (2x Me NHAc), 17.6 (Cq t-Bu 
OTBDMS), 16.2 (C-6’), -4.8, -5.8 (2x Me OTBDMS); HRMS (ESI) m/z calcld. for [C158H172N2NaO33Si]
+
: 
2676.1504, odsd.: 2676.1509. 
 
 
Tert-butyldimethylsilyloxy  2-deoxy-2-azido-4-O-
(4-O-[2-O-{2,3,4-tri-O-acetyl-β-D-xylopyranosyl}-
3,6-di-O-{2-O-benzoyl-3,4,6-tri-O-benzyl-α-D-
mannopyranosyl}-4-O-benzyl-β-D-
mannopyranosyl]-3,6-di-O-benzyl-2-deoxy-2-
[2,2,2-trichloroethoxycarbonylamido]-β-D-
glucopyranosyl)-6-O-benzyl-3-O-(2,3,4-tri-O-benzyl-α-L-fucopyranosyl)-β-D-glucopyranoside (49a). Penta 
imidate (85) (89.3 mg, 0.039 mmol) and acceptor (51) (99 mg, 0.12 mmol), were co-evaporated together 
with toluene (3x), then dissolved in dry toluene and activated molecular sieves (4 Å) where added. The 
resulting suspension was stirred at rt for 1h, cooled to 0°C and TfOH (20 µL, 1M in toluene) was added. the 
resulting solution was allowed to warm up to rt and two additional portions of TfOH (20µL and 10 µL, 1M in 
toluene) were added after 3,5h and 7h cooling the reaction to 0°C before each subsequent addition. The 
resulting mixture was then left to stir for an additional 15h after which EtOAc was added, then the organic 
fraction was filtered over cotton wool, washed with sat. aq. NaHCO3 (2x), Brine (1x), dried over MgSO4 
filtered and concentrated in vacuo. Purification using flash chromatography (silica gel, 2%  3% EtOAc in 
toluene) to remove acceptor followed b (silica gel, PE/EtOAc, 3/1, v/v) to remove oxazoline TLC Rf: 0.32 
(Pe/EtOAc, 2/1, v/v); to yield the title compound (49a) as a colourless oil. (43 mg); TLC Rf: 0.43 (Pe/EtOAc, 
2/1, v/v); HRMS (ESI) m/z calcld. for [C161H177Cl3N4NaO39Si]
+
: 2946.0717, odsd.: 2946.0723 
 
Tert-butyldimethylsilyloxy  2-acetamido-2-
deoxy-4-O-(2-acetamido-2-deoxy-4-O-(2-O-
(2,3,4-tri-O-acetyl-β-D-xylopyranosyl)-3,6-di-O-
(2-O-benzoyl-3,4,6-tri-O-benzyl-α-D-
mannopyranosyl)-4-O-benzyl-β-D-
mannopyranosyl)-3,6-di-O-benzyl-β-D-
glucopyranosyl)-6-O-benzyl-3-O-(2,3,4-tri-O-benzyl-α-L-fucopyranosyl)-β-D-glucopyranoside (97). 
heptamer (49a) (7.0 mg, 0.00239 mmol) was dissolved in THF (0.2 mL), activated zinc was added (104 mg, 
132 
 
1.50 mmol) followed by aq. KH2PO4 (0.04 mL, 1M), the resulting suspension was stirred vigorously for 5h and 
until completion by TLC analysis. The reaction mixture was diluted with EtOAc, filtered over celite to remove 
unreacted zinc, and co-concentrated with pyridine. The resulting oil was dissolved in pyridine/Ac2O (0.3mL, 
2/1) and left to stir until ninhydrin stain showed complete disappearance of amine (1.5 h). The reaction was 
diluted with EtOAc, and the organic fraction washed with sat. aq. NaHCO3 (3x) until no further gas was 
formed and brine (1x), dried over MgSO4, filtered and concentrated. Purification of the residue by column 
chromatography (silica gel, PE/EtOAc, 2/11/1, v/v) yielded the title compound (97) (4.6 mg, 0.0164 mmol, 
68%) as a colourless oil. Rf: 0.49 (Pe/EtOAc, 1/2, v/v) ; IR (ν): 3063, 3032, 2928, 1756, 1725, 1670, 1541, 
1497, 1454, 1366, 1266, 1221, 1099, 1073, 839, 738, 698, 633 cm
-1
; 
1
H NMR (600 MHz, ((CD3)2CO): δ 8.1-8.04 
(m, 4H, CHarom OBz), 7.66-7.62 (m, 2H, CHarom OBz), 7.51-7.06 (m, 71H, 2x NH NHAc, CHarom), 5.88 (t, J = 2.3 
Hz, 1H, H-2’’’’’ or H-2’’’’’’ ), 5.81 (t, J = 2.3 Hz, 1H, H-2’’’’’ or H-2’’’’’’ ), 5.30 (d, J1’,2’ = 1.9 Hz, 1H, H-1’), 5.20 (t, 
J2’’’’,3’’’’ = J3’’’’,4’’’’ = 9.0 Hz, 1H, H-3’’’’), 5.17 (s, 1H, H-1’’’’’), 5.10 (dd, , J1’’’’,2’’’’ = 7.1 Hz, J2’’’’,3’’’’ = 9.0 Hz, 1H, H-
2’’’’), 5.01 (d, Jab = 11.5 Hz, CH2 Bn), 4.97 (d, J1’’’’,2’’’’ = 7.1 Hz, 1H, H-1’’’’), 4.95-4.53, 4.46-4.38 (m, 29H, CH2 
Bn), 4.83 (H-1’’’), 4.82 (H-1’), 4.74 (H-1), 4.71 (H-1’’’’’’), 4.27-4.24 (m, 1H, H-5’), 4.22 (d, J1’’’,2’’’ = 3.0 Hz, 1H, H-
2’’’), 4.21-4.17, 4.16-4.09, 4.04-3.95, 3.92-3.70, 3.69, 3.66-3.49, 3.39 (d, J = 8.8 Hz, 1H), 3.22, (dd, J = 9.3 Hz, J 
= 11.6 Hz, 1H), 3.2-3.18 (m, 1H), (H-2, H-2’’, H-2’’’’’, H-2’’’’’’, H-3, H-3’, H-3’’, H-3’’’, H-3’’’’’, H-3’’’’’’, H-4, H-4’, 
H-4’’, H-4’’’, H-4’’’’’, H-4’’’’’’, H-5, H-5’’, H-5’’’, H-5’’’’, H-5’’’’’, H-5’’’’’’, H-6, H-6’’, H-6’’’, H-6’’’’’, H-6’’’’’’), 2.12, 
1.99, 1.98, 1.89, 1.85 (5x s, 15H, Me NHAc, OAc), 1.12 (d, J5’,6’ = 6.3 Hz, 3H, H-6’), 0.88 (s, 9H, Me t-Bu 
OTBDMS), 0.10, 0.09 (2x s, 6H, Me OTBDMS); 
13
C NMR (150 MHz, CDCl3): δ 170.0, 169.6, 169.5, 169.4, 169.2, 
169.1 (5x Me 2 x NHAc, 3 x OAc), 165.1, 165.0 (2x C=O Bz), 139.6, 139.3, 139.04, 139.02, 139.00, 138.98, 
138.84, 138.80, 138.77, 138.6, 138.4, 138.38, 138.37, 133.3, 133.2, 130.3, 130.1, 129.64, 129.61, 129.1, 
129.0, 128.6, 128.5, 128.4, 128.32, 128.29, 128.28, 128.24, 128.21, 128.19, 128.17, 128.16, 128.14, 128.11, 
128.06, 128.04, 128.02, 128.01, 127.99, 127.97, 127.95, 127.94, 127.87, 127.7, 127.6, 127.52, 127.51, 
127.48, 127.44, 127.39, 127.34, 127.30, 127.24, 127.23, 127.22, 127.19, 127.14, 127.10, 127.08, 127.0, 
126.9, 126.4 (62x CHarom), 101.23, 101.17 (C-1’’’, C-1’’’’), 99.31, 99.28 (C-1, C-1’’’’’), 97.7 (C-1’’’’’’), 96.5 (C-1’), 
95.8 (C-1’’), 79.8, 79.2, 78.9, 78.6, 78.23, 78.17, 78.1, 77.0, 76.7, 76.6, 76.3, 75.8, 75.5, 75.0, 74.9, 74.85, 
74.74, 74.68, 74.60, 74.58, 74.5, 74.3, 74.2, 74.0, 73.94, 73.91, 73.12, 73.07, 73.04, 73.00, 72.96, 72.81, 
72.80, 72.72, 72.68, 72.6, 72.5, 72.4, 72.1, 72.0, 71.9, 71.8, 71.5, 71.4, 71.3, 71.1, 71.0, 70.1, 70.0, 69.9, 
69.69, 69.65, 69.61, 69.33, 69.26, 69.2, 69.0, 68.5, 66.5, 66.2, 66.1, 61.8, 56.7, 54.9, 54.1, 51.8, 25.2 (Me t-Bu 
OTBDMS), 22.7, 22.5 (2x Me NHAc), 20.4, 19.92, 19.90 (3x Me OAc), 17.6 (Cq t-Bu OTBDMS), 16.3 (C-6’), -4.8, 
-5.8 (2x Me OTBDMS); HRMS (ESI) m/z calcld. for [C162H182N2NaO39Si]
+
: 2830.1981, odsd.: 2830.1987 
(coupling constant) 101.23, 101.17 (C-1’’’, C-1’’’’), 99.31, 99.28 (C-1, C-1’’’’’), 97.7 (C-1’’’’’’), 96.5 (C-1’), 95.8 
(C-1’’) 
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2-acetamido-2-deoxy-3-O-α-L-fucopyranosyl-4-O-(2-
deoxy-2-acetamido-4-O-[3,6-di-O-α-D-
mannopyranosyl]-2-O-β-D-xylopyranosyl-β-D-
mannopyranosyl)- β-D-glucopyranosyl)-α/β-D-
glucopyranose (104). Heptamer (97) (5.0 mg, 0.0018 
mmol) was dissolved in dry THF (2 mL), NH3 (l)(15 
mL) was added followed by the carful addition of sodium (s) until the blue colour remained. The solution 
was stirred for 1.5 h under refluxing NH3, then MeOH was added (4 mL) and resulting solution allowed to 
warm up to rt and the NH3 was evaporated. The solution was neutralized by the addition of activated Dowax 
H
+
, after 15 min the organic phase was filtered and concentrated under reduced pressure. Purification by 
size exclusion (biorad, BioGel P-2 extra fine, H2O) and reverse phase column chromatography (HyperSep C8 
Column, H2O) yielded title compound (104).
1
H NMR (500 MHz, (CDCl3): δ 5.10 (s, 1H), 4.89 (s), 4.53 (t, J = 8.0 
Hz, 1H), 4.45-4.41 (m), 4.44 (s), 4.02-3.32 (m), 3.23 (t, J = 10.8 Hz, 1H), HRMS (ESI) m/z calcld. for 
[C45H76N2NaO34]
+
: 1211.4172, odsd.: 1211.4165 
 
2-acetamido-2-deoxy-4-O-(2-acetamido-2-deoxy-4-
O-[3,6-di-O-α-D-mannopyranosyl]-2-O-β-D-
xylopyranosyl-β-D-mannopyranosyl)-β-D-
glucopyranosyl)-α/β-D-glucopyranose (103). Xylose 
hexasaccharide (96) (5.5 mg, 0.0022 mmol) was 
dissolved in dry THF (3 mL), NH3 (l)(15 mL) was added followed by the careful addition of sodium (s) until the 
blue colour remained. The solution was stirred for 1.5 h under refluxing NH3, then MeOH was added (4 mL) 
and resulting solution allowed to warm up to rt and the NH3 was evaporated. The solution was neutralized 
by the addition of activated Dowax H
+
, after 30 min the organic phase was filtered and concentrated under 
reduced pressure. Purification by size exclusion (biorad, BioGel P-2 extra fine, H2O) and reverse phase 
column chromatography (HyperSep C8 Column, H2O) yielded title compound (103) (1.3 mg, 65%).
1
H NMR 
(500 MHz, (CDCl3): δ 5.16 (s, 1H), 5.10 (s, 1H), 4.89 (s), 4.57 (m, 1H), 4.42 (d, J = 7.3 Hz, 1H), 4.24 (d, J = 2.3 
Hz, 1H), 4.02-3.59, 3.56-3.47 (m), 3.41 (t, J = 9.0 Hz, 1H), 3.35 (t, J = 8.0, 1H), 3.22 (t, J = 11.0 Hz 1H), 2.05, 
2.01 (2x s, 3H Me NHAc); 
 
 
2-acetamido-2-deoxy-4-O-(2-acetamido-2-deoxy-4-
O-[3,6-di-O-α-D-mannopyranosyl-β-D-
mannopyranosyl]-β-D-glucopyranosyl)-α/β-D-
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glucopyranose (102). Pentasaccharide (95) (5.5 mg, 0.0024 mmol) was dissolved in dry THF (0.5 mL), NH3 
(l)(15 mL) was added followed by the careful addition of sodium (s) until the blue colour remained. The 
solution was stirred for 1.0 h under refluxing NH3, then MeOH was added (1 mL) and resulting solution 
allowed to warm up to rt and the NH3 was evaporated. The solution was neutralized by the addition of 
activated Dowax H
+
, after 30 min the organic phase was filtered and concentrated under reduced pressure. 
Purification by size exclusion (biorad, BioGel P-2 extra fine, H2O) and reverse phase column chromatography 
(HyperSep C8 Column, H2O) yielded title compound (102) (1.4mg, 70%). 
1
H NMR (500 MHz, (CDCl3): δ 5.17 (s, 
1H), 5.09 (s, 1H), 4.90 (s), 4.60 (m, 1H), 4.25 (s, 1H), 4.09 (dd, J = 7.3 Hz, J = 14.4 Hz), 4.06 (s, 1H), 3.89 (s, 1H), 
3.92-3.52 (m), 2.07, 2.03 (2x s 3H, Me NHAc); HRMS (ESI) m/z calcld. for [C34H58N2NaO26]
+
: 933.3170, odsd.: 
933.3169. 
 
 
2-acetamido-2-deoxy-3-O-α-L-fucopyranosyl-4-O-(2-
acetamido-2-deoxy-4-O-[3,6-di-O-α-D-
mannopyranosyl-β-D-mannopyranosyl]- β-D-
glucopyranosyl)-α/β-D-glucopyranose (101). Fucose 
hexasaccharide (94) (10 mg, 0.0038 mmol) was 
dissolved in dry THF (0.5 mL), NH3 (l)(15 mL) was added followed by the careful addition of sodium (s) until 
the blue colour remained. The solution was stirred for 1.0 h under refluxing NH3, then MeOH was added (4 
mL) and resulting solution allowed to warm up to rt and the NH3 was evaporated. The solution was 
neutralized by the addition of activated Dowax H
+
, after 20 min the organic phase was filtered and 
concentrated under reduced pressure. Purification by size exclusion (biorad, BioGel P-2 extra fine, H2O) and 
reverse phase column chromatography (HyperSep C8 Column, H2O) yielded title compound (101) (1.5 mg, 
37%) together with pentasaccharide (102) (1.2mg, 35%); 
1
H NMR (500 MHz, (CDCl3): δ 5.21 (s), 5.17 (s), 4.53 
(d, J = 8.0 Hz, 1H), 4.24,(s, 1H) 4.17 (m, 1H), 4.09 (m, 1H), 4.05 (s, 1H), 3.95-3.40 (m), 2.04, 2.01 (2x s, 3H, Me 
NHAc), 1.22 (d, J = 6.3 Hz, 3H, H-6’), 1.18 (d, J = 6.3 Hz, 3H, H-6’); HRMS (ESI) m/z calcld. for [C40H68N2NaO30]
+
: 
1079.3749, odsd.: 1079.3744. 
 
 
 2,3,4-Tri-O-acetyl-β-D-xylopyranosyl acetate (60). D-xylose 59 (25 g, 166 mmol) was 
suspended in acetic anhydrate (60 mL, 0.66 mol, 4 equiv.) followed by addition of 
sodium acetate (3.5 g, 0.042 mol) the resulting suspention was left to stir at 35°C until all solids dissolved. 
Then sat. aq. NaHCO3 (60 mL) was added, followed by NaHCO3 (s) until solids remained and no additional gas 
is formed. EtOAc was added and the organic phase washed with sat. aq NaHCO3 (3), and brine (1x), then 
dried over MgSO4, filtered, and concentrated in vacuo. Purification by crystallisation (PE/EtOAc, 3x) yielded 
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title compound 60 as transparent needles. (15.2 g, 47.9 mmol, 29%) and also alpha product was isolated 
(15.7g, 50.0 mmol, 30%).
1
H NMR (500 MHz, CDCl3): δ 5.71 (d, J1,2 = 6.9 Hz, 1H, H-1), 5.20 (t, J3,4 = J4,5 = 8.3 Hz 
1H, H-3) 5.02 (dd, J1,2 = 6.9 Hz, J2,3 = 8.3 Hz 1H, H-2), 4.97 (dt, J4,5a = 4.9 Hz, J3,4,5b = 8.3, 1H, H-4), 4.14 (dd, J4,5a 
= 4.9 Hz, J5a,5b = 12.0 Hz, 1H, H-5a), 3.52 (dd, J4,5b = 8.3 Hz, J5a,5b = 12.0 Hz, 1H, H-5b) 2.10, 2.052, 2.045, 2.04 
(4 x, s 12H, CH3 Ac); 
13
C NMR (125MHz, CDCl3): δ 169.85, 169.83, 169.3, 169.1 (4, C=O, Ac), 92.0 (C-1), 71.0 
(C-3), 69.5 (C-2), 68.3 (C-4), 62.6 (C-5), 20.8, 20.72, 20.66, 20.6 (4 CH3 Ac). HRMS(ESI) m/z calcld. for 
[C11H16O8+Na]
+
: 299.0743, obsd.: 299.0743. 
 
2,3,4-Tri-O-acetyl-α/β-D-xylopyranose (68). To a cooled solution (0°C) of H2NNH2·H2O 
(0.40 mL, 8.2 mmol, 1.3 equiv.) in DMF (15 mL), AcOH (0.47mL, 8.2mmol, 1.3 equiv.) was 
added drop wise, followed by addition of peracetelated xylose 60 (2.0 g, 6.3 mmol,) in DMF (15 mL). The 
resulting solution was then allowed to warm up to rt. and left to stir until TLC analysis (PE/EtOAc, 1/3, v/v) 
showed complete conversion of starting material (45 min). Then EtOAc was added and the organic phase 
washed with sat. aq. NaHCO3 (2), and brine (1x). The combined aqueous layers were extracted with EtOAc 
(2), and the organic fractions combined, then dried over MgSO4, filtered, and concentrated in vacuo. 
Purification by column chromatography (PE/EtOAc, 6/1  1/1, v/v) and crystallisation (PE/EtOAc) yielded 
the title compound 68 (1.3 mg, 4.9 mmol, α/β, 2/1, 60%) as white needles. Rf : 0.37 (PE/EtOAc, 1/3, v/v); 
[α]D
20
: +2.6 (c = 10.0 in CHCl3); 
1
H NMR (500 MHz, CDCl3) α-product: δ 5.51 (t, J = 9.5 Hz, 1H, H-3), 5.38 (d, J1,2 
= 3.5 Hz, 1H, H-1), 4.96 (dt, J4,5 = 6.1 Hz, J3,4 = 9.5 Hz 1H, H-4) 4.84 (dd, J1,2 = 3.4 Hz, J2,3 = 9.5 Hz 1H, H-2), 3.88 
(t, J = 10.5 Hz, 1H, H-5a), 3.81 (dd, J5a,5b = 5.8 Hz, J4,5 = 11.0 Hz, 1H, H-5b), 2.05, 2.042, 2.039 (3, s, 3H, CH3 
Ac); 
13
C NMR (125MHz, CDCl3) α-product: δ 170.9 170.1, 170.0 (3, C=O, Ac), 90.3 (C-1), 71.2 (C-2), 69.24 (C-
3), 69.18 (C-2), 58.5 (C-5), 20.8, 20.70, 20.69 (3 CH3 Ac); 
1
H NMR (500 MHz, CDCl3) β-product: δ 5.23 (t, J = 
9.3 Hz, 1H, H-3), 4.98 (dt, J4,5 = 4.6 Hz, J = 10.0 Hz, 1H, H-4), 4.84 (d, J = 9.2 Hz, 1H, H-2), 4.68 (d, J1,2 = 7.6 Hz, 
1H, H-1), 4.13 (dd, J4,5 = 5.4 Hz, J5a,5b = 11.9 Hz, 1H, H-5a), 3.37 (dd, J4,5 = 10.0 Hz, J5a,5b = 11.7 Hz, 1H, H-5b), 
2.09, 2.05, 2.042, (3 x, s 9H, CH3 Ac); 
13
C NMR (125MHz, CDCl3) β-product: δ 170.3, 170.15, 170.10 (3, C=O, 
Ac), 85.9 (C-1), 76.8 (C-2), 73.1 (C-3), 69.0 (C-4), 62.7 (C-5), 20.8, 20.7, 20.69 (3 CH3 Ac); HRMS(ESI) m/z 
calcld. for [C11H16O8+Na]
+
: 299.0743, obsd.: 299.0743. 
 
 O-(2,3,4-tri-O-acetyl-α/β-D-xylopyranosyl) N-(phenyl)trifluoro -acetimidoyl (70). 
Hemiacetal 68 (52.6 mg, 0.19 mmol) was co-evaporated with toluene (3), 
dissolved in acetone (1 mL), and N-(phenyl)trifluoroacetimidoyl chloride (75 µL, 0.56 mmol, 3 equiv.) was 
added at 0°C, followed by Cs2CO3 (120 mg, 0.37 mmol, 2 eq). The resulting suspention was left to stir until 
TLC analysis (PE/EtOAc, 2/1, v/v) showed complete conversion of starting material. The reaction was then 
filtered over celite to remove unreacted Cs2CO3 and the organic fraction concentrated in vacuo. Purification 
of the residue by column chromatography (PE/EtOAc, 20/1 10/1, v/v) yielded the title compound 70 (73.7 
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mg, 0.16 mmol, 89%, α/β 2/1) as an colourless oil. Rf: 0.35 (PE/EtOAc, 2/1, v/v); 
1
H NMR (500 MHz, CDCl3) α-
product: δ 7.32-7.26 (m, 2H, CHarom m-N-Ph), 7.11 (t, J = 7.5 Hz, 1H, CHarom p-N-Ph), 6.79 (d, J = 7.5 Hz, 1H, 
CHarom o-N-Ph), 5.54 (t, J2,3 = J2,3 = 9.8 Hz, 1H, H-3), 5.12-5.02 (m, 2H, H-2 and H-4), 4.01-3.96 (m, 1H, H-5a), 
4.80-3.72 (m, 1H, H-5b), 2.08 (s, 3H, Me OAc), 2.06 (2x s, 6H, Me OAc); 
13
C NMR (125MHz, CDCl3) α-product: 
δ 170.02, 169.97, 169.9 (3x, C=O OAc), 143.1 128.9, 124.7, 119.4 (4x CHarom NPh), 92.4 (C-1), 69.7 (C-2), 69.4 
(C-3), 68.6 (C-4), 60.8 (C-5), 20.8, 20.7, 20.6 (3x Me OAc); 
1
H NMR (500 MHz, CDCl3) β-product: δ 7.32-7.26 
(m, 2H, CHarom m-N-Ph), 7.11 (t, J = 7.5 Hz, 1H, CHarom p-N-Ph), 6.83 (d, J = 7.5 Hz, 1H, CHarom o-N-Ph), 5.12-
5.10 (m,1H, H-3), 5.12-5.02 (m, 1H, H-4), 4.95-4.90 (m, 1H, H-4), 4.23 (bd, J = 10.5 Hz, 1H, H-5a), 3.62 (bs, 1H, 
H-5b), 2.10, 2.09, 2.08 (3x s, 9H, Me OAc); 
13
C NMR (125MHz, CDCl3) β-product: δ 169.9, 169.6, 169.2 (3x, 
C=O OAc), 143.1 128.9, 124.7, 119.4 (4x CHarom NPh), 94.1 (C-1), 68.5 (C-3), 67.7 (C-4), 67.4 (C-2), 61.7 (C-5), 
20.9, 20.7, 20.6 (3x Me OAc);HRMS(ESI) m/z calcld. for [C11H16O8+Na]
+
: 470.1033, obsd.: 470.1030. 
 
 
O-(2,3,4-tri-O-acetyl-α/β-D-xylopyranosyl) trichloroacet-imidate (69). Hemiacetal 
68 (203 mg, 0.74 mmol) was co-evaporated with toluene (3), dissolved in dry 
CH2Cl2 (2.5 mL), and trichloroacetonitrile (0.40 mL, 3.7 mmol, 5 equiv.) was added at 0°C, followed by 1,8-
diazabicycloundec-7-ene (DBU) (11 µL, 0.074 mmol, 0.1eq). The resulting solution was left to stir until TLC 
analysis (PE/EtOAc, 2/1, v/v) showed complete conversion of starting material. The reaction was then 
concentration in vacuo and purification of the residue by column chromatography (PE/EtOAc, 10/1  6/1, 
v/v) yielded the title compound 69 (250 mg, 0.059 mmol, 80%, α/β) as an amorphous yellow solid. Rf α: 0.23, 
Rf β: 0.34 (PE/EtOAc, 2/1, v/v); 
1
H NMR (500 MHz, CDCl3) α-Imidate: δ 8.65 (s, 1H, NH, CNHCCl3), 6.44 (d, J1,2 
= 3.6 Hz, 1H, H-1), 5.53 (t, J = 10.0 Hz, 1H, H-3), 5.04 (dt, J4,5 = 4.8 Hz, J3,4 = 9.5 Hz 1H, H-4), 5.03 (d, J1,2 = 3.7 
Hz, J2,3 = 10.2 Hz 1H, H-2), 3.95 (dd, J5a,5b = 3.9 Hz, J4,5 = 11.2 Hz, 1H, H-5a), 3.78 (t, J4,5 = 11.0 Hz, 1H, H-5b), 
2.02, 2.01, 1.99 (3, s, 3H, CH3 Ac); 
13
C NMR (125MHz, CDCl3) α-Imidate: δ 170.09, 170.08, 170.0 (C=O, Ac), 
161.1 (CN, CNHCl3), 93.3 (C-1), 69.5 (C-4), 68.7 (C-3), 68.5 (C-2), 60.9 (C-5), 20.9, 20.8, 20.6 (3 CH3 Ac); 
1
H 
NMR (500 MHz, CDCl3) β-Imidate: δ 8.70 (s, 1H, NH, CNHCCl3), 5.99 (d, J1,2 = 4.4 Hz, 1H, H-1), 5.13 (t, J = 5.9 
Hz, 1H, H-3), 5.07 (t, J2,3 = 4.2 Hz,Hz 1H, H-2) 4.90 (dt, J4,5 = 3.9 Hz, J3,4 = 5.6 Hz 1H, H-4), 4.26 (dd, J5a,5b = 3.9 
Hz, J4,5 = 12.5 Hz, 1H, H-5a), 3.69 (dd, J5a,5b = 5.4 Hz, J4,5 = 12.7 Hz, 1H, H-5b), 2.07, 2.063, 2.060 (3, s, 3H, CH3 
Ac); 
13
C NMR (125MHz, CDCl3) β-Imidate: δ 169.9, 169.7, 169.2 (C=O, Ac), 160.6 (CN, CNHCl3), 95.0 (C-1), 
68.5 (C-3), 67.8 (C-2), 67.5 (C-4), 61.8 (C-5), 21.0, 20.9, 20.8 (3 CH3 Ac); HRMS(ESI) m/z calcld. for 
[C13H16O8NCl3+Na]
+
: 441.9839, obsd.: 441.9839. 
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Experimental: Azasugars 
Unless otherwise stated all reactions were performed under atmospheric air. THF (Lab-Scan) was distilled 
from sodium wire prior to use. Triethylamine was distilled and stored over KOH pellets. Pyridine was distilled 
over KOH prior to use. EtOAc (Panreac), MeOH (Pure Science), EtOH (absolute, Pure Science), AcOH (Lab 
Scam), CH2Cl2 (LabServ), 30% aqueous NH3 (Fisher Science), triethylsilane (Fluka), D-fructose, NaCNBH3 
(Aldrich), and NaOH (Pure Science), sodium (Aldrich), imidazole (Aldrich), I2 (BDH), aminodiphenylmethane 
(Aldrich), were used as received. Zn dust was activated by the careful addition of conc. H2SO4. All solvents 
were removed by evaporation under reduced pressure (in vacuo). Reactions were monitored by TLC-analysis 
on Macherey-Nagel silica gel coated plastic sheets (0.20 mm, with fluorescent indicator UV254) with 
detection by UV-absorption (254 nm), by dipping in 10% H2SO4 in MeOH or 3% ninhydrin in EtOH followed 
by charring at ~150 °C. Column chromatography was performed on Pure Science silica gel (40-63 micron). 
DOWEX® H
+
 50wx8-100 ion exchange resin was activated by overnight exposure to 1M HCl. C8 and C18 
reverse phase column were performed on thermo fisher scientific HypoerSep Columns. High-resolution 
mass spectra were recorded on a Waters Q-TOF PremierTM Tandem Mass Spectrometer using positive 
electro-spray ionisation. Optical rotations were recorded using a Perkin-Elmer 241 polarimeter at the 
sodium D-line. Infrared spectra were recorded as thin films using a Bruker Tensor 27 FTIR spectrometer, 
equipped with an Attenuated Total Reflectance (ATR) sampling accessory, and are reported in wave 
numbers (cm-1). Nuclear magnetic resonance spectra were recorded at 20 °C in chloroform or deuterium 
oxide using either a Varian Unity-INOVA operating at 300 MHz or a Varian Unity operating at 500 MHz. 
Chemical shifts are given in ppm (δ) and are relative to chloroform or water, all given 
13
C spectra are proton 
decoupled. NMR peak assignments were made using COSY, HSQC, TOCSY and HMBC experiments.  
  
Methyl D-fructofuranoside (170).
128
 To a solution of D-fructose (156) (3.6 g, 20 
mmol) in MeOH (200 mL), H2SO4 (1mL, 18 mmol) was added. The resulting solution 
was stirred at rt for 15 min, after which triethylamine (6 mL, 40 mmol) was added, 
and the solvent was removed in vacuo. The resulting oil was used without further purification. Rf for the 
alpha product: 0.57 Rf, and for the beta product: 0.70 (EtOAc/isopropanol/H2O, 6/4/1, v/v/v). 
 
 Methyl 6-deoxy-6-iodo-D-fructofuranoside (155).
128
 To a solution of 170 (368 mg, 
1.9 mmol) in dry THF (15 mL) were added PPh3 (748 mg, 2.85 mmol) and imidazole 
(259 mg, 3.8 mmol). The mixture was heated to reflux and a solution of I2 (723 mg, 
2.85 mmol) in dry THF (7 mL)was added over 30 min. After an additional 15 min the 
reaction mixture was cooled to room temperature, filtered and concentrated. The residue was purified by 
collumn chromatography (PE/EtOAc, 1/1→1/2) followed by reverse phase flash chromatography to remove 
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remaining Ph3P=O (H2O→MeOH, 9/1 v/v) to yield the title compound 155 as a colourless oil (399 mg, 1.3 
mmol 69% over 2 steps). Rf for the alpha product : 0.34 Rf for the beta product: 0.29 (CH2Cl2/MeOH, 5/1, 
v/v); IR (ν): cm
-1
; NMR data of Methyl 6-deoxy-6-iodo-α-D-fructoside:Spectroscopic data matched with 
previously reported.
128
 
 1
H NMR (500 MHz, CDCl3): δ 4.13 (d, J3,4 = 3.1 Hz, 1H, H-3), 3.91-3.88 (m, 2H, H-4 and 
H-5), 3.77 (d, Ja,b = 12.2 Hz, 1H, H-1a), 3.66 (d, Ja,b = 12.5 Hz, 1H, H-1b), 3.47 (dd, J5,6 = 4.6 Hz, Ja,b = 11.0 Hz, 
1H, H-6a), 3.38-3.34 (m, 1H, H-6b), 3.30 (s, 3H, Me OMe); 
13
C NMR (125MHz, CDCl3): δ 108.1 (C-2), 81.7, 80.8 
(C4 and C-5), 80.4 (C-3), 57.6 (C-1), 48.2 (OMe), 5.2 (C-6); NMR data of Methyl 6-deoxy-6-iodo-β-D-
fructoside:
 1
H NMR (500 MHz, CDCl3): δ 4.18 (d, J3,4 = 8.2 Hz, 1H, H-3), 4.04 (t, J3,4 = J4,5 = 7.9 Hz, 1H, H-4), 
3.84-3.82 (m, 1H, H-5), 3.71 (d, Ja,b = 12.4 Hz, 1H, H-1a), 3.64 (d, Ja,b = 12.4 Hz, 1H, H-1b), 3.47 (dd, J5,6 = 4.6 
Hz, Ja,b = 11.0 Hz, 1H, H-6a), 3.38-3.34 (m, 1H, H-6b), 3.34 (s, 3H, Me OMe); 
13
C NMR (125 MHz, CDCl3): δ 
103.7 (C-2), 80.1 (C-5), 78.6 (C-4), 77.0 (C-3), 59.4 (C-1), 49.27 (OMe), 6.8 (C-6); HRMS(ESI) m/z calcld. for 
[C7H13INaO5]
+
: 326.9700, obsd.: 326.9705. 
 
(3R,4R)-2-(R/S)-(diphenylmethyl)amino-hex-5-ene-1,3,4-triol (172a-b). To a 
solution of methyl iodoglycoside (155) (179 mg, 0.59 mmol) in EtOH (11 mL) was 
added water (0.25 mL), activated Zn (192 mg, 2.94 mmol), 
aminodiphenylmethane (120 µL, 0.71 mmol), NaCNBH3 (111 mg, 1.76 mmol), and AcOH (0.6 mL). The 
mixture was stirred at reflux for 3 h, then cooled, and the solvent removed in vacuo. Purification by silica gel 
column chromatography [(CH2Cl2/EtOH/MeOH/30% aqueous NH3, 5/2/2/1, v/v/v/v)/CH2Cl2 5/1 v/v] gave 
172a and 172b as a mixture of diphenylmethylamine and product, which was used without further 
purification. Rf : 0.88, 0.80 [(CH2Cl2/EtOH/MeOH/30% aqueous NH3, 5/2/2/1, v/v/v/v)/CH2Cl2 1/1 v/v]; IR (ν): 
cm
-1
; 
1
H NMR (500 MHz, CDCl3): δ 5.86 (ddd, J4,5 = 4.9 Hz, J5,6-cis = 10.5 Hz, J5,6-trans = 17.3 Hz, 1H, H-5), 5.45 
(d, J5,6-trans = 17.4 Hz, 1H, H-6-trans), 5.25 (d, J5,6-cis = 10.5 Hz, 1H, H-6-cis), 5.10 (s, 1H, CH NHCHPh2), 4.07-
4.06 (m, 1H, H-4), 3.92 (dd, J1,2 = 4.9 Hz, Ja,b = 11.7 Hz, 1H, H-1a), 3.77-3.66 (m, 2H, H-3, H-1b), 2.77 (t, J1,2 = 
J2,3 = 2.0 Hz, 1H, H-2);
1
H NMR (500 MHz, CDCl3): δ 5.81 (ddd, J4,5 = 6.1 Hz, J5,6-cis = 10.5 Hz, J5,6-trans = 17.8 
Hz, 1H, H-5), 5.32 (d, J5,6-trans = 17.4 Hz, 1H, H-6-trans), 5.16 (d, J5,6-cis = 10.5 Hz, 1H, H-6-cis), 5.08 (s, 1H, CH 
NHCHPh2), 4.24 (t, J3,4 = J3,4 = 4.9 Hz, 1H, H-4), 3.77-3.66 (m, 3H, H-3, H-1a H-1b), 2.72 (dd, J = 4.4 Hz, J = 9.3 
Hz, 1H, H-2); HRMS(ESI) m/z calcld. for [C19H24NO3]
+
: 314.1751, obsd.: 314.1752. 
 
(3R,4R)-2(R/S)-Amino-hex-5-ene-1,3,4-triol hydrochloride(154a-b). To a solution 
of (3R,4R)-2-(R/S)-(diphenylmethyl)amino-hex-5-ene-1,3,4-triol (172a-b) and 
(diphenylmethyl)amine in TFA (4 mL) triethylsilane (200 µL, 1.25 mmol) was added 
and the mixture stirred at reflux for 3 h. The solution was cooled and the solvent 
removed under reduced pressure. The product was dissolved in water (50 mL) and washed with EtOAc 
(three times 50 mL). The water layer was then concentrated and purified by reverse phase (HP20, H2O) and 
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gradient flash chromatography (CH2Cl/EtOH/MeOH/30% aqueous NH3, 5/2/2/1, v/v/v/v) to give 154a-b 
(70% from 170, 61 mg, 0.41 mmol) which was converted to the HCl salt by co-evaparting with 1M HCl. Rf = 
0.30 ((CH2Cl2/EtOH/MeOH/30% aqueous NH3, 5/2/2/1, v/v/v/v)/ CH2Cl2, 2/1); [α]D
20
: 0.4 (c = 1.0 in H2O); IR 
(ν): 3219, 3069, 2959, 2925, 1668, 1437, 1200, 1136, 841.8, 801, 772, 724 cm
-1
; 
1
H NMR (500 MHz, D2O): δ 
5.94 (ddd, J4,5 = 5.8 Hz, J5,6-cis = 10.7 Hz, J5,6-trans = 17.3 Hz, 1H, H-5), 5.34 (d, J5,6-trans = 17.6 Hz, 1H, H-6-
trans), 5.31 (d, J5,6-cis = 10.7 Hz, 1H, H-6-cis), 4.31-4.29 (m, 1H, H-4), 3.87 (dd, J1,2 = 4.4 Hz, Ja,b = 12.2 Hz, 1H, 
H-1a), 3.82-3.78 (m, 1H, H-3), 3.77 (dd, J1,2 = 7.1 Hz, Ja,b = 12.2 Hz, 1H, H-1b), 3.53-3.47 (m, 1H, H-2);
13
C NMR 
(125MHz, CDCl3): δ 136.3 (C-5), 117.2 (C-6), 72.7 (C-4), 69.1 (C-3), 59.0 (C-1), 54.9 (C-2);
1
H NMR (500 MHz, 
D2O): δ 5.90 (ddd, J4,5 = 6.6 Hz, J5,6-cis = 10.5 Hz, J5,6-trans = 17.1 Hz, 1H, H-5), 5.34 (t, J5,6-trans = J5,6-cis = 17.6 
Hz, 2H, H-6a and H-6b), 4.21(dd, J3,4 = 5.6 Hz, J4,5 = 6.8 Hz, 1H, H-4), 3.93 (dd, J1,2 = 4.1 Hz, Ja,b = 12.2 Hz, 1H, 
H-1a),3.87-3.85 (m, 1H, H-3), 3.80-3.77 (m, 1H, H-1b), 3.53-3.47 (m, 1H, H-2);
13
C NMR (125MHz, CDCl3): δ 
135.5 (C-5), 118.5 (C-6), 72.7 (C-4), 70.7 (C-3), 57.5 (C-1), 54.5 (C-2);HRMS(ESI) m/z calcld. for [C6H14NO3]
+
: 
148.0968, obsd.: 148.0974. 
 
 
 
(5R/S,6R,7R,7aR/S)-6,7-Dihydroxy-5-(hydroxymethyl)-tetrahydro-pyrrolo[1,2-c]oxazol-3-
one. To a solution of alkenylamine hydrochloride 172a-b (10.6 mg, 0.72 mmol) in sat. aq. 
NaHCO3 (1.0 mL) was added I2 (30 mg, 0.11 mmol). The solution was stirred for 18 h at 
room temperature then filtered and concentrated in vacuo. The product was purified by 
silica gel chromatography (EtOAc/MeOH, 10/1, v/v) followed by removal of the excess salt by the addition of 
DOWEX® H
+
 to give the carbamates as an amorphous white solid. NMR data of the major product 
1
H NMR 
(500 MHz, D2O): δ 4.64 (t, J5,6 = Ja,b = 9.1 Hz, 1H, H-6a), 4.51 (dd, J5,6 = 3.4 Hz, Ja,b = 9.1 Hz, 1H, H-6b), 4.48 (d, J 
= 4.9 Hz, 1H, H-3), 4.34 (dt, J = 2.7 Hz, J = 8.6 Hz, 1H, H-5), 4.10-4.08 (m, 1H, H-4), 3.92 (dd, J2,3 = 5.4 Hz, J1,2 = 
12.7 Hz, 1H, H-2); 
13
C NMR (125 MHz, CDCl3): δ 164.8 (C7), 77.2 (C-3), 75.5 (C-4), 64.0 (C-6), 62.0 (C-2), 61.7 
(C-5), 59.7 (C-1); NMR data of the minor product 
1
H NMR (500 MHz, D2O): δ 4.70-4.67 (m, 1H, H-6a), 4.50-
4.46 (m, 1H, H-6b), 4.13 (dd, J2,3 = 5.9 Hz, J3,4 = 12.4 Hz, 1H, H-3), 4.02-3.98 (m, 2H, H-4 and H-5), 3.86-3.82 
(m, 1H, H-1a), 3.71 (dd, J1,2 = 5.7 Hz, Ja,b = 12.0 Hz, 1H, H-1b), 3.66 (dd, J1,2 = 4.0 Hz, J1,2 = 5.9 Hz, 1H, H-2); 
13
C 
NMR (125 MHz, CDCl3): δ 163.2 (C7), 78.7 (C-4), 78.1 (C-3), 67.7 (C-6), 64.8 (C-2), 91.2 (C-5), 60.8 (C-1); 
HRMS(ESI) m/z calcld. for [C7H11NNaO5]
+
: 212.0529, obsd.: 212.0533.  
 
2,5-dideoxy-2,5-imino-L-iditol hydrochloride 112 and 2,5-
dideoxy-2,5-imino-D-mannitol hydrochloride 106. To a solution 
of the carbamates (4.1 mg, 0.022 mmol) in EtOH (1 mL) was 
added NaOH (7 mg, 0.18 mmol). The solution was stirred at reflux 
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for 2 h then cooled and purified directly using DOWEX® H
+
. Products 112 and 106 were eluted 30% aqueous 
NH3, concentrated in vacuo. Purification was attempted on silica column chromatography 
(CH2Cl/EtOH/MeOH/30% aqueous NH3, 5/2/2/1, v/v/v/v)/CH2Cl2, 2/1→1/0) to give compounds 106 and 112 
as a clean mixture of diastereoisomers. (2.1 mg, 0.013 mmol, 60%) white solid. Rf : 0.71 
(CH2Cl/EtOH/MeOH/30% aqueous NH3, 5/2/2/1, v/v/v/v); NMR data of 2,5-dideoxy-2,5-imino-L-iditol
146
; 
1
H 
NMR (500 MHz, CDCl3): δ 4.47 (d, J = 3.3 Hz, 2H), 4.02-3.96 (m, 4H), 3.92-3.88 (m, 2H); 
13
C NMR (125 MHz, 
CDCl3): δ 74.5, 62.8, 57.4; NMR data of 2,5-dideoxy-2,5-imino-D-mannitol hydrochloride
147
; 
1
H NMR (500 
MHz, CDCl3): δ 4.13-4.08 (m, 2H), 3.95-3.85 (m, 4H), 3.60-3.57 (m, 2H); 
13
C NMR (125 MHz, CDCl3): δ 74.1, 
62.3, 57.7 ; HRMS(ESI) m/z calcld. for [C6H14NO4]
+
: 164.0917, obsd.: 164.0926. 
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